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resumo 
 
 
A Terapia Fotodinâmica (do inglês Photodynamic Therapy, PDT) tem sido 
aplicada com bastante sucesso no tratamento de doenças oncológicas. Esta 
terapia baseia-se na utilização conjunta de luz e de um agente 
fotossensibilizador (do inglês photosensitizer, PS) para gerar reações 
citotóxicas no tecido tumoral. A vasta gama dos PSs usados na clínica para o 
tratamento de cancro apresenta baixas solubilidade em meios fisiológicos e 
seletividade para as células tumorais. Este projeto surge de uma colaboração 
entre químicos e bioquímicos e tem como objetivo principal o desenvolvimento 
de novos PSs conjugados com moléculas de galactose para serem 
reconhecidos por proteínas com afinidade por galactose sobrexpressas nas 
células tumorais. Numa primeira fase foram avaliadas as propriedades foto-
químicas e –físicas dos novos conjugados. Na presença de características 
reveladoras de um potencial terapêutico, o seu potencial em PDT foi avaliado 
em diferentes modelos biológicos. 
No primeiro capítulo desta dissertação faz-se uma introdução ao uso da PDT 
no tratamento de doenças oncológicas e ao potencial em PDT de PSs 
conjugados com galactose. No segundo capítulo, descreve-se a síntese de 
PSs ligados a unidades dendríticas de galactose ou a galactose através de 
conjugação ao carbono-3 deste açúcar. No terceiro capítulo, foram realizados 
estudos in vitro com as linhas celulares do cancro da bexiga HT-1376 e UM-
UC-3 (células em monocamada), para avaliar o potencial fotodinâmico de uma 
ftalocianina conjugada com unidades dendríticas de galactose (PcGal16). As 
proteínas galectina-1 e GLUT1 demonstraram estar envolvidas no uptake da 
PcGal16 pelas células tumorais. Posteriormente, no quarto capítulo, foi 
demonstrado que as vias de endocitose mediadas por clatrina e cavéolas são 
importantes na internalização da PcGal16. Estudos ao nível celular revelaram 
que a foto-toxicidade em células HT-1376 resistentes à PDT pode ser 
aumentada por alteração das vias endocíticas. O potencial biológico in vitro e 
in vivo de uma porfirina conjugada com unidades dendríticas de galactose 
(PorGal8) é descrito no quinto capítulo deste trabalho. O uptake e a foto-
toxicidade da PorGal8 são superiores na linha tumoral UM-UC-3 que contém 
níveis elevados da proteína galectina-1. Os estudos in vivo, utilizando as 
células UM-UC-3 para indução do tumor, comprovaram o efeito terapêutico da 
PorGal8 após PDT. No sexto capítulo, aborda-se um tratamento repetido de 
PDT com uma clorina conjugada com unidades dendríticas de galactose 
(ChlGal8), como uma abordagem terapêutica promissora em células HT-1376 
resistentes à terapia. No sétimo capítulo, descreve-se o potencial 
anticancerígeno de uma porfirina conjugada com galactose através do 
carbono-3 (Por-C3-Gal4) em células de cancro de cólon HCT-116, de cancro 
da mama MCF-7, de cancro da bexiga UM-UC-3 e de cancro cervical HeLa, 
tanto em monocamadas como em esferoides. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
Photodynamic Therapy, Cancer, Porphyrins, Phthalocyanines, Chlorins, 
Galactose, Galectin-1, GLUT1 
 
abstract 
 
The combination of a photosensitizing molecule (Photosensitizer, PS) and light 
to induce toxicity by Reactive Oxygen Species (ROS) production is very 
attractive in the treatment of cancer by Photodynamic Therapy (PDT). 
Unfortunately, the PSs used in clinic for the treatment of cancer have low 
cancer selectivity and poor water solubility. The success of new PDT agents in 
cancer treatment requires a strong collaboration between chemists for the 
synthesis of the porphyrinoid molecule and conjugation with a cancer-targeting 
motif, physicists for the development of appropriate light irradiation devices, 
biochemists for understanding cellular responses, and clinicians for the clinical 
studies. In this study, we have combined the knowledge of chemists and 
biochemists to develop new PSs by conjugating them with specific galactose 
motifs to be used in the treatment of cancer by PDT. These new galactose-PSs 
were designed for a specific target such as a galactose-binding protein 
overexpressed in cancer cells, and their photophysical properties evaluated. 
We have tested the photo-chemical and –physical properties of the new PSs 
and their photodynamic potential in different biological models.  
Chapter I of this dissertation presents a brief introduction to the use of PDT in 
the treatment of cancer and the potential of galactose-PSs in PDT. Chapter II 
reports the synthesis of water-soluble porphyrinoids attached to dendritic units 
of galactose or to galactose through carbon-3. In Chapter III, HT-1376 and UM-
UC-3 bladder cancer cells growing as monolayers were used to determine the 
uptake and photodynamic potential of a phthalocyanine conjugated with 
galactodendritic units (PcGal16). The galactose-binding proteins galectin-1 and 
GLUT1 demonstrated to be involved in the uptake and further phototoxicity of 
PcGal16 by bladder cancer cells. The role of caveolae- and clathrin-mediated 
endocytosis in the internalization of PcGal16 by bladder cancer cells is reported 
in Chapter IV. Cellular studies revealed that interfering with endocytic pathways 
led to increased phototoxicity in HT-1376 cancer cells resistant to PDT. 
Chapter V describes the in vitro and in vivo photodynamic properties of a 
porphyrin conjugated with dendritic units of galactose (PorGal8). PorGal8 
uptake and PDT-induced cytotoxicity were higher in UM-UC-3 compared to HT-
1376 bladder cancer cells. These differences were correlated with the levels of 
galectin-1 protein expression and cytoskeleton alterations. PorGal8 
accumulated in UM-UC-3 xenograft tumors and induced tumor ablation after 
PDT. Chapter VI discussed the potential of a repeated PDT treatment to 
increase in vitro and in vivo phototoxicity with a galactodendritic chlorin 
(ChlGal8) in HT-1376 cells resistant to PDT. Chapter VII reports the potential of 
a porphyrin conjugated with C3-galactose (Por-C3-Gal4) in monolayers and 
spheroid cultures of HCT-116 colon cancer cells, MCF-7 breast cancer cells, 
UM-UC-3 bladder cancer cells and HeLa cervical cancer cells. 
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Chapter I Introduction 
 
1.1 General overview 
 
Photodynamic Therapy will never be the right or only answer for every type of cancers, but it has a great 
potential… 
“Photodynamic Therapy: A Light at the End of the Tunnel for Cancer Patients” 
  Ellen Blum Barish, Roswell Park Cancer Institute, The Better World Report, 2010 
 
Cancer is the term used to describe malignant diseases in which abnormal cells divide 
without control and are able to invade the tissues and the organs of the body. In 2012, an 
estimated 14.1 million new cases of cancer occurred worldwide and 8.2 million people died 
from cancer. Cancer is an important public health problem and its incidence is likely to 
increase in the future due to worldwide population ageing.  
Redox regulation, with increasing generation of reactive oxygen species (ROS) and 
upregulated antioxidant capacity in adaptation to intrinsic oxidative stress, has long been 
observed in cancer cells, especially those in advanced disease stages [1]. This is a biochemical 
property that can confer drug resistance to cancer cells. Redox modulation by pharmacological 
agents could have significant therapeutic benefits since it could contribute to intracellular ROS 
increase and/or protective antioxidant systems depletion, which abrogates such drug-resistant 
mechanisms and leads to the induction of cancer cell death and tissue destruction [2, 3]. It has 
been shown that agents counteracting such adaptive mechanisms by an additive or synergistic 
effect become more effective against these cancer cells [1, 2]. 
Photodynamic therapy (PDT) is an oxidative stress-based therapy which makes use of 
the production of ROS to induce toxicity, by combining light at specific wavelength, 
molecular oxygen and a photosensitizer (PS) [4]. PDT is a two-step therapy, involving the 
administration of the PS and in situ irradiation with light at appropriate wavelength [5]. The 
phototoxicity induced by PDT is a result of several direct and indirect mechanisms including 
toxicity at the cancer cellular level, alterations in the intrinsic anti-tumor immune activity, 
increase in leukocyte function, alteration in the tumor vessels leading to tumor ischemia and 
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amplification of proinflamatory cytokines [6, 7]. Currently available PSs exhibit accumulation 
in the cancer cells, but their uptake by the non-cancerous cells cannot be completely avoided. 
PDT has shown significant advances in recent years, not only on the optimization of light 
delivery systems but also on the synthesis of new PSs [8]. The precise light irradiation of the 
tumor tissue using flexible fiber optic devices promotes a therapeutic selectivity. Selective 
therapeutic effect can be enhanced if selectivity in the PS accumulation in cancer cells can be 
achieved. Their cellular uptake and subcellular localization are controlled by PS intrinsic 
properties such as lipophilicity, type and number of groups and/or charges and degree of 
asymmetry [9-11]. Concerning cancer cellular uptake, PS internalization is also influenced by 
diffusion or endocytosis processes [12] or membrane pumps (e.g. the adenosine-triphosphate 
(ATP)-binding cassette transporter ABCG2) [13]. PS subcellular localization is considered 
one of the most important parameters for predicting the PDT outcome. 
One way of generating molecular-targeted PSs with practical application in PDT is to 
conjugate a porphyrinoid (porphyrin, chlorin or phthalocyanine) with a carbohydrate, since 
they are able to bind to proteins called lectins, found on surface of the cancer cells [14, 15]. 
Galectins are a family of lectins, non-enzymatic proteins with altered expression in cancer 
cells. Galectins and certain other carbohydrate-binding proteins such as glucose transporters 
are found to be overexpressed on cancer cells [16, 17]. As a result, noteworthy research has 
been devoted to develop porphyrinoids conjugated with galactose molecules [15, 18-42] able 
to bind galectins (mainly galectin-1) or even the glucose transporter GLUT1 overexpressed in 
cancer cells. Galactose units, in addition to providing interaction of the conjugate with 
galactose-binding proteins, have the potential to provide amphiphilicity or even water 
solubility to the conjugate. Galactose-conjugates are envisaged to tackle the obstacles of first 
or second generation PS agents.  
This Chapter deals with the use of the oxidative stress-based therapy PDT in the 
treatment of cancer. The role of three components in PDT – PS, light and molecular oxygen – 
is highlighted. The mechanism of action of PDT, the steps involved in the photodynamic 
efficiency of a new PS (ranging from its photophysical/photochemical properties to its uptake 
by cancer cells and induction of cell death) and the different in vitro and in vivo biological 
models available for the evaluation of a new PS in oncology are discussed in this chapter. 
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Finally, promising results in cancer PDT with porphyrinoids conjugated with galactose and 
dendritic units of galactose are described. 
 
1.1.1 Publication 
 
This chapter comprises the following publication: 
Patrícia M. R. Pereira, João P. C. Tomé, Rosa Fernandes, “Molecular Targeted 
Photodynamic Therapy for Cancer”, in Handbook of Porphyrin Science, Karl M Kadish, 
Kevin M Smith, Roger Guilard, Eds., World Scientific, 2016, in press. 
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1.2 Photodynamic Therapy: Brief history 
 
Perhaps the best way to start is the beginning… A detailed description of the PDT history is too complex 
to be encompassed here. Nevertheless, some key findings are important to understand the urgent necessity for 
new and effective PSs. 
 
The idea of combining light and a chemical compound has ancient beginnings. Scientific 
records of the therapeutic effect of sunlight activation of psoralens (extracted from plants) date 
back to approximately 3,000 years ago when this early photochemotherapy was used for 
repigmentation of vitiligo [43, 44]. The most important discoveries in the history of PDT are 
described in the following topics, focusing those who encouraged the medical applications of 
PDT in the oncologic field. A timeline starting with the ancient developments and leading into 
the more recent milestones in the evolution of PDT in oncology is presented in Figure 1.1. 
 
Figure 1.1 Timeline showing selected milestones in the historical development of photodynamic therapy in 
oncology. PDT-photodynamic therapy, PS = photosensitizer, HP = Hematoporphyrin, HpD =Hematoporphyrin 
Derivative. 
 
The first application of PDT in cancer treatment was described by von Tappeiner and 
Jesionek in 1903 [45], who applied eosin to basal cell carcinomas prior to illumination. 
Porphyrins (Pors), the most explored class of drugs in PDT, were initially investigated by 
Meyer-Betz in 1913 [46]. In these investigations, the PDT effects with Hematoporphyrin in rat 
tumors are reported. Meyer-Hertz also performed a heroic self-experiment: he injected himself 
with Hematoporphyrin and irradiated a small area at his forearm. Consequently, exposure to 
direct sunlight led to phototoxic reactions with swelling and burning sensation. Modern time 
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of PDT applications was stimulated after Schwartz [47] and Lipson´s findings in which the 
acid treatment of Hematoporphyrin yielded a mixture of Pors and other chemical species, 
termed Hematoporphyrin Derivative. Hematoporphyrin Derivative after red light activation 
demonstrated better PDT effect than Hematoporphyrin [44]. Although the chemical 
characterization of Hematoporphyrin Derivative was not completely clear, in 1975 Dougherty 
[48] reported that the combination of this drug and red light results in mammary tumor 
eradication. This exciting result encouraged the first clinical experiments with 
Hematoporphyrin Derivative to treat patients with bladder cancer and skin tumors [49, 50]. 
PDT researches were demonstrating successful results (despite some gaps, mostly in PS 
chemistry) and in the late 1980s, Quadra Logic Technologies Photo Therapeutics (Vancouver, 
British Columbia, Canada) and Lederle Laboratories (American Cyanamid, Pearl River, NY) 
formed a partnership to achieve approvals for the clinical use of PDT [44]. The first PDT 
approval occurred in 1993 in Canada using Photofrin®, a more purified and better 
characterized version of Hematoporphyrin Derivative, for the treatment of bladder cancer [51]. 
The first Food and Drug Administration approval of PDT in the United States was also 
obtained with Photofrin®, in 1995, for palliation of obstructive esophageal cancer [51]. The 
favourable results obtained with Photofrin® and the PDT approvals generated curiosity in the 
scientific community, as a brief search on Web of Science for the keyword “photodynamic” 
for the period 1900-2010. The number of papers increased from 128 in the first half of the 
century (1900-1955) to more than 10,000 in the second half (1955-2010). Additionally, in the 
last 14 years (2000-2016) they have been published more than 25,000 papers. The new recent 
time of clinical PDT is stimulating organic chemists to develop synthetic pathways that make 
possible the production of potential PSs.  
 
1.3 Photodynamic Therapy: Components and mechanism of action 
 
Photosensitization reactions have been successfully applied in a wide variety of medical areas. However 
the photophysical and photochemical mechanisms by which an activated PS (by light) induces biological 
response are challenges in photobiological and photochemical research areas… 
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1.3.1 Photosensitizer 
 
PSs are naturally occurring substances or synthetic derivatives (containing a 
chromophore in their structure) which are therapeutically inert until irradiated by light [52]. 
An “ideal” PS for cancer PDT should exhibit the following chemical, physical and biological 
properties [53-55]: (1) readily available in pure form with known chemical composition; (2) 
have low dark toxicity and exhibit high phototoxicity, which is frequently mediated by the 
production of singlet oxygen (1O2); (3) photostable and soluble in aqueous media; (4) high 
molar absorption coefficient in the 600-900 nm range of the electromagnetic spectrum; (5) 
selective to the cancer cells and (6) limited skin phototoxicity. Porphyrinoid compounds, such 
as porphyrins (Pors), chlorins (Chls), bacteriochlorins, phthalocyanines (Pcs), and related 
structures (Figure 1.2) are the most appropriate PSs for PDT [53, 56, 57]. Porphyrins have a 
chemical structure composed of four modified pyrrole subunits, interconnected via methane 
carbon atoms. Such types of free base macrocycles (i.e. a porphyrins without metal-ions in 
their cavity) have an absorption spectrum characterized by five bands, the strongest known as 
Soret band (around 400 nm) and four smaller absorption bands (Q-bands) at wavelengths in 
the red region. Their low water solubility, poor absorption in the red region of the 
electromagnetic spectrum and low selectivity to the cancer cells result in unwanted side effects 
in cancer PDT. Chlorins (dihydroporphyrins) are porphyrinoids which have one of the pyrrole 
subunits reduced. Compared to porphyrins, the intensity of the lowest energy absorption band 
(near 650 nm) is increased in Chls. Phthalocyanines consist of a ring of four isoindole units 
linked by imine nitrogen atoms, where the pyrrole groups are fused with benzene rings. Due to 
their chemical structure, Pcs absorb strongly in the red region of the electromagnetic spectrum, 
with a maximum at around 670 nm. 
Normally, PSs are in a low energy level named the ground-state (1PS). To initiate the 
photodynamic effect, a PS is irradiated with light at a specific wavelength promoting its 
excitation from the stable 1PS to the excited-singlet-state energy level (1PS*). The photo-
excited 1PS* is extremely unstable with a half-life generally less than 1 µs. To obtain the 
photodynamic effect, 1PS* must undergo intersystem crossing to a longer-lived electronically 
different excited state, the excited-triplet-state (3PS*) [8, 52, 58].  
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Figure 1.2 Basic chemical structures of the porphyrinoids porphyrin, chlorin and phthalocyanine. 
 
At this stage, the excited PS returns to its ground-state by type I (electron transfer) and 
type II (energy transfer) photochemical reactions [59]. These two competing mechanisms are 
instantaneous and can occur simultaneously [60]. The occurrence of the two mechanisms is 
mainly dependent on the PS, oxygen content, the abundance of the biological substrate and the 
microenvironment where the PS is localized, as well as the binding affinity of the PS to the 
substrate [60-63]. In the type I reaction, the 3PS* interacts with a biological substrate forming 
free radicals able to react with subcellular components such as nucleic acids, proteins, peptides 
and plasma membrane [60]. In the type II reaction, 1O2 is formed as a result of energy transfer 
from the 3PS* to the triplet-ground-state of molecular oxygen (3O2). The role of 
1O2 in the 
cytotoxicity induced by a PS after PDT was introduced in 1976 by Dougherty and coworkers 
[64]. The type II photochemical reaction is considered to be the major path of phototoxicity 
(Figure 1.3), in that 1O2 exhibits high chemical reactivity and irreversible destruction of cancer 
cells [65]. Although 1O2 is generally accepted as the main damaging species in PDT, ROS 
formation from the type I mechanism may amplify PDT response under hypoxic conditions 
[63, 66]. 
 
Figure 1.3 Modified Jablonski diagram showing Type II photochemical reaction in photodynamic therapy. PS = 
photosensitizer, 3O2 = molecular oxygen, 1O2 = singlet oxygen. Adapted from Ref. [53]. 
Chapter I. Introduction 
 
10 
 
ROS generated during type I and type II photochemical reactions are characterized by 
high reactivity and short lifetimes [67-69]. Therefore, the phototoxic effect should be limited 
to the local and proximal irradiated area containing the PS. The lifetime of 1O2 has been 
estimated to be inferior to 0.04 milliseconds, which limits its diffusion distance to 
approximately 20 nm from its point of origin within a cell [69-71]. Contrary to this idea, 
Skovsen et al. have demonstrated that in experiments performed in a single nerve cell from the 
hippocampus of Wistar rats, 1O2 generated by the PS 5,10,15,20-tetrakis(N-methyl-4-pyridyl)-
21H,23H-porphyrin (TMPyP) can be quite long-lived in a cell and able to diffuse across the 
cell membrane into the extracellular environment [67]. It should be noted that factors such as 
the location of 1O2 formation and the nature of the surrounding medium influence both the 
distance over which 1O2 can diffuse and the probability with which it undergoes biomolecular 
reactions [10, 68]. In a heterogeneous biological sample, the lifetime of 1O2 is highly 
dependent on the presence of dissolved solutes that can quench 1O2 (e.g. proteins) and on the 
solvent covering the cells [68, 70]. For example, an increase in 1O2 lifetime has been described 
when cells were exposed to deuterium oxide (D2O) instead of water (H2O) [72]. 
The standard method used to perform quantitative time-resolved detection of 1O2 is 
based on its specific phosphorescence at 1270 nm. However, the phosphorescence quantum 
yield in a biological sample is strongly reduced due to the presence of quenchers [67]. Sodium 
azide (NaN3) and carotenoids are well-known quenchers of 
1O2 and they can also be used to 
qualitatively infer if these reactive species are generated during a specific PDT treatment [41, 
73]. However, quenching is affected by the concentration of quencher and the intracellular 
location of the species, and such quenchers can be unspecific. The probes (e.g. 1,3-
diphenylisobenzofuran, DPBF, and 2',7'-dichlorodihydrofluorescein, DCFDA) which exhibit 
spectral changes in the presence of 1O2, have been also used for qualitative determination of 
1O2 production by a certain PS [41, 74-76]. However, these probes are often unspecific and the 
results obtained do not always correlate with the photocytotoxic effects. Other techniques have 
been developed to detect the formation of 1O2, for example: by observation of oxygen 
quenching of triplet-excited single molecules, by time-resolved experiments of 1O2 
luminescence in vivo, by novel luminescent 1O2 probes and the time-resolved detection of 
1O2 
in a transmission microscope [68, 70]. 
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The aggregation of the PSs can also influence their production of ROS and mechanism 
of action. Aggregation can be easily identified by changes in the electronic absorption 
spectrum of the PS and it can be affected by PS concentration, temperature, interaction with 
molecules and ionic strength [77-82]. The aggregation of PSs can be reduced by controlling 
the ionic strength, stabilizing the most active groups of the PS or by conjugating the PS with 
one or more biomolecules. Nuñez et al. reported that the photodynamic activity of the PS 
methylene blue against Candida albicans is improved when the assays are performed in 
aqueous urea solution [82]. Urea stabilizes the monomeric species of methylene blue by a 
direct (water replacement) or indirect mechanism (decrease in solvation entropy of water/urea 
mixtures) [83]. Lourenço et al. have compared the photoactivity of a Pc conjugated with α-, β- 
and γ-cyclodextrins [78]. Interestingly, the Pc conjugated with α- and γ-cyclodextrins 
demonstrated higher water solubility, 1O2 production and photoactivity against bladder cancer 
cells when compared with Pc conjugated with β-cyclodextrin. 
  
1.3.2 Tissue oxygenation 
 
The content of oxygen plays an important role in PDT effect induced by type II 
photochemical reaction. An inadequate supply of oxygen to cancer tissues limits 
photodynamic effectiveness in hypoxic tumors [84-86]. In addition, an increase in hypoxia can 
be observed during PDT due to fast depletion of oxygen supply. As a result, the PDT effect 
can be impaired by the secretion of angiogenic factors which lead to the formation and growth 
of new blood vessels (Figure 1.4) [84]. It is well established that hypoxic tumors are less 
susceptible to PDT [87] and that the development of hypoxia after PDT favors the treatment 
response[88]. However, the consequences of hypoxia induced during PDT are less straight 
forward. Krzykawska-Serda et al. have described that the level of hypoxia generated after 
PDT is an important factor in the phototoxic induced by 5,10,15,20-tetrakis(2,6-difluoro-3-N-
methylsulfamoylphenyl)bacteriochlorin (F2BMet) [89]. When PDT was performed with a PS-
to-light interval of 15 min (cancer vascular-targeted PDT), there was induction of chronic 
and/or extreme hypoxia which resulted in long-term tumor responses. On the other hand, when 
PDT was performed with a PS-to-light interval of 72 hours (cancer cell-targeted PDT) there 
Chapter I. Introduction 
 
12 
 
was mild and transient hypoxia associated with tumor re-growths. Lee See et al. [86] 
described a 50% decrease in the photodynamic effect when partial pressure of oxygen (pO2) 
was reduced from 180 to about 50 mmHg, while Moan and Sommer [85] detected a 50% 
reduction in cell photosensitivity at a pO2 of 7.6 mmHg, with full PDT effect at about 40 
mmHg. Further studies performed by Henderson and Fingar demonstrated that lowering pO2 
levels below 40 mmHg resulted in a decrease of cellular photo-inactivation [84]. 
 
Figure 1.4 Hypoxia in solid tumors and acute hypoxia induced after PDT. 
 
Several preclinical and clinical studies have also demonstrated changes in blood flow 
during and immediately after PDT [90-94], which can alter the rate of oxygen transported to 
the tissue. The changes on blood flow during PDT are due to the cancer vascular effects 
mediated by this therapy, such as damage to tumor vasculature [6, 92], vasoconstriction [93], 
vasodilatation induced by edema [93], or by decrease or increase in the production of 
vasoactive substances [94, 95], such as nitric oxide. Wang et al. reported that a blood flow 
decrease was mediated by a decrease of nitric oxide production during PDT with 5-
aminolevulinic acid (ALA) [94]. Nitric oxide is used by endothelium of blood vessels to 
induce relaxation in the surrounding smooth muscle, signaling vasodilatation and blood flow 
increase. On the other hand, a decrease in nitric oxide may result in vasoconstriction and 
decreased blood flow. Thus, a decrease in tissue oxygen levels during PDT may reduce the 
production of nitric oxide, since its biosynthesis requires molecular oxygen [95]. 
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Approaches that can locally produce oxygen have been proposed for PDT treatment of 
hypoxic tumors. Chen et al. have developed an interesting strategy based on a nanoparticle 
composed of a PS and catalase, functionalized with a ligand that recognizes an integrin 
overexpressed in cancer cells [96]. In this approach, intracellular hydrogen peroxide (H2O2) is 
catalyzed by catalase to generate O2 when it penetrates into the shell, which leads to the 
release of the PS. Upon irradiation, the released PS generates ROS inducing cell death. 
 
1.3.3 Light source and light delivery 
 
Light sources used in PDT comprised of laser (diode laser, metal vapor-pumped dye 
laser, argon laser and argon-pumped dye laser, solid state laser, etc.) and non-laser 
sources/lamps (metal halide lamps, xenon arc lamps, quartz halogen lamps, phosphor-coated 
sodium lamp, fluorescent lamps, etc.) [97, 98]. Light emitting diodes (LEDs) and femtosecond 
solid state lasers are other sources of light with potential to be used in PDT. LEDs are less 
expensive when compared with all the other sources described so far and they can be 
engineered in arrays to irradiate large areas. However, the power output is a limiting factor in 
their use for PDT. For example, Ambulight is a magnetic LED lighting system for the 
treatment of non-melanoma skin cancer. Femtosecond lasers have been proposed for two-
photon PDT, however they have technical limitations [97, 98]. Lasers and non-lasers have 
been both used as light sources in PDT and the superiority of one source over the other one 
has not been demonstrated. Noncoherent light sources and conventional arc lamps are more 
suitable, because they are less expensive and may be used with various PSs since they produce 
a wide spectrum of light. The LumaCare irradiation system is an example of a compact 
portable irradiation source, equipped with interchangeable fiber-optics and optical filters, 
capable of producing light between 350 to 800 nm. The conjunction of a LumaCare system 
with filters or interchangeable fiber-optic probes allows the emission of light at restricted 
wavelengths. Although noncoherent light sources are preferred in PDT studies, they have the 
disadvantage of significant thermal effect. The choice of light source for PDT is dependent on 
the absorption properties of the PS used, the optical characteristics of the tissue and the light 
dose [98]. Additionally, the type of light source used in PDT is highly dependent on the 
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location of the tumor (Figure 1.5): surface illumination for treating superficial tumors, 
intraoperative cavitary illumination for brain tumors, bronchoscopic for pulmonary diseases, 
endoscopic for gastroenterology and transurethral for urologic diseases [51, 98]. 
 
Figure 1.5 Representation for light delivery during surface and interstitial photodynamic therapy. Adapted from 
Ref. [99]. 
 
The time interval between PS administration and irradiation can highly influence the 
effectiveness of PDT. For example, benzoporphyrin derivative monoacid ring A (Verteporfin) 
induces microvascular damage when irradiation is performed at 15 minutes post-injection of 
the PS and damage to both microvasculature and cancer cells occur at later time points (3 
hours post-injection) [100, 101]. Chen et al. have demonstrated that targeting both cellular and 
tumor vascular compartments by combining a long drug-light interval PDT with a short drug-
light interval is more effective than each individual or combinative PDT treatments [100]. 
As the therapeutic efficiency of PDT is highly dependent on the levels of oxygen in the 
tissue, the light delivery method should be optimized to improve oxygen maintenance during 
the treatment. Xiao et al. have demonstrated in a preclinical study that continuous light 
delivery is less effective than computer-switched fractionated light delivery with seven 
interstitial fibers in PDT of solid tumors (rat prostate carcinomas) [102]. The rationale of the 
experimental design is that in the light-off period of a fractionated light delivery protocol there 
is reoxigenation of the tumor, improving phototoxicity. However, in these protocols it is 
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difficult to define the most appropriate light-off and light-on periods for each type of tumor. 
Preclinical studies have shown that PDT response is enhanced when a light-fractionated 
approach (two light fractions separated by a dark interval of several hours) is used with ALA-
PDT in the treatment of superficial basal cell carcinoma [103-105]. Additionally, it was also 
demonstrated that this increase in PDT effect is higher when a low-dose light fraction is 
followed by a high-dose light fraction, separated by a dark interval of 2 hours [105]. Based on 
these preclinical studies, further clinical studies were performed, comparing the traditional 
non-fractionated ALA-PDT (single irradiation of 75 J/cm2) with fractionated treatment (20 
and 80 J/cm2, with a dark interval of 2 hours) [106, 107]. Long-term follow-up demonstrated 
higher efficacy of ALA-PDT with a two-fold irradiation protocol, compared to ALA-PDT 
with single irradiation in the treatment of superficial basal cell carcinoma. 
Photosensitizers containing absorption bands in the range between 600 to 900 nm have 
particular interest for PDT. A tissue generally contains chromophores which are able to absorb 
light used during a PDT treatment, reducing its absorption by the administrated PS. 
Hemoglobin (λmax at 420 nm) and bilirubin (λmax at 460 nm) are examples of these endogenous 
chromophores. Water molecules are also able to absorb light at wavelengths higher than 1000 
nm. Another fact is that at wavelengths higher than 900 nm, the photons have reduced energy 
to induce a photochemical reaction. As a result, PDT is usually performed at wavelengths 
higher than 600 nm where the penetration of light through the tissues is higher. Briefly, the 
absolute penetration of a light in a certain tissue depends on both the characteristics of the 
light and the optical properties of the tissue [108, 109]. The optical penetration depth (OPD, 
i.e. the depth at which the intensity of the propagating light is reduced 37% of its initial value 
at the air/tissue interface) [110] is reduced in optically dense tissues (0.8 mm and 0.9 mm in 
the brain and liver tissues, respectively) and 4 mm at 633 nm in the bladder tissue [109]. 
Additionally, PDT is most effective when light delivery is homogeneous and in tumors that 
can be reached directly by light or light delivery devices such as optic fibers. 
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1.4 Photosensitizing agents used in oncology 
 
Clinical PDT is a two-stage and a dual selective process with the first stage corresponding to the 
administration of the PS. After a certain period of time the PS is preferentially retained in tumor (first time 
selective). The tumor is illuminated with light at a specific wavelength, a process which constitutes the second 
and final stage in the therapy… 
 
In the clinic, a typical PDT session involves two crucial steps: the administration of the 
PS and the local irradiation of the target tissue where the PS is accumulated (Figure 1.6). The 
session begins with the administration of the PS (intravenous in most of the tumors or topical 
in skin lesions). Next, there is a period of time for systemic PS (intravenous injection) to be 
retained preferentially in the cancer cells, or for topical PS to be absorbed by the skin. If the 
PS is also accumulated in normal tissues during the initial post-administration period, its 
clearance from those tissues should occur before irradiation. 
 
Figure 1.6 The crucial steps in clinical cancer PDT. Adapted from Ref. [5]. 
 
The preferential accumulation of the PS in the tumor tissue, compared to certain normal 
tissues, can be favored by the large tumor interstitial compartment with increased levels of 
collagen and leaky vasculature, reduced lymphatic drainage and/or higher proliferative rates of 
cancer cells. The irradiation of the target tissue at early times post-administration can result in 
tumor vascular effects (preferential for highly vascularized tumors) [111] and PDT treatment 
at later times post-administration would favor a phototoxic effect at the cancer cellular level 
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(Figure 1.7) [101]. There is a strong clinical interest in combining different doses of PS and 
light, as well as different intervals between PS administration and light exposure, in order to 
promote vascular and selective tumor destruction or even immunomodulatory effects [53]. 
Fluorescent monitoring and prediction of the outcome of PDT for cancer can be accomplished 
if a fluorescent PS is used [112]. Unfortunately, the use of fluorescent PSs for both detection 
of disease and treatment outcome (named theranostics) is underused. The dosages of both PS 
and light should be adjusted for each treatment [58]. Excellent response rates are obtained 
when using low PS drug dose and high light fluences (more light photons). On the other hand, 
combination of high PS dose with high light fluence may eventually lead to normal tissue 
damage, since normal cells are also able to accumulate PS. The use of high light fluence is 
normally associated with necrotic pathways, while low light fluence allows for apoptosis, 
reduced inflammation and immune response. 
 
Figure 1.7 Phototoxicity induced in cancer vasculature (left) and cancer cells (right) after PDT. 
 
Currently, several compounds have been identified as PSs, but a few of those have 
reached an advanced stage and entered human clinical trials or have been approved by the US 
Food and Drug Administration (FDA). PSs currently on the market for the treatment of cancer 
are briefly described in Table 1.1. Some PSs have also been clinically approved in specific 
countries but they are not licensed to be administrated in other ones [53, 54]. There are other 
PSs such as the methyl ester of ALA (methyl aminolevulinate, MAL, Metvix, or Metvixia) 
and benzoporphyrin derivative monoacid ring A (Visudyne) used in non-oncologic treatments. 
Metvix was approved by the FDA in 2004 for treatment of actinic keratosis [113, 114]. 
Visudyne was approved in 1999 by the FDA for the wet form of age-related macular 
degeneration in ophthalmology [53]. 
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Table 1.1 Properties of some PSs approved for PDT treatment in oncology. 
Compound Trademark 
λmax (nm); 
ɛmax (M-1 cm-1) 
Country/ Year approved 
Porfirmer sodium Photofrin 632; 1,170 US 1990s 
5-Aminolevulinic acid (ALA) Levulan 632; 5,000 US 2000 
Tetrakis(m-hydroxyphenyl) chlorin Foscan 652; 35,000 Europe 2003 
N-Aspartylchlorin e6 (NPe6; LS-11) Laserphyrin 664; 40,000 Japan 2003 
Aluminum phthalocyaninetetrasulfonate (AlPcS4) Photosens 676; 20,000 Russia 2001 
 
1.4.1 Porfimer Sodium (Photofrin) 
 
Photofrin was the first PS to be approved by FDA and to be commercially available, 
having the most clinical experience [115, 116]. The success of PDT with this PS is dependent 
on its complex chemical structure composed of a mixture of various oligomers of 
hematoporphyrin. This PS is clinically approved for the treatment of early and late-stage lung 
cancers, esophageal cancer, bladder cancer, early stage cervical cancer, and malignant and 
nonmalignant skin diseases. 
Photofrin is a long-acting PS which is retained in the skin for six to eight weeks post-
administration which causes photosensitivity in patients receiving PDT. Severe burns can be 
produced after an unintentional exposure of skin to sunlight or strong artificial light after PDT 
treatment. The time interval between Photofrin administration and irradiation (50-500 J/cm2) 
is usually 48 hours. In addition to being a mixture of porphyrin oligomers, it has low water 
solubility, reduced selectivity to the cancer cells and low molecular absorption coefficient at 
632 nm. Photogem [117] and Photosan-3 [118] are other types of hematoporphyrin derivatives 
which have been approved for clinical applications in Russia/Brazil and the EU, respectively. 
 
1.4.2 5-Aminolevulinic Acid (ALA, Levulan) 
 
ALA (commercial name Levulan) acts as a prodrug, since it is enzymatically converted 
to the potent PS protoporphyrin IX via the heme biosynthetic pathway [119, 120]. ALA can be 
administered topically or intravenously and it is the PS of choice in the treatment of superficial 
lesions in the skin [119, 121] and oral cavity [122]. Additionally, this PS is also used in the 
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treatment of stomach and oesophageal malignancies and epithelial dysplasia [123]. The 
advantages of ALA-esters when compared with ALA have allowed the approval of these 
molecules. ALA-esters contain a lipophilic chain attached to ALA which improves their tissue 
penetration and diffusion through the stratum corneum. The metabolism of ALA-esters also 
results in the formation of high intracellular levels of protoporphyrin IX. Hexaminolevulinate 
is the n-hexyl ester of ALA (HAL, commercial name Cysview) ant it was approved by FDA in 
2010 for the diagnosis of bladder cancer. HAL is converted into protoporphyrin IX more 
efficiently than Levulan [124]. The application of HAL for the treatment of cervical 
intraepithelial neoplasia and genital erosive lichen planus is under clinical trials. 
 
1.4.3 Tetrakis(m-hydroxyphenyl)chlorin (Foscan) 
 
Tetrakis(m-hydroxyphenyl) chlorin (commercial name Foscan) is a synthetic PS 
containing a mixture of four atropoisomers. This PS was approved in Europe (2003) for the 
treatment of neck and scalp cancer, and it was successfully used for the treatment of breast, 
prostate and pancreatic cancers [125, 126]. Foscan has higher absorption in the red region 
when compared with Photofrin, which allows a low fluence rate PDT light (10 J/cm2) 
protocol. Additionally, the time of treatment with this PS is generally measured in seconds. 
After administration of Foscan, the patient should stay in a dark room for 24 hours since the 
PS can cause severe burns. The treatment with this PS is generally performed with the patients 
under anesthesia, since it is quite painful. 
 
1.4.4 N-Aspartylchlorin e6 (NPe6, Talaporfin, LS-11, Laserphyrin) 
 
N-Aspartylchlorin e6, NPe6 (commercial name Laserphyrin) is a chemically pure 
hydrophilic chlorin PS which can be activated with light at 664 nm, and was approved for the 
treatment of fibrosarcoma, brain, liver and oral cancers. In 2003, Laserphyrin was approved in 
Japan for the treatment of lung cancer [116]. This PS does not cause the dark toxicity observed 
with Foscan. Contrary to Photofrin or Foscan, PS administration and light irradiation can be 
performed on the same day. 
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1.4.5 Aluminum PhthalocyanineTetrasulfonate (AlPcS4, Photosens) 
 
Aluminum phthalocyaninetetrasulfonate, AlPcS4 (commercial name Photosens), is a 
specific phthalocyanine derivative which can be activated with light at 676 nm. This PS has 
been approved in Russia for the treatment of stomach, skin, lip, oral and breast cancers [53]. 
However, like Photofrin, Photosens produces high skin photosensitivity for several weeks 
post-administration. 
 
1.5 Cellular steps involved in the efficiency of a photosensitizer 
 
Because of short lifetime and limited migration of 1O2  from the site of its formation, sites of damage are 
closely related to the localization of the PS… 
 
When a biological system is treated with a PS, a number of steps must take place before 
the irradiation step. The different biological models used to determine the effectiveness of a 
PS are described in the next section. In this section the steps occurring from PS administration 
until induction of phototoxicity are described. The PS must be specifically accumulated in the 
target tissue, internalized into the cancer cell, accumulated in subcellular compartments and 
then photo-activated to trigger oxidative stress-induced cell death (Figure 1.8). All of these 
steps have a great effect on the effectiveness of the therapy. However, predicting them all is a 
difficult task. In fact, studies have demonstrated that some hydrophilic PSs induce damage in 
tumor vasculature and block the supply of molecular oxygen and essential nutrients, 
compromising cancer cells in an indirect way [127-129]. This effect is due to the binding of 
hydrophilic PSs to serum albumin protein (a protein that mediates PS accumulation in vascular 
stroma) or to vascular structures/components (e.g. collagen). Other studies have demonstrated 
that hydrophobic PSs have a direct mechanism of action in the cancer cells. These PSs are 
transported inside the body by association with low density proteins, being targeted and 
accumulated in cancer intracellular sites [128, 130]. The studies at the in vivo biological level 
are rather complex and quite far from the molecular scale, since the in vivo PS intracellular 
localization is influenced by several factors, namely formation of complexes of systemically 
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injected PS with blood proteins. The reports available on the in vivo subcellular localization 
and cell death pathway of a certain PS are much more fragmentary than those for in vitro 
studies based on cultured cells. Herein, the steps involved in the efficiency of a PS based on in 
vitro cancer biological considerations at the molecular and cellular levels are discussed. 
 
Figure 1.8 Proposed steps that should occur before induction of cell death by PDT. 
 
1.5.1 PSs targeting cancer cells, uptake and subcellular localization 
 
Once the PS targets cancer cells by either a passive or active mechanism [131], it should 
be accumulated inside these cells. The mechanisms of PSs cellular uptake and subcellular 
localization are highly dependent on the degree of lipophilicity, type and number of neutral 
and charged peripheral groups and degree of asymmetry in the molecular structure of the PS 
[9-11, 132]. The cancer cellular uptake of the PSs can occur by diffusion (few cases) or 
endocytosis [9, 133]. The intracellular uptake of PSs is also regulated by the ATP-binding 
cassette transporter ABCG2, which belongs to the family of multi-drug resistant proteins 
involved in the protection of cells from exogenous and endogenous toxins through the efflux 
system [13, 134]. The ABCG2 membrane pump mediates the porphyrins efflux from cancer 
cells, which influence their uptake and further phototoxicity. 
Lipophilic compounds (characterized by high n-octanol/water partition coefficients) are 
able to bind and penetrate trough biological membranes [9]. On the other hand, hydrophilic 
PSs (containing polar or charged side chains) are too polar to cross biological membranes by 
diffusion and they are usually internalized by endocytosis [133]. The endocytosis of PSs can 
occur by caveolae and/or clathrin-dependent mechanisms [135, 136]. Unfortunately, scarce 
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information is available concerning the influence of the endocytic pathways on the uptake, 
subcellular localization and further phototoxicity of PSs.  
The subcellular localization of the PS within subcellular compartments is one of the 
most important factors in terms of the PDT outcome, even for PSs with preferential 
localization at the plasma membrane [12, 137]. Cationic PSs have a higher accumulation in the 
mitochondria than in the cytoplasm due to electrostatic interaction with mitochondria negative 
electrochemical transmembrane potential [60, 138]. However, cationic PSs are also able to 
form complexes with nucleic acids which can result on the induction of genotoxicity and 
mutagenicity after PDT [139]. In fact, none of the cationic PSs have been clinically approved. 
Non-cationic PSs such as pheophorbide a (a product of chlorophyll degradation) and a diaryl 
brominated porphyrin were shown to accumulate in the mitochondria [140, 141]. Anionic PSs 
and compounds containing weak base amines tend to be accumulated in lysosomes after their 
cancer cellular uptake by endocytosis [142-144]. The simultaneous administration of PSs with 
different intracellular localization has demonstrated to be a promising strategy to improve 
PDT efficiency when compared with conventional PDT treatments where a single PS is used 
[145, 146]. Kessel and Reiners have elegantly shown an enhancement in the photokilling of 
cells by using the chlorin NPe6 and Verteporfin into separately targeted lysosomes and 
mitochondria, respectively [146]. Interestingly, the approach was less effective when the 
sequence of PSs administration was reversed [146]. The PS can also be coupled with specific 
targeting moieties which allow their accumulation in specific organelles. For example, 
conjugation of PSs with monoclonal antibodies targeting epidermal growth factor receptors 
promotes their accumulation in the mitochondria [147]. Zhang et al. have developed a PS with 
specific accumulation in mitochondria by targeting the 18 kDa mitochondrial translocator 
protein [148]. An intracellular redistribution after light irradiation, has also been demonstrated 
in the case of PSs, with initial accumulation at membrane-delimited subcellular compartments 
[149, 150]. Membrane damage induced by ROS after PDT promotes the release of the PS 
from its initial organelle targets, which can influence the cell death response. Therefore, 
different irradiation protocols, namely continuous and fractionated irradiation, have been 
explored. 
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1.5.2 Mechanisms of cell death 
 
Activation of PSs with light at specific wavelengths (in the absorption spectrum of the 
photosensitizers) can evoke photochemical reactions with production of ROS, leading to 
cytodamage by oxidizing and degrading cell components [151]. If cell repair mechanisms fail, 
damaged cells undergo cell death by apoptosis, necrosis or by autophagy [65, 152-156]. 
Due to the limited lifetime of ROS generated after PDT, it is envisaged that the 
subcellular localization of the PS determines the targets of the primary damage. Considerable 
effort has been expended to design and develop PS that are able to target mitochondria and to 
identify the key molecular effectors regulating the cross-talk between apoptosis and 
necrosis/autophagy is an area deserving intense attention in cancer therapy. Due to the 
polarization and the presence of specific lipids and proteins in the inner and outer membranes 
of mitochondria, many PSs accumulate in this organelle, either as a consequence of their 
charge in the case of positively charged molecules, or their hydrophobicity, in the case of 
negatively charged molecules. The localization is influenced by the prevailing charge on 
porphyrinoid side chains, in which cationic or anionic characteristics show a tendency for 
mitochondrial and lysosomal distribution, respectively [157, 158]. It is well-established that 
PSs localized in mitochondria are able to induce apoptosis very rapidly. However, lysosomal 
localized PSs can elicit either a necrotic or an apoptotic response. In the plasma membrane, a 
target for various PSs, apoptosis and necrosis can be initiated. When PSs localize in the 
endoplasmic reticulum, an autophagic cell death response can be induced [159]. 
Moreover, most of the evidence of subcellular localization of PS is extrapolated from in 
vitro studies. Due to the existence of numerous cellular targets, it has been difficult to 
ascertain the key events in PDT-induced cell death. In vivo and in vitro results may differ 
because pharmacokinetics or effectiveness of the PS are affected by factors such as 
lipophilicity, serum binding, clearance [160, 161] and degree of stromal binding [162, 163]. 
Novel and more sensitive molecular and biochemical assays have provided important insights 
into cellular events occurring during and after photoactivation. The fact that cancer cells can 
die after PDT, through a number of different mechanisms [158, 164, 165], is an important hint 
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in the choice and design of anticancer PDT. Therefore, in order to combat a particular cancer it 
is important to know the level and mode of cell death.  
 
A. Apoptotic cell death in PDT 
Apoptosis is a complex, multi-step, multipathway process of cell death characterized by 
morphological hallmarks, such as: changes in the surface of plasma membrane, with 
appearance of blebs and consequent formation of the so-called apoptotic bodies, cell 
shrinkage, nuclear fragmentation, chromatin condensation and aggregation [165]. Two major 
apoptotic pathways have been characterized: the death receptor-mediated or extrinsic pathway 
and the mitochondria-mediated apoptosis or intrinsic pathway [166]. As regards the extrinsic 
apoptotic pathway, it is activated by death receptors, such as tumor necrosis factor receptor 1 
(TNFR1) or Fas/CD95. The intrinsic pathway requires the permeabilization of the outer 
mitochondrial membrane leading to the release of cytochrome c into the cytosol. After 
development of the mitochondrial transition pore, released cytochrome c binds apoptosis 
activating factor-1 (Apaf-1) which, in the presence of dATP, recruits and activates the initiator 
caspase-9 and the effector caspase cascade. Evidence suggests that in both two pathways 
occurs the activation of a family intracellular cysteine aspartyl proteases (caspases 8 and 9) 
leading to activation of executioner caspases, such as caspase-3, -6 and -7 [167, 168], which 
can then activate other effector molecules to digest cellular contents. In addition, the binding 
of BH3-only members of the B-cell lymphoma 2 (Bcl-2) family to and inhibiting the action of 
pro-survival proteins can promote an apoptotic response to PDT. Several studies reported 
changes in expression of members of Bcl-2 family proteins after PDT in various cancer cell 
lines and tumors. Kessel and Castelli reported that three different photosensitizers [tin 
etiopurpurin, 9-capronyloxy-tetrakis-porphyrin and tetrakis(m-hydroxyphenyl)chlorin] 
induced selective photodamage in Bcl-2, without affecting other proapoptotic proteins such as 
Bax [169]. Xue et al. also reported that the anti-apoptotic Bcl-2 decreased in a dose dependent 
manner after PDT with phthalocyanine 4 (Pc4, a silicon phthalocyanine bearing a 
dimethylaminopropylsiloxy ligand on the central silicon), indicating that this protein is highly 
sensitive to PDT and PDT damage to Bcl-2 contributed to its efficient induction of apoptosis 
[170]. Mfouo-Tynga et al. used a zinc phthalocyanine (ZnPcSmix) in PDT to determine the 
Chapter I. Introduction 
 
25 
 
induced cell death pathways in a breast cancer cell line (MCF-7). ZnPcSmix was found to 
localize in mitochondria and was efficient at inducing cytodamage after PDT, leading 
preferentially to apoptosis, as revealed by nuclear fragmentation, oligonucleosomal 
degradation and increased expression of Bcl-2, DNA fragmentation factor alpha (DFFA1) and 
caspase 2 (CASP2) genes [171]. Release of cytochrome c from mytochondria has been 
described to occur in PDT-induced apoptosis. PDT using several PSs (Pc4 and hypericin) 
resulted in release of cytochrome c to the cytosol [172, 173], with loss of the mitochondrial 
membrane potential. 
 
B. Necrotic cell death in PDT 
Necrosis has been described as a less orderly cell death event than is apoptosis. It is 
caused by external stimuli to the cell or tissue, such as infection, toxins or trauma [151, 174, 
175]. Necrosis is characterized morphologically by cytoplasm swelling, destruction of 
organelles and loss of cell membrane integrity accompanied by an uncontrolled release of 
cellular contents into the extracellular space and consequent inflammation [176]. 
Photodynamic therapy mediated by phthalocyanine- and chlorin-based PSs has shown to 
induce cell death by necrosis in vitro and in vivo studies. After photoactivation, liposomal 
aluminum chloro-phthalocyanine was shown to induce 90% necrotic cell death on oral cancer 
and tumoral vascular shutdown [177]. A Chl-based photosensititizer, TMMC, was found to 
accumulate in cytoplasm and nuclear membranes and, after PDT, an evident increase in 
necrotic cell death, as well as reduction of growth of Eca-109 tumors in nude mice were 
observed [178]. 
Two critical factors in determining cellular necrosis following PDT are PS accumulation 
in cell and conditions of PDT. Nagata et al. reported that using an amphiphilic iminochlorin 
aspartic acid derivative ATX-S10(Na)and human malignant melanoma cells, higher 
phototoxicity is obtained with higher dye and/or laser doses [179]. Lysosomes were the 
primary site of ATXS10(Na) accumulation and after PDT, cells showed changes in 
mitochondrial transmembrane potential. When induced less than 70% cytotoxicity, most of the 
dead cells were apoptotic. However, when cytotoxicity was higher (99%), most of the dead 
cells were necrotic. Thus, it is possible that PDT directly damaged lysosomes, leading to 
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inactivation of enzymes and other factors such as the caspases, executing apoptosis and 
releasing a large number of proteases into cytosol, thereby inducing necrosis of target cells 
[179]. Other studies revealed that after irradiation, Zn(II) phthalocyanines (pyridinium Zn(II), 
tetrasulfonated Zn(II) and tetradiethanolamine Zn(II) phthalocyanines) can undergo 
relocalization to different organelles within the cell in a charge dependent manner and that the 
secondary sites are more important in producing cell killing during PDT compared to primary 
sites of PSs localization [180]. 
 
C. Autophagic cell death in PDT 
Autophagy is morphologically characterized by large-scale autophagic vacuolization of 
the cytoplasm. During the process of autophagy, a double-membrane known as an 
autophagosome surrounds the targeted cytoplasmic constituents, creating a vesicle that 
separates its content from the rest of the cell. The autophagosome fuses with a lysosome 
(forming the autophagolysosome) and the contents are degraded and recycled. Autophagy is 
generally thought as a survival mechanism when cells are exposed to stress. However, in some 
cases, it appears to promote cell death. Autophagic cell death is a process that is associated 
with autophagosomes and autolysosomes [181]. Many autophagy-related genes (Atg) and 
proteins that have been identified in autophagosomal assemblage and molecular degradation 
[151]are damaged by PDT induced ROS [182, 183]. PDT with phthalocyanines that localize in 
the endoplasmic reticulum and mitochondria affects mammalian target of rapamycin (mTor; a 
cell growth regulator that takes part in the autophagic signaling pathway) and Beclin-1 (a pro-
autophagic protein) function [184]. 
Depending on the oxidative damage, PDT may induce autophagy [185] that can work as 
cytoprotective or cell death mechanism [158, 186]. Although autophagy and apoptosis may 
occur independently, it is possible that there exist molecular switches between these two cell 
death pathways. In agreement with this hypothesis, there is a study showing that PDT with a 
porphycene PS in mouse leukemia L1210 cells induces a rapid wave of autophagy, presumed 
to represent the recycling of some damaged organelles, followed by apoptosis [187]. Attempts 
at extensive recycling of damaged organelles by autophagy seem to be associated with 
apoptosis. However, PDT efficacy is not affected when cancer cells cannot undergo apoptosis 
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through Bax knockdown with shRNA or pharmacological inactivation of Bcl-2 function. Loss 
of cell viability was associated with a highly-vacuolated morphology consistent with 
autophagic cell death [187]. 
 
1.6 Biological models used to determine the efficiency of a photosensitizer 
 
 The most suitable in vitro and in vivo biological models should be used to evaluate the PDT efficacy of a 
new PS. 
 
1.6.1 In vitro models 
 
In vitro models, including conventional two-dimensional monolayer cell culture 
systems, have been extensively used to determine the efficacy of a PS [77, 188, 189]. 
However, monolayer cultures are too simple to replicate the several heterogeneous treatment 
effects found in vivo. Three-dimensional spheroid cultures characterized by cells in suspension 
growing in clumps have advantages when compared with monolayer cultures, since they 
mimic cell-cell and cell-matrix interactions (Figure 1.9) [190]. However, studies with 
spheroids are less easy to perform and not all cell lines are able to aggregate and form 
spheroids. When compared with in vivo biological models, these cultures do not mimic 
vascularization and tumor heterogeneity [191]. Nevertheless, properties found in tumors such 
as oxygen, pH and nutrient gradients are present in spheroids. As PDT is an oxygen-dependent 
therapy, the oxygen gradients found in spheroids (a decrease in oxygen partial pressure from 
the periphery towards the center of spheroid) make them an interesting approach for research 
in the field of PDT.  
 
Figure 1.9 Monolayer and spheroid cancer cell cultures in vitro biological models for cancer PDT studies. 
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Bigelow et al. have demonstrated that in spheroids, the well-oxygenated cells in the 
outer layer are more sensitive to PDT than cells in the inner layers [192]. Interestingly, the 
surviving cells are able to form a new generation of spheroids with high sensitivity to repeated 
PDT. Yang et al. have developed an in vitro three-dimensional model in a microfluid culture 
system with human breast cancer cells and primary adipose-derived stromal cells to mimic 
tumor heterogeneity [193]. In addition, the system allowed real-time imaging of tissue 
development, light penetration for PDT and dynamic flow of the medium and PS.  
 
1.6.2 In vivo models 
 
The choice of the most appropriate in vivo biological model for PDT studies requires 
knowledge about its biological features. Before evaluating anticancer efficacy of a new PS 
using in vivo models, the properties of the PS should be assayed in vitro. Additionally, the 
pharmacological properties of the PS can be determined a priori by administration of the PS 
(through different routes) to non-tumor bearing mice. In addition, the photodynamic efficacy 
of a certain PS can be determined using in vivo models such as chorioallantoic membrane 
(CAM) [194, 195], subcutaneous syngeneic mouse and rat tumors [129, 196, 197], human 
xenograft tumors [112],orthotopic syngeneic mouse and rat tumors and orthotopic xenografts 
[198, 199], autochthonous tumors [200-203], and genetically-engineered mouse models 
(Figure 1.10) [204, 205]. 
 
Figure 1.10 Chorioallantoic membrane (CAM) and mice in vivo biological models for cancer PDT studies. 
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The CAM model is based on a fertilized chicken egg in which CAM is exposed by 
cutting a window through the eggshell. A suspension of cancer cells can be applied onto the 
surface of the membrane and under specific conditions they are able to turn into "tumors" 
developing their own blood supply by angiogenesis. The process of angiogenesis in this model 
occurs in a similar fashion to real tumors in mice, making it a suitable approach for the study 
of vascular damage in cancer with PDT [194, 195]. The PS can be administered into the blood 
vessels or it can be topically applied to the xenografted tumors on the CAM and then tumors 
can easily be irradiated with light. This model allows in vivo real-time microscopy to follow 
changes on blood flow in normal and tumor vessels. 
The most common in vivo approach used in PDT experiments is based on subcutaneous 
tumors in laboratory mice. The syngeneic mouse tumor approach is often used because the 
mice have intact immune systems, allowing the study of the effect of PDT on the anti-tumor 
immune response. There are several mouse tumor cell lines available for the induction of 
subcutaneous syngeneic models which differ in the type of tissue or organ that originated the 
tumor and also on the syngeneic inbred mouse strain that the tumors belong to. In addition to 
murine tumor cell lines, there are also rat tumor cell lines, but they are less common. In some 
situations, the cells can be injected with an extracellular matrix, named Matrigel. Nevertheless, 
it is necessary to point out that the use of Matrigel alters the response of the developed tumors 
to PDT [129]. The administration of PS in subcutaneous mouse tumors is normally performed 
intravenously in the tail vein. The injection of PS into the abdominal cavity (intraperitoneal) 
[196] or directly into the tumor (intratumoral) [197] is less frequent. After PDT, a 
circumscribed black eschar can be observed if tissue response to damage elicits a cancer 
vascular response. When PDT effects are induced at the cancer cellular level, tumor volume 
shrinkage is generally observed. The use of syngeneic mouse models on the photodynamic 
evaluation of new PSs is limited by the number of available tumor types and the rapid growth 
of the tumor. Additionally, PSs action can have different features in murine tumors when 
compared to those derived from humans. 
Human xenograft tumors can be obtained by engraftment of human tumor cells into 
athymic nude mice or into severe combined immunodeficient mice that are T- and B-cell 
deficient. The mechanism of action of a certain PS in this model is more closed to solid human 
Chapter I. Introduction 
 
30 
 
tumors, when compared with subcutaneous syngeneic mouse and rat tumors. In the human 
xenograft tumor model, several tumor types are available, since patient explants and cell-line 
derived models have been reported for all major histological samples of tumors. Additionally, 
therapeutic or genetic manipulation can be performed ex vivo on cells before 
xenotransplantation. For example, mouse xenograft models bearing luciferase-expressing 
cancer cells have been established to monitor PDT efficacy with non-invasive 
bioluminescence imaging [206]. Several human cancer cell lines grown as xenograft tumors in 
a subcutaneous location, in either nude or severe combined immunodeficient mice, have been 
subjected to PDT [207, 208]. The disadvantages associated with this model are the facts that 
blood supply and neovascularization are provided by the host mice and the tumors are 
developed in murine stroma in an artificial tissue compartment (subcutaneous site). 
Considering the disadvantages of human xenograft tumors, orthotopic models have been 
developed by injecting the cancer cells into the tissue of the organ of origin. The blood vessels 
developed to supply the tumor and the propensity to spontaneously metastasize are very 
different in orthotopic models [198, 199]. Chen et al. have compared the PDT efficacy of 
Verteporfin in orthotopic (in the prostate) and subcutaneous tumor models [199]. They 
showed that the uptake of the PS is highly different in the two models. The uptake was higher 
in the orthotopic model than in the subcutaneous one at 15 minutes post-injection, and it 
became similar in the two models at 3 hours after administration. Light irradiation performed 
15 minutes after PS injection led to similar cancer vascular phototoxicity in the two models. 
When PDT was performed at 3 hours after injection of Verteporfin, there was induction of 
necrosis which was higher in the orthotopic when compared with subcutaneous model. A 
disadvantage of orthotopic models is the need for a surgical procedure in some organs, which 
can be technically difficult. Additionally, it is necessary to have a suitable light source to 
perform PDT in specific organs. 
Autochthonous tumors have been developed in laboratory for PDT studies by using 
specific chemical carcinogens, viruses and physical carcinogenic stimuli (e.g. UV radiation) 
[200-203]. These models include mice, rats and hamsters treated topically, intraperitoneally or 
orally with polycyclic aromatic hydrocarbons or reactive organic chemicals alone or in 
combination with known tumor promoters.  
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Genetically-engineered mouse models of cancer have been constructed to more closely 
mimic the development of human disease and have also been used in PDT studies [204, 205]. 
These models include transgenic, knockout, and knocking mouse models [209] and, in some 
of them, an additional application of a carcinogen needs to be used to initiate tumor 
development. 
 
1.7 Molecular targeted photosensitizers 
 
PSs are the key element in PDT. None of the existing PS can be seen as an ideal one. 
 
A selective phototoxicity is highly dependent on the specific accumulation of the PS in 
the target tissue if compared to normal cells. The majority of the PSs have low selectivity to 
the tumor tissue, with ratios of 2-5:1 in tumors vs. normal tissues, resulting in undesired 
phototoxic side effects [210]. In order to achieve maximum concentration of the PS in the 
cancer cells, it can be conjugated with a biomolecule with selectivity for structural features 
overexpressed in cancer cells [211]. Additionally, it is important to define the most 
appropriate time interval between the administration of the PS and the start of light irradiation, 
so that the concentration ratio between tumor and normal tissues is maximized [60]. The 
fluorescent properties of the PSs can be used to monitor its accumulation in the tumor [210]. 
PSs have been conjugated with sugars [14, 15, 41, 76, 78, 212, 213], serum albumins 
[189, 214], low density lipoproteins [215, 216] and epidermal growth factor [131, 217], since 
tumors exhibit higher glycolysis rates, higher serum albumin turnover, and overexpress low 
density lipoproteins and epidermal growth factor receptors when compared to normal cells. In 
addition, PSs have been also conjugated with antibodies, antibody fragments, peptide ligands, 
proteins and non-protein ligands (e.g. folic acid) [189, 218-222]. Another strategy is PSs with 
pH-dependent distributions, which induce high photodynamic activity in response to acidic pH 
of cancer cells [77, 223]. As glutathione levels are higher in cancer cells than in normal cells, 
glutathione-activated PSs have been also proposed [224]. 
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1.7.1 Galactose binding proteins as targets of galactose-conjugated photosensitizers 
 
Lectins are proteins able to bind carbohydrates attached to proteins and lipids 
(glycoconjugates) present on cell surface and extracellular matrix. Amongst lectins, galectins 
(Figure 1.11) are well-known by their ability to recognize β-galactose as well as by their 
consensus amino-acid sequences [225]. Therefore, the biocompatibility of galactose and their 
specific recognition by galectins have led to the development of promising galactose-
conjugated porphyrinoids as potential molecular targeted PSs [14, 15, 226]. 
Galectins are small soluble proteins (molecular weight 14-35 kDa) with carbohydrate-
recognition domains (CRDs), which are responsible for the specific and individual binding of 
each galectin to carbohydrates [227]. To date, 15 galectins have been identified in mammals. 
Galectins are divided into three main family members, prototypical galectins, tandem-repeat-
type galectins and chimaera-type galectin-3 (Figure 1.11) [228]. Prototypical galectins have 
one CRD (galectin-1, -2, -5, -7, -10, -11, -13, -14 and -15), tandem-repeat-type galectins 
contain two homologous CRDs in a single polypeptide chain connected by a linker (galectin-4, 
-6, -8, -9 and -12), and galectin-3 has a non lectin N-terminal region (composed of unusual 
tandem repeats of proline- and glycine-rich short stretches) connected to a CRD.  
Considering the carbohydrate-binding activities of galectins, they can be bivalent or 
multivalent. Prototypical galectins (one-CRD) exist as monomers (galectin-5, -7 and -10) or 
homodimers (galectin-1, -2, -11, -13, -14 and -15), tandem-repeat-type galectins (two-CRD) 
are inherently bivalent (contain two distinct CRDs in tandem connected by a linker). 
Therefore, the binding of galectins with multivalent carbohydrates results on the formation of 
ordered arrays (galectin-glycan lattices) [229, 230]. 
Galectins exhibit dual localization, being found in both the intracellular (nucleus and 
cytoplasm) and the extracellular (cell surface and medium) compartments [228]. 
Intracellularly, galectins are involved in fundamental processes [231] such as pre-mRNA 
(precursor messenger ribonucleic acid) splicing and the regulation of intracellular signalling 
pathways (e.g. mitosis, apoptosis and cell-cycle progression) after binding intracellular ligands 
(Figure 1.12). 
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Figure 1.11 Three main family members of galectin (a: prototypical galectins, b: chimaera-type galectin-3 and c: 
tandem-repeat-type galectins) and the lattices formed by galectins after binding multivalent glycoconjugates. 
CRD = Carbohydrate recognition domain. Adapted from Ref. [228].  
 
Interestingly, these proteins do not have a classical signal sequence, which is necessary 
for protein secretion through the classical secretory pathway (endoplasmic reticulum/Golgi 
pathway). Nevertheless, under specific conditions, they are secreted by the cells (involving an 
unusual mechanism of externalization) and these galectins can exert functions outside cells 
[228, 232, 233]. Extracellularly, the function of galectins includes the binding to 
carbohydrates on and around cells, and carbohydrate-mediated endocytosis (in a carbohydrate-
dependent manner). Additionally, galectins are also involved in cell-cell adhesion and cell-
matrix-adhesion biological processes. 
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Figure 1.12 The biological functions of galectins outside cells (interaction with cell-surface glycoconjugates, 
cell-cell and cell-matrix interaction) and inside cells (intracellular functions in regulating metabolism). Adapted 
from Ref. [228]. 
 
Some galectins are widely distributed in different tissues, while others exhibit high 
tissue-specific patterns of distribution. The expression of galectins is modulated during the 
development of tissues and organisms and it is altered under several pathological and 
physiological conditions [234]. Of particular interest is the altered expression of galectins in 
cancer cells when compared with their normal counterparts [235-238]. Studies have indicated 
that altered expression of galectins is correlated with the progression and aggressiveness of the 
tumor, implying the influence of these proteins during tumor development [239]. 
Depending on the cell type, cell differentiation state, cell metastatic potential, cell 
oncogene expression, and cell anatomical growth site [240], the expression of galectins can be 
upregulated or downregulated in cancer cells. The expression of galectin-1 and galectin-3 is 
heightened in several tumors including melanomas, astrocytomas, bladder, osteosarcoma and 
ovarian tumors and their expression is normally correlated with the aggressiveness of the 
disease and the metastatic potential [238, 241, 242]. Additionally, these galectins have 
important roles in tumor progression [17, 243]. In the fight against cancer using PDT, both 
galectin-1 and galectin-3 are interesting molecular targets for the development on new PSs. 
Galectin-1 was the first protein discovered in the family of galectins and it is classified 
as S-type lectin [244, 245], since it requires reducing conditions to maintain its activities (S 
stands for sulphydryl or thiol). The crystal structure of this protein is composed by a six-
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stranded and a five-stranded β-sheet in an antiparallel arrangement [246]. In solution, galectin-
1 is able to form homodimers and there is evidence for the extracellular and intracellular 
presence of this protein [228, 231, 233]. The overexpression of galectin-1 has been described 
for several tumor types [247] and it has been associated with low prognosis and high 
metastatic potential [238]. The galectin-1 expressed by cancer cells is involved in tumor 
growth, tumor progression and metastasis, as a result of its participation in a variety of 
biological processes. Galectin protein regulates cell migration, cell adhesion and angiogenesis, 
and suppresses the anti-tumor immune response [238, 248]. The protein galectin-1 is also an 
interesting target for anti-angiogenic therapy [249, 250] due to its overexpression on tumor 
vasculature. 
Galectin-3 is a 31 kDa protein and it is the only member of the galectin family with an 
extended N-terminal region containing a tandem repeats of short amino-acid segments 
connected to a C-terminal CRD. The crystal structure of this protein is similar to the galectin-1 
[251]. Unlike galectin-1, galectin-3 can exist in monomeric form in solution [252]. Besides 
being a cytosolic protein, galectin-3 is able to cross the intracellular and plasma membranes to 
reach the nucleus [253] and mitochondria or to get externalized. Galectin-3 is overexpressed in 
a variety of human cancer cells and the expression level correlates with the stage of tumor 
progression, invasiveness and metastatic potential [238]. 
 
1.7.2 Conjugation of Porphyrins, Chlorins and Phthalocyanines with galactose and 
dendritic units of galactose 
 
The conjugation of galactose targeting moieties with a porphyrinoid is a valuable way to 
achieve a high local concentration of PSs in tumor tissues, due to the overexpression of 
galactose-binding proteins (i.e. galectin-1 and galectin-3) in cancer tissues [254]. Another 
advantage of galactose-conjugation is the possibility of tuning the PS macrocycle 
amphiphilicity [255]. The exact interaction mechanism of galactose-PS conjugates with cancer 
cells is still unknown. However, it is expected that the specific (non-covalent) binding of 
carbohydrates with galectins [19, 24, 254, 256] increases the accumulation of the conjugate 
around cancer cells. As PSs conjugated with carbohydrates are too large to be accumulated 
Chapter I. Introduction 
 
36 
 
inside cancer cells by sugar transporters, it is envisaged that their uptake is mediated by 
diffusion or endocytosis. 
Amongst galactosylated porphyrinoid derivatives, meso-substitued aryl porphyrins 
(Figure 1.13) have received great attention. Most of these meso-substituted porphyrins have 
symmetrical phenyl groups at the meso-positions (i.e. position-5, 10, 15 and 20) of the 
macrocycle. In these porphyrins, the carbohydrate substituents have been introduced at ortho-, 
meta- or para-positions of the phenyl groups. The meso-substituted galactosylated porphyrins 
are mainly obtained by total synthesis strategies (starting from pyrroles) and using procedures 
already described for porphyrin conjugated with glucose units. In this context, the protected or 
unprotected sugar can be used in the synthesis of meso-galactose-conjugated PSs. The use of 
protected sugars enhances the reproducibility of the reaction yields and it is helpful in the 
isolation and characterization of the products by chromatography and nuclear magnetic 
resonance (NMR) spectroscopy, respectively. In general, deprotection can be easily and 
selectively achieved by removing the protecting groups in the presence of other functional 
groups, leading to the desired galactose-porphyrins with the sugar moiety bearing free 
hydroxyl groups [76]. 
Most biological studies using galactose-conjugated PSs involve conjugates containing 
unprotected sugars to allow sugar interaction with CRD present at galactose-binding proteins. 
Nevertheless Vedachalam et al. have reported that conjugates containing galactose residues 
protected by isopropylidene groups have improved metabolic stability and facilitated cancer 
cells internalization [20]. It was suggested that the isopropylidene groups in these conjugates 
are cleaved in the acidic medium within cancer cells, being accumulated intracellularly in the 
lysosomes of cancer cells and able to induce caspase-dependent apoptotic pathway after PDT. 
The ability of porphyrin conjugated with protected galactose moieties to enter cancer cells was 
not observed by Chen et al. in studies with acetal-protected porphyrin conjugates [212].  
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Figure 1.13 Chemical structure of meso-substituted aryl porphyrins. 
 
Additionally, Mori et al. reported that acetal-protected galactose-conjugated Pc induced 
dark toxicity in human fibrosarcoma cells [257]. In some cases, deprotection of galactose 
sugar is not enough to achieve solubility in aqueous solution and in vitro studies are performed 
with the compounds prepared in liposomal suspensions  [27]. Gomes et al. have reported that 
liposomal suspensions of Chl conjugated with one glucose or fructose molecule have no 
cancer cell selectivity, exhibiting phototoxicity in both cervical cancer cells and keratinocytes 
[27]. In spite of the similar intracellular distribution pattern of liposomal suspensions of 
galactose-Chl conjugate in both cancer and non-cancerous cell lines, the conjugate was able to 
induce selective phototoxicity in cancer cells. Choi et al. have also reported difficulties on the 
removal of the isopropylidene protecting groups of Pcs conjugated with galactose molecules 
[29]. Therefore, in vitro assays in colon adenocarcinoma cells were performed using 
conjugates in Cremophor EL emulsions. Lee et al. have also reported the use of Cremophor 
EL emulsions to perform in vitro studies in human hepatocellular carcinoma cells with Pcs 
containing one or two acetal-protected galactose substituent(s) [25]. 
Laville et al. have described the synthesis of galactosylated porphyrins containing 
diethylene glycol as linker [132]. In vitro studies in human retinoblastoma cells Y79 (a cell 
line containing β-galactose receptors) [258] demonstrated that lipophilic galactose-porphyrins 
have low accumulation inside cancer cells. In contrast, amphiphilic galactosylated porphyrins 
have high uptake. Additional studies in a melanoma cell line (B16) overexpressing β-galactose 
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receptors and in an adenocarcinoma colon cell line (HT29), which do not express these 
receptors in high levels, demonstrated that the uptake of galactose-conjugated porphyrins was 
independent on the cell line. Nevertheless, a decrease on the uptake of the compounds was 
detected when the cells were pre-incubated with glucose or glycosylated albumin suggesting 
that glucose-binding receptors can also contribute for the uptake of the galactosylated 
porphyrins. In fact, other studies have demonstrated that depending on the cell line, the uptake 
of a galactodendritic Pc is dependent on both galactose-binding protein (galectin-1) and 
GLUT1 [41]. The involvement of glucose-binding receptors on the uptake of galactose-PSs 
can be explained by the fact that galactose is a C4 epimer of glucose and the hydroxyl groups 
in C1, C3 and C4 positions of galactose are involved in hydrogen bonds with GLUT1 [259]. 
Most studies with galactose-PSs are related to their synthesis and photobiological 
properties (uptake, toxicity in darkness and after PDT). Only a few studies have been 
performed to assess the interaction of galactose-PSs with galactose-binding proteins. Li et al. 
have studied the ability of benzochlorin-galactose conjugates to bind galectin-1 protein [24]. 
Enzyme-linked immunosorbent assays (ELISA) have indicated that benzochlorin-galactose 
exhibits higher ability to bind galectin-1 when compared with benzochlorin-glucose conjugate 
or the non-conjugated benzochlorin. The interaction of the non-conjugated benzochlorin with 
galectin-1 was explained by hydrophobic interactions between the well-conserved 
hydrophobic core of the protein [260] and the porphyrinoid macrocycle. In fact, D´Auria et al. 
have demonstrated by spectrometric assays that non-galactose-conjugated porphyrinoids are 
able to bind galectin-1 protein [256]. Additionally, molecular modeling studies have 
demonstrated that the Chl macrocycle does not interfere in the binding of galactose with the 
galactose binding site of galectin-1, since it is far from this site in the protein [19]. 
Another interesting characteristic of galactose-PSs is that they prevent the efflux of the 
PS by the ABCG2 membrane pump [261]. Zheng et al. have tested the in vitro efficacy of 
galactose-PSs using murine radiation-induced fibrosarcoma and colon carcinoma cell lines, 
which express both galectin-1 and galectin-3 in similar levels and ABCG2 in different levels 
[261]. The uptake of non-conjugated PS was low in murine radiation-induced fibrosarcoma 
cells containing high levels of ABCG2, suggesting that the non-conjugated PS is a substrate 
for the ABCG2 transporter [23, 261]. On the other hand, the galactose-conjugated PS was not 
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a substrate for ABCG2 transporter and its accumulation in cancer cells was not affected by the 
tyrosine kinase inhibitor imatinib mesylate (an inhibitor of the ATP-dependent transport of 
ABCG2) [23, 261]. Additionally, the conjugation of porphyrinoid with galactose also changed 
its localization from mitochondria to lysosomes [261]. In vivo studies revealed that in spite of 
the lower uptake of galactose-conjugated PS in tumors when compared with non-conjugated 
PS, the conjugate exhibited high photodynamic efficacy in the tumors. The reduced 
accumulation of the galactose-PS in the tumors was due to its predominant localization in the 
liver, probably due to clearance through galactose receptor system on hepatic cells. The ability 
of galactose-conjugated PSs to be accumulated in the liver has prompted their use as in vivo 
probes for diagnosis of liver cancer [22]. 
The uptake of galactose-PSs inside cancer cells is dependent not only on the presence of 
galactose-binding proteins on the cells, but also on the balance between hydrophobicity and 
hydrophylicity [18, 21, 26, 28]. Hao et al. have demonstrated that a hydrophobic galactose-
tetrabenzoporphyrin has higher accumulation in carcinoma HEp2 cells than the corresponding 
galactose-tetraphenylporphyrin [26]. In addition, an increase in the number of galactose 
molecules conjugated with tetraphenylporphyrin led to a decrease on the uptake and different 
subcellular localization. The most hydrophobic porphyrin (tetraphenylporphyrin conjugated 
with one molecule of galactose) was accumulated mainly on the endoplasmatic reticulum and 
endosomes, while a porphyrin conjugated with four molecules of galactose was found in the 
lysosomes. The authors did not report the ability of the galactose-porphyrins to induce 
phototoxicity upon light irradiation. Nevertheless, it is envisaged that the different subcellular 
localization of the compounds will influence the phototoxicity [33, 132]. The role of 
hydrophobicity on the uptake of galactose-conjugates was not observed by Fujimoto et al[28]. 
In these studies, the amide-linked octa(galactose) derivative of tetraphenylporphyrin exhibited 
higher specificity for liver cancer cells (containing receptors for galactose residues) when 
compared with the corresponding octa(glucose) conjugate. It was envisaged that these 
hydrophilic PSs have remarkable saccharide specificity which masked the non-specific 
hydrophobic interactions of the PS core with cancer cells. Hirohara et al. have demonstrated 
that the insertion of zinc in the core of porphyrin macrocycle and the position of sugar 
conjugation affects the uptake of galactose-conjugated porphyrins, by altering the shape of the 
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conjugates in water [33]. The meta-substituted free base galactose-porphyrin showed lower 
uptake when compared with para-substituted free base compound and higher uptake than the 
corresponding zinc compound. Interestingly, deprotection of para-substituted zinc compound 
led to the precipitation of the conjugate in cancer cells. 
The specificity of galactose-conjugated PSs for cancer cells has been studied by in vitro 
studies: (1) compare the efficiency of the conjugates with the correspondent non-conjugated 
PS, commercially available PS and other glycoconjugated PSs [21, 28, 31, 33-35, 38, 41, 132, 
212]; (2) using both cancer and non-cancerous cell lines [27] and (3) were performed in cell 
lines containing high and low levels of galactose-binding proteins [41, 132, 261]. 
Additionally, the efficiency of the galactose-conjugates has been validated using in vivo 
biological models [35, 261-263]. Overall, galactose-conjugation improves the selectivity and 
photo-efficacy of the PS. It should be pointed out that in vitro efficacy of galactose-conjugated 
PSs is not always correlated with in vivo efficacy [35]. 
The galactose sugar has been covalently conjugated with porphyrinoids via N-, S-, C- 
and O- galactosylation (Figure 1.14) [14, 21, 28, 30, 36, 39, 132]. Carbon-carbon bonds are 
expected to be chemically and metabolically robust and they retain the angles and 
conformations found in the O-glycoside linkage [30]. Nevertheless, C-galactosylated 
compounds have not been studied for cancer PDT. O- and S-galactose-conjugated 
porphyrinoids have been compared in terms of enzymatic hydrolysis of the glycoside bond by 
glycosidases, metabolism upon incubation with cancer cells and solubility in water [21, 36, 
132]. Mass spectrometry studies of cancer cellular extracts have indicated that O-galactose-
conjugated porphyrins undergo metabolic degradation, probably due to the ability of 
endogenous glycosidases to cleave the glycoside bonds [132]. In addition to metabolic 
stability, anomerically tetragalactosylated S-galactose Pc exhibits higher water solubility when 
compared with O-galactose conjugate [36]. These differences in water solubility were not 
observed for the corresponding octagalactosylated conjugates, and these compounds exhibited 
higher water solubility when compared with the tetragalactosylated conjugates [36]. 
Interestingly, Iqbal et al. have reported that replacement of the oxygen with sulfur in the non-
peripherally tetra-galactose-conjugated Pc resulted in a red shift in the absorption spectra of 
the conjugate [39]. The linker/spacer separating the sugar from the porphyrinoid macrocycle 
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has also a key role in photodynamic efficiency of galactose-conjugated porphyrinoid [40, 42, 
76, 132]. Lafont et al. have compared the photodynamic efficiency of galactose-conjugated 
Pcs obtained by the classical galactosylation grafting or by click conjugation [40]. 
Interestingly, the triazole linkage formed by click conjugation had a negative effect on the 
uptake and further phototoxicity of the compounds in HT-29 human colon adenocarcinoma 
cells. 
 
Figure 1.14 Representation of galactose-conjugated porphyrinoids. Adapted from Ref. 12. 
 
The solubility of galactose-conjugated porphyrinoids has demonstrated to be higher than 
the corresponding non-conjugated PS [19]. Additionally, the solubility of the conjugates in 
aqueous solutions is highly dependent on the number, position and nature of the sugar 
substituents [36, 264]. Tetra-α-galactose substituted Pc exhibits less aggregation than tetra-α-
glucose substituted Pc[36]. Additionally, octagalactosylated Pc containing galactose 
anomerically attached to the Pc ring in the β-position has a lower water solubility than Pc 
conjugated with eight galactose molecules through the carbon-6 of the sugar. Contrary to the 
results reported by Lyubimtsev et al. describing the different lipophilicity of gluco- and 
galactose-conjugates [36], Zheng et al. have reported that porphyrinoid conjugated with 
galactose or glucose moieties have similar lipophilicity [261]. Mori et al. have described that 
fluorine atoms on galactose-Pcs have a key role on phototoxicity, since these groups 
contribute to the amphiphilic character of the conjugate [257]. Fluorescence microscopy 
studies have demonstrated that the uptake of tetra-beta galactose-conjugated Pc (formulated 
with Cremophor EL) is negligible in adenocarcinoma cells due to their aggregation in the 
culture media [29]. On the other hand, tetra-alpha galactose-conjugated Pc and the mono-
substituted conjugate demonstrated high fluorescence in the cytoplasm of cancer cells. The 
intracellular fluorescence intensity was higher for mono-conjugated than that for tetra-
conjugated Pc. The differences in the uptake were correlated with different photoxicity of the 
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compounds and they were in accordance with other studies reporting the higher efficiency of 
unsymmetrical tetrapyrrolic PSs when compared with symmetrical analogues [32, 132]. Lv et 
al. have suggested that the in vitro reduced water solubility of galactose-conjugated Pcs did 
not limit their application as fluorescent markers in vivo[22], due to the disaggregation 
phenomenon of glycosylated PSs by the organs or tissues. 
The conjugation of PSs with galactose molecules alters not only solubility and 
specificity of PS for cancer cells, but it also influences the fluorescence emission spectra of the 
conjugates [22]. The conjugation of zinc Pcs with galactose molecules induced red shifts on 
the emission spectra, which were dependent on the number of galactose substituents attached 
to the PS macrocycle. 
It is envisaged that PSs containing dendritic units of galactose [76] have even higher 
water solubility and ability to interact with galactose binding proteins [18, 265], since these 
units would benefit from the ability of galectins to establish multivalent interactions with 
dendritic units of the sugar. Therefore, it is expected that a porphyrinoid conjugated with 
dendritic units of galactose will bind to a higher number of galactose-binding proteins 
overexpressed in cancer cells, when compared with the corresponding porphyrinoid 
conjugated with monomers of galactose (Figure 1.15). Such an enhancement in the binding of 
a conjugate with galactose-binding proteins will increase the amount of the porphyrinoid 
around the cancer cell. Pereira et al. have described that a Pc conjugated with eight dendritic 
units of galactose have an improved water solubility, a greater efficiency in the generation of 
1O2 as well as high accumulation and larger phototoxicity in bladder cancer cells 
overexpressing galactose-binding proteins [41]. Additionally, it was demonstrated that the 
uptake and phototoxicity of the conjugate was reduced after knockdown of these proteins via 
small interfering RNA (siRNA). 
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Figure 1.15 Representation of a PS conjugated with monomers of galactose (left) and dendritic units of galactose 
(right) and their possible interaction with the galactose-binding protein (galectin-1). 
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1.8 Hypothesis and thesis structure 
 
PSs conjugated with galactose sugar have potential for the treatment of cancer by PDT. 
Cancer cells overexpress galectin-1, a galactose-binding protein that promotes the uptake of a 
galactose-PS. We hypothesize that galactodendritic-PSs (Chapter II) will have increased 
uptake by cancer cells. Dendritic units of galactose sugar will improve the uptake and further 
phototoxicity of a porphyrinoid (Chapters III-VI), due to their multivalent binding with 
galectin-1 protein in the surface of cancer cells. GLUT1 protein, a well-known glucose 
transporter overexpressed in cancer cells, can also have a role in the uptake of 
galactodendritic-PSs (Chapter III). Monolayers (Chapters III-VI) and spheroids (Chapter VII) 
of cancer cells containing different levels of GLUT1 and galectin-1 proteins are suitable in 
vitro biological models for studying phototoxicity of a galactose-PS, before in vivo validation 
(Chapters V and VI). 
We hypothesize that after accumulation of a galactodendritic-PS around cancer cell 
membranes, its internalization occurs through endocytic mechanisms (Chapter IV). The 
knowledge about the endocytic mechanisms by which a galactose-PS is accumulated inside 
cancer cells can help in the design of more effective PSs. Additionally, the resistance of cancer 
cells to PDT can be overcome by interfering with PS endocytic pathway (Chapter IV). 
The activation of an antioxidant response (Chapter III) or alterations in the cytoskeleton 
(Chapter V) after PDT, as well as the subcellular localization of PS before light irradiation 
(Chapter VI) can influence the phototoxicity of a galactodendritic-PS. We hypothesize that a 
repeated dose of light irradiation can decrease the resistance of cancer cells to PDT (Chapter 
VI).  
The high affinity of compounds conjugated with galactose through carbon-3 to galectin-
1 has been reported, however, this strategy has not been explored in the attachment of 
galactose to a porphyrinoid. We hypothesize that a porphyrin conjugated with galactose 
through carbon-3 will have increased uptake by cancer cells (Chapters II and VII).  
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1.9 Aims of the study 
 
The objectives of this thesis were: 
 
1. To synthesize new porphyrinoids with increased affinity for galactose-binding 
proteins overexpressed in cancer cells: 
1.1 conjugate a porphyrin, phthalocyanine and chlorin with dendritic units of galactose; 
 1.2 conjugate a porphyrin with galactose through carbon-3. 
 
2. To demonstrate the photodynamic efficacy of a new galactose-PS: 
3.1 use cancer cells growing as monolayers and spheroids and containing different levels 
of galactose-binding proteins; 
 3.2 use in vivo biological models. 
 
3. To improve the phototoxicity of a new galactose-PS in cancer cells resistant to 
therapy: 
2.1 interfere with the endocytic pathway by which the PS is accumulated inside cancer 
cells; 
 2.2 use a repeated PDT protocol. 
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Figure 1.16 Schematic representation of this PhD project. Synthesis of porphyrinoids conjugated with galactose 
through carbon-3 or with dendritic units of galactose, which will be recognized by galactose-binding proteins 
overexpressed in cancer cells. Select the most promising galactose-PSs, accounting their photo–chemical and –
physical characterization for in vitro, using monolayers and spheroids of cancer cell lines, and in vivo studies. 
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Chapter II Synthesis of galactose-conjugated photosensitizers 
 
2.1 General overview 
 
Porphyrins are well-known first generation PSs and they are the main compounds 
used in clinical and pre-clinical settings for the treatment of cancer by PDT. 
Phthalocyanines (Pcs) and chlorins (Chls) are second generation PSs, having strong 
absorption in the wavelength range between 650 and 850 nm, where tissue light penetration 
is rather high. Unsubstituted Pors, Pcs and Chls are highly insoluble in aqueous solvents. 
The conjugation of PSs with galactose units increases their water solubility [1-9] and 
provides the possibility for specific interaction of the resulting galactose-conjugate with 
galactose-binding proteins overexpressed in cancer cells. In this work, the following 
compounds were developed (Figure 2.1)1: 
PorGal8: a porphyrin conjugated with four dendritic units of galactose (a total of four 
galactose sugars); 
ChlGal8: a chlorin conjugated with four dendritic units of galactose (a total of four 
galactose sugars); 
PcGal16: a phthalocyanine conjugated with eight dendritic units of galactose (a total 
of eight galactose sugars); 
Por-C3-Gal4: a porphyrin conjugated with four galactose sugars through carbon-3; 
Por-C3-Gal4: a porphyrin conjugated with four galactose sugars through carbon-1. 
 
                                                          
1 The synthesis and characterization of protected PcGal16 were performed by Doctor Sandrina Silva, postdoc 
student, in the laboratory of Doctor João Tomé, Department of Chemistry – University of Aveiro, Aveiro, 
Portugal. Por-C3-Gal4 and Por-C1-Gal4 were synthesized and characterized by Doctor Dinesh Bhupathiraju 
(postdoc student) and Waqar Rizvi (PhD student) in the laboratory of Professor Charles Michael Drain, 
Department of Chemistry – Hunter College of CUNY, New York, United States. 
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Figure 2.1 Chemical structures of PorGal8, ChlGal8, PcGal16, Por-C3-Gal4 and Por-C1-Gal4. 
 
2.1.1 Methods 
 
The following experimental protocols (please see Methods and Materials chapter IX) 
were used to obtain the data presented in this chapter: 
 Synthesis of galactose-conjugates (9.1) 
 
2.1.2 Publication 
 
This chapter comprises the following publications: 
Sandrina Silva, Patrícia M. R. Pereira, Maria A. F. Faustino, João P. C. Tomé, José 
A. S. Cavaleiro, “Porphyrin and phthalocyanine glycodendritic conjugates: synthesis, 
photophysical and photochemical properties”, Chem. Commun., 2012, 48, 3608-3610. 
 
Patrícia M.R. Pereira, N. V. S. Dinesh K. Bhupathiraju, Waqar Rizvi, Rosa 
Fernandes, João P.C. Tomé, Charles M. Drain, Comparative studies of porphyrin C3-
galactose and porphyrin C1-galactose conjugates for enhanced photodynamic therapy, 
under final preparation.   
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2.2 Synthesis of galactodendritic porphyrin PorGal8, chlorin ChlGal8 and 
phthalocyanine PcGal16 
 
2.2.1 Rationale for the synthesis 
 
The rationale for the synthesis of PorGal8, ChlGal8 and PcGal16 was to improve the 
solubility and to increase the binding of porphyrinoids with galactose-binding proteins 
overexpressed in cancer cells. We have hypothesized that PSs coupled with 
galactodendritic units should be effective in targeting cancer cells, because galactose 
carbohydrates with a dendritic structure have increased affinity for galactose-binding 
proteins (namely galectin-1) [9-11]. 
 
2.2.2 Synthesis of galactodendritic unit 2 
 
The selected dendritic framework was 2,4,6-trichloro-1,3,5-triazine (TCT) because of 
its well-known selective reactivity concerning substitution of the chlorine atoms at different 
temperatures. 1,2:3,4-di-O-isopropylidene-α-D-galactopyranose was chosen as the 
carbohydrate moiety. The synthesis of galactodendritic unit 2 was carried out in two steps 
as depicted in Scheme 2.1. Di-nucleophilic substitution of TCT by the galactose moiety 
was carried out in dry toluene, in the presence of an excess of N,N-Diisopropylethylamine 
(DIPEA), providing di-galactotriazine 1 in 92% yield. Reaction of di-galactotriazine 1 
with 1,3-dimercaptopropane provided the galactodendritic unit 2 in 89% yield.  
 
Scheme 2.1 General demonstration of the synthesis of galactodendritic unit 2. i)DIPEA, toluene, 48 h, 92%; 
ii) HS(CH2)3SH, DIPEA, toluene, 80 ºC, 48 h, 89%. 
 
Di-galactotriazine 1 was easily identified by the resonances of carbohydrate units, 
and the double substitution was confirmed by two triazine carbon resonances at δ 171.9 and 
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172.6 ppm. 1H and 13C NMR of galactodendritic unit 2 show, additionally, the resonance 
of the mercaptopropane chain. 
 
2.2.3 Synthesis of galactodendritic porphyrinoids 
 
The synthesis of PorGal8 was achieved by reacting the commercially available 
platform, 5,10,15,20-tetrakis(2,3,4,5,6-pentafluorophenyl)porphyrin (TPPF20) with four 
equivalents of galactodendritic unit 2 (Scheme 2.2). 
 
Scheme 2.2 General demonstration of the synthesis of PorGal8. i)DIPEA, DMF, 50 ºC, N2, 24 h, 78%; (ii) 
TFA/H2O (9:1, v/v), 80%. 
 
1H, 19F and 13C NMR spectra of protected PorGal8 clearly illustrate the conjugation 
and the symmetry of PorGal8 structure. Accounting the ratio 1:1 between β-pyrrolic 
protons of Por and anomeric protons of carbohydrate, the tetra-substitution o the Por 
macrocycle is evident. The tetra-substitution of TPPF20 was further supported by 19F NMR 
data, showing the absence of the signals corresponding to the Por para fluorine atoms. 
PorGal8 shows two quartet signals at δ -157.4 and δ -160.2 ppm, corresponding to the meta 
and ortho fluorine atoms. Hydrolysis of the isopropylidene protective groups with a 
mixture of TFA/H2O (9:1, v:v) produced α/β mixtures of unprotected PorGal8. 
Unprotection of the isopropylidene groups was confirmed by the complete disappearance of 
the corresponding 1H and 13C resonances. For the anomeric mixture of unprotected 
PorGal8, 19F NMR spectra show two multiplets between δ -158.0 to δ -158.1 and δ -162.7 
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to δ -162.8 ppm corresponding to meta and ortho fluorine atoms. Besides the NMR data, all 
structures were further confirmed by HRMS mass spectrometry. 
 
The ChlF20 was synthesized as previously described in the literature, by using 1,3-
dipolar addition of TPPF20 with azomethine ylides [12, 13], and it was used as a core 
platform to synthesize the new galactodendritic chlorin (ChlGal8, Scheme 2.3). ChlGal8 
was obtained in 70% yield by reacting ChlF20 with four equivalents of the previously 
reported galactodendritic unit and it was characterized by 1H, 19F and 13C NMR 
spectroscopy and mass spectrometry. The tetra-substitution of the para fluorine atoms in 
ChlF20 by the galactodendritic unit was supported by 
19F NMR data, showing the absence 
of the signals corresponding to the Chl para fluorine atoms. Unprotection of the 
isopropylidene groups was confirmed by the complete disappearance of the corresponding 
1H resonances of the corresponding CH3 groups of the isopropylidenes. Besides the NMR 
data, all structures were further confirmed by HRMS mass spectrometry. 
 
Scheme 2.3 General demonstration of the synthesis of ChlGal4 and ChlGal8. i)DIPEA, DMF, 40 ºC, N2, 30 
h, 70%; (ii) TFA/H2O (9:1, v/v), 87% for ChlGal8 and 88% for ChlGal4. 
 
The synthesis and characterization of PcGal16 were performed by Doctor Sandrina 
Silva, postdoc student, in the laboratory of Doctor João Tomé, Department of Chemistry – 
Chapter II. Synthesis of galactose-conjugated photosensitizers 
 
80 
 
University of Aveiro, Aveiro, Portugal. Briefly, the synthesis of PcGal16 was achieved by 
reacting the commercially available platform, hexadecafluorophthalocyaninato zinc(II) 
(ZnPcF16) with eight equivalents of galactodendritic unit 2. Deprotection was then 
performed as aforementioned for PorGal8 and ChlGal8. 
 
2.3 Synthesis of porphyrin Por-C3-Gal4 and Por-C1-Gal4 
 
2.3.1 Rationale for the synthesis 
 
The rationale for the synthesis of Por-C3-Gal4 was to improve the solubility and to 
increase the binding of porphyrinoids with galectin-1 protein overexpressed in cancer cells. 
We have hypothesized that the conjugation of a PS with galactose through carbon-3 will 
increase the affinity of the PS to galectin-1 [14]. To validate the specificity of Por-C3-Gal4 
to galectin-1 protein, the same porphyrin was conjugated with galactose through carbon-1 
(Por-C1-Gal4). 
 
2.3.2 Synthesis of galactose porphyrinoids 
 
Por-C3-Gal4 and Por-C1-Gal4 were synthesized and characterized by Doctor Dinesh 
Bhupathiraju (postdoc student) and Waqar Rizvi (PhD student) in the laboratory of 
Professor Charles Michael Drain, Department of Chemistry – Hunter College of CUNY, 
New York, United States. Briefly, 3-azido-galactose-tetraacetate and a 5,10,15,20-
Tetrakis(4’-propargyloxyphenyl)-2H-porphyrin (synthesized from commercially available 
4’-propargyloxy benzaldehyde and pyrrole) four alkyne groups were synthesized as 
previously described in the literature [15, 16]. 1-azido-1-deoxy-β-D-
galactopyranosidetetraacetate was purchase from commercially available source. Porphyrin 
was then reacted with 3-azido-galactose-tetraacetate or with the commercially available 1-
azido-galactose-tetraacetate by copper catalysis (Scheme 2.4). Por-C3-Gal4 and Por-C1-
Gal4 were obtained after deprotection of galactose-acetate groups using sodium methoxide 
in methanol. Zn demetalation on porphyrins were carried out using TFA at room 
temperature 
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Scheme 2.4 General demonstration of the synthesis of Por-C1-Gal4 and Por-C3-Gal4. i) CuSO4, sodium 
ascorbate, Cu, THF/H2O, reflux, 24 h, 90% for C1 galactose and 85% for C3 galactose. ii) NaOMe/MeOH, 
CH2Cl2/MeOH, overnight, r.t., 90% for C1 galactose and 89% for C3 galactose. iii) TFA, r.t. 6h, 86%. 
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Chapter III Galactodendritic phthalocyanine targets carbohydrate 
binding proteins enhancing photodynamic therapy 
 
3.1 General overview 
 
The molecular mechanisms underlying PDT are not clearly understood. However, it has 
been described that the generation of ROS will trigger signalling pathways that ultimately 
destroy the targeted tissue. Cell death in PDT may occur by apoptotic and by non-apoptotic 
mechanisms (e.g. necrosis), or even by a combination of the two mechanisms [1]. 
Additionally, studies suggest that cell death pathway induced after PDT depends on the PS 
and its intracellular localization, the PDT dose and the cell metabolic potential (e.g. its 
intrinsic antioxidant capacity) [1]. To enhance the specific deliver/target of PSs in cancer cells, 
third generation PSs have been synthesized, by conjugating them with galactose sugar [2-12]. 
Due to their high ROS production and strong absorption in the wavelength range 
between 650 and 850 nm, where tissue light penetration is rather high, Pcs have been studied 
as PSs of excellence. Recently, we have reported the synthesis of a new Pc decorated with 
sixteen molecules of galactose (in a dendritic manner, PcGal16, Figure SI3.1). PcGal16 
demonstrated strong absorbance in the red spectral region (600-800 nm), fluorescence 
emission bands at 734 and 805 nm, solubility in a phosphate buffered saline (PBS) solution 
and interaction with human serum albumin (HSA)[12]. Additionally, PcGal16 demonstrated 
photostability and ability to generate ROS after photoactivation 
It is envisaged that the galactose sugar around Pc macrocycle will interact with galectins 
overexpressed in cancer cells (e.g. galectin-1 and galectin-3 [13]). Besides galectins, galactose 
carbohydrates can bind to GLUT1 (a well-known glucose transporter [14]). The 
steriospecificity of GLUT1 (recognizing both D-glucose and D-galactose) has been reported 
[14]. Galactose is a C4 epimer of glucose that can bind the glucose-binding site of GLUT1.  
The excellent photo-chemical and –physical properties of PcGal16 prompted us to 
validate its efficacy against two bladder cancer cell lines, HT-1376 and UM-UC-3 (Figure 
3.1). In this section, we define the role of galactodendritic units in promoting the uptake of a 
Pc through interaction with GLUT1 and galectin-1. The photoactivation of PcGal16 induces 
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cell death by generating oxidative stress. Although PDT with PcGal16 induces an increase on 
the activity of antioxidant enzymes immediately after PDT, bladder cancer cells are unable to 
recover from the PDT-induced damage effects for at least 72 h after treatment. PcGal16 co-
localization with galectin-1 and GLUT1 and/or generation of oxidative stress after PcGal16 
photoactivation induces changes in the levels of these proteins. Knockdown of galectin-1 and 
GLUT1, via siRNA, in bladder cancer cells decreases intracellular uptake and phototoxicity of 
PcGal16.  
 
Figure 3.1 Hypothetic illustration of phototoxicity of PcGal16 in human bladder cancer cells. The uptake of 
PcGal16 by bladder cancer cells is modulated by the presence of carbohydrate-binding proteins present at the cell 
surface (i.e. GLUT1 and galectin-1). PcGal16 is a nontoxic compound per se, and has high photocytotoxic 
efficiency against bladder cancer cell lines. Treatment with ROS quenchers demonstrated that cell death in 
bladder cancer cells is mediated by the production of ROS after PDT. Immediately after PDT with PcGal16 there 
is an increase on the activity of antioxidant enzymes (superoxide dismutase SOD, catalase CAT and glutathione 
reductase GR antioxidant enzymes). The photoactivated PcGal16 co-localizes with galectin-1 and GLUT1and 
reduces their levels. 
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3.1.1 Methods 
 
 The following experimental protocols (please see Methods and Materials chapter IX) 
were used to obtain the data presented in this chapter: 
 Biological models – Culture of HT-1376 and UM-UC-3 bladder cancer cells (9.3.8A) 
 Fluorescence spectroscopy and microscopy – uptake of PcGal16 (9.3.8C-E) 
 PDT treatments – Photosensitizer PcGal16 (9.3.8F) 
 Cell viability assays – MTT, Trypan blue and TUNEL assays (9.3.8G) 
 Antioxidant enzyme activities (9.3.8H) 
 Transfection assays – knockdown of galectin-1 and GLUT1 using siRNA (9.3.8I) 
 Intracellular levels of Reactive Oxygen Species (9.3.8J) 
 Redox quenching assays (9.3.8K) 
 Western blotting assays – galectin-1, GLUT1, β-actin (9.3.8L) 
 Immunocytochemistry assays – galectin-1, GLUT1 (9.3.8M) 
 
3.1.2 Publication 
 
This chapter comprises the following publication: 
Patrícia M. R. Pereira, Sandrina Silva, José A. S. Cavaleiro, Carlos A. F. Ribeiro, João 
P. C. Tomé and Rosa Fernandes, Galactodendritic phthalocyanine targets carbohydrate-
binding proteins enhancing photodynamic therapy, PLOS ONE, 2014, 9, e95529. 
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3.2 PcGal16 accumulates in cancer cells and is non-toxic in darkness 
 
To study the cellular uptake of PcGal16, HT-1376 and UM-UC-3 bladder cancer cells 
have been incubated with increasing concentrations (0.5, 2.5, 5 and 9 µM) of PcGal16 in PBS 
for up to 4 h. PcGal16 intracellular accumulation was determined by quantitative 
spectrofluorimetry and fluorescence microscopy. As shown in Figure 3.2, the uptake of 
PcGal16 was both concentration- and time- dependent, reaching a plateau in less than 2 h. 
Addition of 5 µM PcGal16 to HT-1376 and UM-UC-3 cells resulted in an intracellular 
concentration of 3531±126 and 2973±119 nmol PcGal16 per mg of protein, respectively, after 
2 h of incubation (Figure 3.2A).  
 
Figure 3.2 PcGal16 accumulates in UM-UC-3 and HT-1376 human bladder cancer cells. Intracellular uptake 
of PcGal16 by HT-1376 and UM-UC-3 bladder cancer cells (A). The concentration of PcGal16 was determined by 
fluorescence spectroscopy and the results were normalized to protein quantity. Data are the mean ± S.D. of at 
least three independent experiments performed in triplicates. Representative fluorescence images (B) of bladder 
cancer cells incubated with PcGal16 (red) in darkness. Cell nucleus is stained with DAPI (blue). Scale bars 20 
µm. 
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This spectrofluorimetric data was confirmed by confocal microscopy showing that cells 
treated with PcGal16 exhibit strong fluorescence, with occasional bright spots in the 
perinuclear region (Figure 3.2B). PcF16, the non-conjugated Pc, was used as control (Figure 
SI3.1). No significant intracellular accumulation was observed when the cells were incubated 
with 0.5-9 µM PcF16 (data not shown), showing that the uptake of the PcGal16 by cancer cells 
is enhanced relatively to unconjugated PcF16. 
 
Figure 3.3 PcGal16 is non-toxic in darkness, PcF16 is non-toxic in darkness and after PDT. Non-dark 
toxicity of various concentrations of PcGal16 in HT-1376 and UM-UC-3 cells (A). Non-dark toxicity was 
assessed using the MTT colorimetric assay 24, 48, and 72 h after treat HT-1376 and UM-UC-3 cells (B). Toxicity 
of PcF16 at 5 µM in darkness and after PDT (C) in HT-1376 and UM-UC-3 cells. The toxicity was assessed 
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using the MTT colorimetric assay 24 h after treat HT-1376 and UM-UC-3 cells. Data are the mean ± S.D. of at 
least three independent experiments performed in triplicates. 
 
After confirmation of PcGal16 uptake by bladder cancer cells (Figure 3.2), its cytotoxic 
effect in darkness was assessed by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT) colorimetric assay (Figure 3.3). No dark toxicity was observed in untreated 
cells (up to 4 h) in the presence of 0.45% v/v or less dimethyl sulfoxide (DMSO) in the 
incubation medium. Moreover, PcGal16 showed no significant cytotoxicity at concentrations 
up to 9 µM for at least 72 h after treatment (Figure 3.3). 
 
3.3 PcGal16 induces cytotoxicity after photodynamic activation 
 
To test the effect of light irradiation (red light at 620-750 nm delivered at 2.5 mW/cm2 
for 40 min, i.e. 6 J/cm2) after PcGal16 uptake on cell viability, MTT was performed 24 h after 
treatment (Figure 3.4). No cytotoxicity was observed in the untreated sham-irradiated cells 
(Figure 3.4A) or untreated irradiated cells in the presence of 0.45% (v/v) or less DMSO in 
PBS (data not shown). However, when HT-1376 and UM-UC-3 cells were incubated with 
PcGal16 and then irradiated, there was an increased phototoxicity in a concentration- and 
uptake time-dependent manner (Figure 3.4A). Data showed that PcGal16 exerted a higher 
phototoxicity on UM-UC-3 cells compared to HT-1376 cells (Figure 3.4A). Moreover, the 
percentage of cell death in treated cells compared to untreated cells was significantly 
influenced by the dose of light (Figure 3.4B). The phototoxicity was higher in cells irradiated 
at 6 J/cm2 than in cells irradiated at 1.5 J/cm2 (cells irradiated with light at 2.5 mW/cm2 for 40 
min or 10 min, respectively). On the other hand, irradiation of cells with light at 10 mW/cm2 
for 10 min (i.e. 6 J/cm2) resulted in induction of cell death in untreated control cells. In 
subsequent experiments, we then performed cells irradiation with light at 2.5 mW/cm2 for 40 
min. Based on the uptake results (Figure 3.2) and MTT data before (Figure 3.3) and after 
PcGal16 photoactivation (Figure 3.4A,B), we estimate the lowest concentration of PcGal16 and 
the lowest dose of light necessary to achieve high phototoxicity for both bladder cancer cell 
lines. When cells were incubated with 5 µM PcGal16 for 2 h and then irradiated with light at 6 
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J/cm2 (cells irradiated for 40 min with light at 2.5 mW/cm2), we observed a significant 
increase in phototoxicity of HT-1376 and UM-UC-3 cells. The cells were also incubated with 
5 µM of PcF16 during 2 h and then irradiated. As shown in Figure 3.3 and Figure 3.4, the 
phototoxicity was higher for PcGal16 than for non-conjugated PcF16.  
 
Figure 3.4 PcGal16 produces toxicity after PDT. Photocytotoxic effects after PcGal16-PDT in HT-1376 and 
UM-UC-3 cells evaluated 24 h after PDT using the MTT assay (A). The percentage of toxicity was calculated 
relatively to control cells (cells incubated with PBS and irradiated). Data are the mean ± S.D. of at least three 
independent experiments performed in triplicates. *P< 0.05, **P< 0.01, ***P< 0.001 significantly different from 
control cells. Irradiation dose-dependent cell death in response to PDT with PcGal16 (B). Cytotoxicity was 
assessed 24 h after treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to 
control cells (untreated cells). Data are the mean value ± S.D. of at least three independent experiments 
performed in triplicates. *P< 0.05, **P< 0.01, ***P< 0.001 significantly different from control cells. 
 
Based on the critical role of ROS in causing cell death after PDT and considering the 
different PDT-induced phototoxicity observed in UM-UC-3 and HT-1376 cells, the 
intracellular production of ROS was evaluated immediately after PDT in the cells previously 
incubated with 5 µM PcGal16 for 2 h. The application of PcGal16 in combination with PDT 
led to a high significant augmentation of ROS in both bladder cancer cell lines compared with 
the control (Figure 3.5A,B). The ROS levels (DCF fluorescence fold increase per mg of 
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protein) in HT-1376 and UM-UC-3 cells were 50.52±12.77 and 74.88±11.49, respectively, 
when 5 µM H2DCFDA was used for ROS detection (Figure 3.5B). 
To assess the contribution of ROS in PcGal16-mediated cell death, quenchers of ROS 
(histidine, sodium azide [15] and cysteine [16]) were added at non-toxic concentrations to the 
incubation medium when the cells were irradiated. Cell viability evaluated 24 h after treatment 
was dependent on the used scavenger and cell type (Figure 3.5C). For the cell line UM-UC-3, 
all quenchers at the employed concentration partially decrease the PcGal16–PDT-induced 
phototoxicity. For the cell line HT-1376, none of the quenchers used in these experiments 
were able to reduce the phototoxicity induced by photoactivated PcGal16. 
 
Figure 3.5 PcGal16 generates ROS after PDT. Representative fluorescence images (A) and quantification (B) of 
DCF fluorescence increase (as a measure of ROS production) in HT-1376 and UM-UC-3 cells, after PDT with 
PcGal16. Scale bars 20 µm. Data are the mean ± S.D. of at least three independent experiments performed in 
triplicates. *P< 0.05, ***P< 0.001 significantly different from control cells. Photocytotoxicity after PDT with 
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PcGal16 in the presence of 50 nM of ROS quenchers (sodium azide, histidine and cysteine) in HT-1376 and UM-
UC-3 cells (C). Cytotoxicity was assessed 24 h after treatment using the MTT assay. The percentage of 
cytotoxicity was calculated relatively to control cells (untreated cells). Data are the mean value ± S.D. of at least 
three independent experiments performed in triplicates. ***P< 0.001 significantly different from MTT reduction 
(%) after PcGal16-PDT. 
 
To assess whether PDT has a long-term phototoxic effect, we evaluated cell viability for 
up to 72 h after PDT treatment. In both cell lines, the results obtained with the MTT 
colorimetric assay (cell metabolic activity) were correlated with the loss of cell membrane 
integrity (trypan blue staining) (Figure 3.6A,B). Overall, UM-UC-3 and HT-1376 bladder 
cancer cells were unable to recover from the PDT-induced damage effects 48 or 72 h after 
treatment, for PcGal16 concentrations above 5 µM.  
 
Figure 3.6 PDT with PcGal16 has a long-term phototoxicity effect. Cytotoxicity was assessed 24, 48, and 72 h 
after PcGal16-PDT using the MTT (A) and trypan blue staining (B) assays. The percentage of cytotoxicity was 
calculated relatively to control cells (cells incubated with PBS in darkness and then irradiated) at the respective 
uptake time. Data are the mean value ± S.D. of at least three independent experiments performed in triplicates. 
*P< 0.05, **P< 0.01, ***P< 0.001 significantly different from MTT reduction (%) or excluded trypan blue (%) 
at 24 h after PDT for the respective concentration. 
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TUNEL data revealed that there is an induction of cell death in a time-dependent manner 
in the cells irradiated after incubation with PcGal16 (Figure 3.7). Twenty-four hours after PDT 
with PcGal16, the percentage of TUNEL positive cells in UM-UC-3 cell line was 1.8 higher 
than that of the HT-1376 cells, but after 72 h there was almost the same percentage of 
TUNEL-positive cells in both cell lines.  
 
Figure 3.7 PDT with PcGal16 has a long-term phototoxicity effect. Representative fluorescence images 
revealing cell death in HT-1376 and UM-UC-3 cells after PDT with PcGal16 by TUNEL staining 24 and 72 h 
after treatment. DAPI was used for nuclei staining (blue) and TUNEL staining was used to visualize dead cells 
(green). Scale bars 20 µm. Quantification of TUNEL-positive cells 24 and 72 h after PDT with PcGal16. *P< 
0.05 significantly. different from control cells. $$P< 0.01 significantly different from TUNEL-positive cells 24 h 
after PDT. #P< 0.05 significantly different from TUNEL-positive UM-UC-3 cells at the respective time after 
PDT. 
 
Table 3.1 Values for photocytotoxic concentration (IC50, µM) of photoactivated PcGal16 on human bladder 
cancer cell lines, HT-1376 and UM-UC-3.  
 
HT-1376 cell line UM-UC-3 cell line 
Hours after PDT 24 48 72 24 48 72 
IC
50
 (µM), CI
95%
 - 3.3 [0.6;10.7] 2.5 [2.2;2.9] 2.1 [0.9;5.0] 2.8 [2.4; 3.2] 2.6 [2.6;2.7] 
IC
50
 is the incubation concentration that inhibits the proliferation of cultures in 50%, after cells´ incubation with PcGal
16
 
and irradiation. IC
50
 values were calculated using the MTT dose response curves (24, 48, and 72 h after PDT), obtained 
for cells incubated with PcGal
16
 at various concentrations for 2 h. 
CI
95%
: 95% Confidence interval. 
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The concentrations of PcGal16 necessary to inhibit the metabolic activity of UM-UC-3 
and HT-1376 bladder cancer cells in 50% can be estimated from Figure 3.6. These values, 
named as “photocytotoxic concentrations” (IC50) are reported in Table 3.1. Data show that 24 
h after PDT, IC50 value is lower for UM-UC-3 when compared with HT-1376 cells and similar 
for these cell lines 72 h after PDT. 
 
3.4 PcGal16 induces antioxidant enzyme response after photodynamic therapy 
 
Considering the different levels of ROS produced in the two bladder cancer cell lines 
after PDT with PcGal16, we investigated (immediately after PDT) the involvement of specific 
antioxidant enzymes [17] in the detoxification of ROS and/or resulting toxic products. For 
that, the activities of the three major antioxidant enzymes, Superoxide dismutase (SOD), 
catalase (CAT), and glutathione peroxidase (GPox) were determined by spectroscopy [18]. 
SOD catalyses the dismutation of superoxide radical anions into hydrogen peroxide and 
molecular oxygen. Hydrogen peroxide is then removed by CAT when it is present at high 
concentrations or by GPox when present at low concentrations. Knowing about the indirect 
antioxidant function [17] of GR in the replenishment of gluthathione levels in reduced form 
(GSH) and of glutathione S-transferase (GST) in the elimination of reactive compounds 
through their conjugation with GSH, their activities were also determined. 
In UM-UC-3 control cells, the activities of GR, SOD and CAT were 1.5-fold, 1.9-fold 
and 1.5-fold higher, respectively, than in HT-1376 control cells (Table 3.2). There was no 
significant difference in the activities of GST and GPox between the control cells of the two 
cell lines. After PDT with PcGal16, there was a 1.3-fold, 3.1-fold and 1.5-fold increase in the 
activities of GR, SOD and CAT in UM-UC-3 cells. In HT-1376 cells, there was a 2.2-fold, 
4.6-fold and 4.8-fold increase in GR, SOD and CAT activities and a 2-fold decrease in the 
activity of GST after PDT with PcGal16. Treatment of HT-1376 resulted in a 2.3-fold 
increased of CAT activity as compared to UM-UC-3-treated cells. The ability of HT-1376 
cells to produce an antioxidant adaptive response, activating the antioxidant enzymes GR, 
SOD and CAT can explain the higher resistance observed 24 h after PDT with PcGal16 as 
compared with UM-UC-3 cells. 
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Table 3.2 Values of activity (mU/mg of protein) of antioxidant enzymes superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPox), glutathione reductase (GR) and glutathione S-transferase (GST) 
determined after PDT. 
Cell line PcGal16-PDT 
Enzyme activity (mU/mg of protein) 
GST GPox GR SOD CAT 
UM-UC-3 
- 44.0±1.4 232.4±23.6 252.3±13.9
$
 56.0±13.1
$
 36.31±1.3
$
 
+ 39.7±2.7 243.6±12.0 316.1±11.3
#
 173.6±4.8
#
 52.89±2.7
#
 
HT-1376 
- 50.4±2.4 236.1±9.9 163.4±1.9 29.56±1.9 24.85±2.2 
+ 24.6±0.5
$,*
 252.3±18.2 356.9±30.6
$
 134.7±4.3
$,*
 119.8±3.3
$,*
 
$
P< 0.05: significantly different from HT-1376 control cells; 
#
P< 0.05: significantly different from UM-UC-3 control cells; 
*
P< 0.05: significantly different from UM-UC-3 treated cells. 
 
3.5 Knockdown of galectin-1 and GLUT1 decreases the uptake and phototoxicity of 
PcGal16 
 
We investigated whether the presence of the dendritic galactose units around the core of 
Pc molecule could facilitate the interaction of this PS with specific domains in the plasma 
membrane of cancer cells. We hypothesized that domains enriched in carbohydrate-binding 
proteins [19] could facilitate the interaction with PcGal16, enhancing somehow its cellular 
uptake, and therefore its photodynamic potential.  
Galectin [13] and glucose transporters [14] are expressed in high levels in cancer cells 
and both have affinity for galactose molecules. Therefore, we have evaluated the protein levels 
of galectin-1 and GLUT 1 in UM-UC-3 and HT-1376 cells, by Western Blotting and 
immunofluorescence (Figure 3.8 and Figure 3.9).  
The galectin-1 protein levels were higher in UM-UC-3 than in HT-1376 control cells 
(Figure 3.8A). To determine whether galectin-1 plays a role in the uptake of PcGal16 by 
cancer cells, siRNA was used to knockdown galectin-1 within UM-UC-3 bladder cancer cells. 
The treatment of UM-UC-3 cells with a pool of three target-specific siRNAs maximally 
suppressed galectin-1 by ≈50% at 24 h and 48 h post-transfection (Figure 3.8B), without 
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affecting the expression of the housekeeping protein β-actin. The transfected cells were then 
treated with PcGal1648 h post-transfection. As shown in Figure 3.8C,D, transfected cells 
displayed a markedly decreased uptake and phototoxicity of PcGal16.  
 
Figure 3.8 Knockdown of galectin-1 decreases the uptake and phototoxicity of PcGal16. Western blotting 
analysis and quantification of galectin-1 protein levels in HT-1376 and UM-UC-3 cells (A). β-actin was blotted 
as loading control. Quantitative analysis of galectin-1 (normalized to β -actin) expressed as a ratio of the levels 
found in HT-1376 cells. *P < 0.05 significantly different from HT-1376 cells. Knockdown of galectin-1 in UM-
UC-3 bladder cancer cells as determined by Western blotting 24 and 48 h post-transfection (B). Quantitative 
analysis of galectin-1 (normalized to β-actin) expressed as a ratio of the levels found in non-transfected control 
cells. Data represents mean ± S.D. of five independent experiments. *P< 0.05, $P< 0.05 significantly different 
from non-transfected control cells or cells treated with scrambled siRNA, respectively. Intracellular uptake of 
PcGal16 by UM-UC-3 bladder cancer cells transfected with galectin-1 siRNA (C). The cells were incubated with 
PcGal16 48 h post-transfection with galectin-1 siRNA. Data are the mean ± S.D. of at least three independent 
experiments performed in triplicates. *P< 0.05 significantly different from non-transfected control cells. 
Photocytotoxic effects after PcGal16-PDT in UM-UC-3 cells transfected with galectin-1 siRNA (D). 
Phototoxicity was evaluated 72 h after PDT. Data are the mean ± S.D. of at least three independent experiments 
performed in triplicates. *P< 0.05, ***P< 0.001 significantly different from control cells. $P< 0.05, significantly 
different from PDT with PcGal16 in non-transfected cells. 
 
The GLUT1 protein levels were higher in HT-1376 than in UM-UC-3 control cells 
(Figure 3.9A). Therefore, HT-1376 bladder cancer cells were also treated with a pool of three 
target-specific GLUT1 siRNAs. Application of GLUT1 siRNA suppressed GLUT1 by ≈50% 
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and ≈90% at 24 h and 48 h post-transfection, respectively (Figure 3.9B). Treatment of HT-
1376 cells with PcGal16 twenty-four hours post-transfection, resulted in a substantial decrease 
in the uptake and phototoxicity (Figure 3.9C,D). 
 
Figure 3.9 Knockdown of GLUT1 decreases de uptake and phototoxicity of PcGal16. Western blotting 
analysis and quantification of GLUT1 protein levels in HT-1376 and UM-UC-3 cells (A). β-actin was blotted as 
loading control. Quantitative analysis of GLUT1 (normalized to β-actin) expressed as a ratio of the levels found 
in HT-1376 cells (A). *P< 0.05 significantly different from HT-1376 cells. Knockdown of GLUT1 in HT-1376 
bladder cancer cells as determined by Western blotting 24 and 48 h post-transfection (B). Quantitative analysis of 
GLUT1 (normalized to β-actin) expressed as a ratio of the levels found in non-transfected control cells. Data 
represents mean ± S.D. of five independent experiments. *P< 0.05, ***P< 0.001 significantly different from non-
transfected control cells. $P< 0.05, $$$P< 0.001 significantly different from cells treated with scrambled siRNA. 
Intracellular uptake of PcGal16 by HT-1376 bladder cancer cells transfected with GLUT1 siRNA (C). The cells 
were incubated with PcGal16 24 h post-transfection. Data are the mean ± S.D. of at least three independent 
experiments performed in triplicates. *P < 0.05 significantly different from non-transfected control cells. 
Photocytotoxic effects after PcGal16-PDT in UM-UC-3 cells transfected with GLUT1 siRNA (D). Phototoxicity 
was evaluated 72 h after PDT. Data are the mean ± S.D. of at least three independent experiments performed in 
triplicates. *P< 0.05, ***P< 0.001 significantly different from control cells. *P< 0.05, significantly different 
from PDT with PcGal16 in non-transfected cells.  
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3.6 PcGal16 decreases the galectin-1 and GLUT1 protein levels 
 
To further explore the role of galectin-1 and GLUT1 in the photodynamic effect induced 
by PcGal16, we determined the levels of these proteins before and after PDT. Both incubation 
of cancer cells with PcGal16 (i.e. incubation of cancer cells with PcGal16 in darkness) and 
PDT with PcGal16 induced a decrease in galectin-1 as observed by Western Blotting and 
immunofluorescence (Figure 3.10A-C). The decrease observed in galectin-1 was higher in 
UM-UC-3 cells as compared to HT-1376 cells and it was more evident after PDT. Using 
confocal fluorescence microscopy, we observed co-localization of PcGal16 with galectin-1 
inside bladder cancer cells (Figure 3.10 C). 
Figure 3.10 PcGal16 reduces the levels of galectin-1 in UM-UC-3 and HT-1376 bladder cancer cells. 
Western blotting analysis and quantification of galectin-1 protein levels in HT-1376 cells (A) or UM-UC-3 cells 
(B) after uptake with PcGal16 in darkness and after PDT. β-actin was blotted as loading control. Quantitative 
analysis of galectin-1 (normalized to β-actin) expressed as a ratio of the levels found in untreated HT-1376 or 
UM-UC-3 cells (A, B). Data represents mean ± S.D. of five independent experiments. *P<0.05 significantly 
different from untreated HT-1376 or UM-UC-3 cells. Representative fluorescence images (C) of galectin-1 
protein (green) in cancer cells before and after incubation with PcGal16 (red), with DAPI staining the nucleus 
(blue). Scale bars 20 µm. 
 
Similar to what was observed for galectin-1, there was also a decrease in GLUT1 
(Figure 3.11A-C) both after PcGal16 uptake and after PDT treatment in HT-1376 cancer cells. 
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Furthermore, in these cancer cells it was higher after PDT than after PcGal16 uptake in 
darkness. In UM-UC-3 cells, PcGal16 was not able to reduce GLUT1 protein levels (Figure 
3.11 B). In both bladder cancer cell lines there was co-localization of PcGal16 with GLUT1 
(Figure 3.11 C). Overall, these findings clearly indicate show the critical involvement of the 
carbohydrate-binding proteins in the potential of PcGal16 as a therapeutic agent.  
Figure 3.11 PcGal16 reduces the levels of GLUT1 in UM-UC-3 and HT-1376 bladder cancer cells. Western 
blotting analysis and quantification of GLUT1 protein levels in HT-1376 cells (A) or UM-UC-3 cells(B) after 
uptake with PcGal16 in darkness and after PDT. β-actin was blotted as loading control. Quantitative analysis of 
GLUT1 (normalized to β-actin) expressed as a ratio of the levels found in untreated HT-1376 or UM-UC-3 cells 
(A, B). Data represents mean ± S.D. of five independent experiments. *P<0.05 significantly different from 
untreated HT-1376 cells. Representative fluorescence images (C) of GLUT1 protein (green) in cancer cells 
before and after incubation with PcGal16 (red), with DAPI staining the nucleus (blue). Scale bars 20 µm. 
 
  
Chapter III. Galactodendritic phthalocyanine targets carbohydrate binding proteins enhancing photodynamic 
therapy 
 
101 
 
3.7 Discussion 
 
Third-generation PSs such as Pc coupled to carbohydrates are interesting for PDT, 
because they can be recognized by glycoprotein-based membrane proteins that are 
overexpressed in tumors [2]. Besides the enhancement of cellular recognition, the presence of 
dendritic galactose molecules improves Pc solubility and biocompatibility [12]. We have 
recently reported the synthesis of a new Pc with dendrimers of galactose sugar (PcGal16) that 
has valuable spectroscopic and photochemical properties [12]. In this study, we showed that 
PcGal16 is a nontoxic compound per se, and has high photocytotoxic efficiency in two bladder 
cancer cell lines, which is paralleled with its high ability to produce ROS and to induce 
oxidative stress. 
The high intracellular uptake of the glycoconjugated PS, PcGal16, can be explained by 
the presence of carbohydrate cellular transporters or receptors present at the cell surface. 
Although the PcGal16 uptake was quite similar in the two bladder cancer cell lines, the 
expression of carbohydrate-binding proteins GLUT1 and galectin-1 is different amongst them. 
Besides its role in the import and export of glucose [14], the isoform of GLUT1 also transports 
D-galactose [14] having lower affinity for it than for D-glucose. Studies have been suggested 
that the hydroxyl groups in C1, C3 and C4 positions of D-galactose are hydrogen bond 
acceptors for GLUT1 sugar uptake site [20]. Like other galectins, galectin-1 has a CRD able to 
recognize and bind β-galactose [21]. Our assays demonstrated that galectin-1 and GLUT1 are 
both expressed by UM-UC-3 and HT-1376 cells. However, HT-1376 cells present higher 
GLUT1 levels compared with UM-UC-3 cells, and the contrary was observed for galectin-1. 
Although a similar PcGal16 uptake was observed in the two bladder cancer cell lines, both 
GLUT1 and galectin-1 may contribute for its specificity modulating the intracellular uptake. 
Knockdown of galectin-1 and GLUT1 in UM-UC-3 and HT-1376 cells, respectively, was 
associated with a marked decrease of PcGal16 uptake and phototoxicity. Together, these data 
demonstrated that galectin-1 and GLUT1 contribute for the efficacy of PDT mediated by 
PcGal16. 
Interestingly, although the similar uptake of PcGal16 by UM-UC-3 and HT-1376 cells, 
the phototoxicity induced 24 h after PDT was higher in UM-UC-3 cells than in HT-1376 cells. 
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Such lack of association between uptake and phototoxicity has been described [22, 23]. We 
investigated whether the higher phototoxicity observed in UM-UC-3 cells was due to higher 
production of ROS and/or higher oxidative damage compared with that in HT-1376 cells. As 
expected, the ability of PcGal16 to produce ROS was higher in UM-UC-3 than in HT-1376 
cells. 
In PDT, it has been described that ROS can be generated by two photochemical 
reactions [24, 25]. In type-II photochemical reactions, the excited PS in its triplet state can 
transfer its energy to molecular oxygen leading to the formation of 1O2. Type-I photochemical 
reactions happen when an excited PS reacts with a biological substrate forming radicals and 
radical ions. Treatment with ROS quenchers demonstrated that in UM-UC-3 cells, 1O2 should 
have a high effect since cell death was highly reduced with quenchers of 1O2 (sodium azide 
and histidine). Further studies using more accurate techniques (e.g. electron spin resonance) 
are needed to gain insight into the contribution of specific ROS in PcGal16-mediated cell death 
after PDT. 
Interestingly, we observed that PDT with PcGal16 has a long-term phototoxic effect in 
both cancer cell lines. Cytotoxicity assays (MTT, trypan blue and TUNEL assays) performed 
72 h after PDT demonstrated that UM-UC-3 cells were not able to recover. Moreover, in HT-
1376 cells there was a marked induction of cell death occurring from 24 to 72 h after PDT 
with PcGal16. The three distinct cytotoxic methods used in the present work are widely 
applied in the study of cell death: MTT (indicator of metabolic activity), trypan blue staining 
(indicator of membrane integrity loss occurring in necrosis or in late stages of apoptosis) and 
TUNEL assay (indicator of DNA fragmentation, a key factor of apoptosis). Cell death in PDT 
may occur by apoptosis or necrosis, or even by a combination of the two mechanisms [1]. A 
more specific and comprehensive study is needed to understand the specific cell death 
pathways induced after PDT with PcGal16 in the bladder cancer cells used in this study. The 
different cell death obtained 24 h after PDT in UM-UC-3 and HT-1376 cells can be partially 
explained by the different amount of ROS present in both cells lines after irradiation. In 
addition, the resistance exhibited by HT-1376 cells could be due to the presence of efficient 
protective mechanisms, at least in the first stages after photodynamic treatment. 
Cytoprotective mechanisms initiated by cancer cells after PDT are well-known [25]. The 
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increase of antioxidant molecules (e.g. gluthathione, vitamin C and vitamin E) [26] and the 
induction of genes encoding proteins involved in apoptosis or in the repair of lesions [27] are 
two of the well-known cytoprotective mechanisms induced after PDT. Another one is based 
on the equilibrium between photo-oxidative impairment of cells by ROS vs. elimination of 
ROS by the activity of cellular antioxidant enzymes. Recent studies have shown that PDT 
caused increased-antioxidant enzymes activity and expression [28]. Thus, PDT efficacy can be 
influenced by the antioxidant response of the enzymes SOD, the GSH system and CAT. 
Our data demonstrated that after PDT with PcGal16 there was an increase in the activity 
of SOD, CAT and GR antioxidant enzymes in both cell lines, being higher in HT-1376 than in 
UM-UC-3 cells. This higher antioxidant defense of HT-1376 cells against ROS can explain 
the results obtained 24 h after treatment. However, it is hypothesized that this was not 
maintained for 72 h after PDT since for this time point there was a massive cell death. This not 
only suggests that in this cell line there is a temporal relationship between ROS levels and cell 
death, but shows that antioxidant enzymes activity is of greater importance in protecting HT-
1376 cells for at least 24 h after PDT with PcGal16. Regarding the activity of antioxidant 
enzymes, in HT-1376 cells it was also observed a decrease in the activity of GST, which is an 
enzyme implicated in cells defense against oxidation products. This enzyme has been 
described as protecting cells from DNA desintegration and drug toxicity [29]. GST isoforms 
are overexpressed in multidrug resistant tumors having an important role in tumors drug 
resistance by direct detoxification or inhibition of the MAP kinase pathway [29]. Thus, the 
higher cell death observed in HT-1376 cells 72 h after treatment can be also related with the 
activity of GST. A decrease in the activity of GST can be associated with DNA fragmentation 
and cell death 72 h after treatment. 
Understanding the role of galactose moieties in the recognition of the PS by cancer cells 
may allow the investigation and development of more focused therapeutic strategies. Thus, we 
investigated whether PcGal16 could be directly recognized by specific carbohydrate-binding 
proteins present at the plasma membrane. Consistently, the photoactivated PcGal16 was shown 
to co-localize and reduce the levels of the plasma membrane proteins galectin-1 and GLUT1. 
Moreover, the immunofluorescence and Western Blotting studies demonstrated that, although 
its non-dark toxicity, PcGal16 decreases the levels of galectin-1 and GLUT1 proteins. A 
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plausible explanation for the decreased levels of the galactose binding proteins, galectin-1 and 
GLUT1, after incubation with PcGal16 can be the masking of the epitope, which can block 
antibody-epitope binding due to changes in protein conformation or, eventually, endocytosis 
of these proteins and subsequent degradation. Thus, the changes observed in the levels of 
galectin-1 and GLUT1 could be induced directly by the binding of PcGal16 to the 
carbohydrate-binding proteins and/or indirectly by the generation of ROS after PDT with 
PcGal16. 
Although significant progress has been made in research related with the role of 
galectins in cancer, the information underlying the molecular mechanisms that control the 
expression of these proteins in tumor cells is scarce. The interaction of PSs with galectins 
(namely galectin-1 and galectin-3) has been studied by spectroscopic studies [30] and 
molecular modeling analysis [2, 9]; however, they have not been validated by in vitro studies. 
As far as we know, there are no in vitro reports indicating whether PSs can modulate the 
expression of carbohydrate-binding proteins such as galectin-1 and GLUT1. Knowing that 
galectin-1 expression is correlated with cell metastatic potential [13, 31] and contributes to 
tumor progression and resistance after conventional cancer therapeutic modalities [13], the 
ability of PcGal16 to reduce the levels of galectin-1 after its uptake and/or photoactivation 
prompted us to envisage PcGal16 as a potential candidate for cancer treatment.  
Knowing that the overexpression of GLUTs is involved in tumor glycolysis - one of the 
biochemical “hallmarks” of cancer - the efficiency of PcGal16 as an efficient anti-cancer PS is 
also evidenced by its ability to reduce GLUT1. GLUT1 is an attractive target to consider in the 
development of new PSs because it is lower expressed in normal-epithelial tissues or benign 
epithelial cell tumors when compared with human cancer cells [32]. The function of GLUT1 
in the tumorogenesis process has been demonstrated by in vitro and in vivo studies, where the 
overexpression of GLUT1 antisense resulted in the inhibition of HL60 leukaemia cells 
proliferation and MKN-45 derived xenografs, respectively [33, 34]. Based on the results of the 
current study, we envisage PcGal16 as a promising therapeutic agent for the treatment of 
bladder cancer.  
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3.9 Supporting information 
 
 
Figure SI3.1 Chemical structures of PcF16 and PcGal16. 
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Chapter IV Role of clathrin- and caveolae-mediated pathways in 
galactodendritic conjugated phthalocyanine uptake by bladder cancer cells 
 
4.1 General overview 
 
The uptake mechanisms and pathways of PSs in cancer cells are highly complex and not 
fully understood. Nevertheless, the mechanism by which PSs are accumulated in cancer cells 
can influence the outcome of PDT. In the previous chapter of this thesis, we demonstrated that 
the uptake of PcGal16 is mediated in somehow by galactose-binding proteins overexpressed in 
cancer cells (such as galectin-1 and GLUT1). We hypothesized that these proteins increase the 
accumulation of PcGal16 around cancer cell membranes. In the present study we seek to 
investigate by which endocytic mechanisms PcGal16 is internalized by HT-1376 and UM-UC-
3 bladder cancer cells. 
Endocytosis is defined as the process by which molecules are internalized from the cell 
surface into internal membrane compartments. Endocytosis can be divided into two main 
pathways: the clathrin-mediated endocytic pathway and the clathrin-independent pathway (the 
lipid-raft-dependent route) [1]. The clathrin-mediated endocytosis is the most well 
characterized mechanism for the uptake of molecules into cells. In this pathway, specific 
adaptor-protein complexes bind directly to clathrin and cargo proteins to for the clathrin-
coated vesicles. After endocytosis, the clathrin-coated vesicles are uncoated and fuse with the 
early endosome. The early endosome can later mature into late endosomes and fuse with 
lysosomes for degradation. Nevertheless, clathrin-mediated endocytosis can also target cargo 
molecules to other intracellular compartments such as the Golgi [2]. One division of the non-
clathrin endocytic pathway is the caveolae-mediated pathway. The caveolae-mediated 
pathway involves the clustering of lipid raft components on the plasma membrane into 
caveolae. Caveolae are flask-shaped invaginations abundant on the cell surface and they 
contain sphingolipids, cholesterol and the caveolin proteins. Studies have demonstrated that 
caveolin-1 protein is of utmost importance in the formation of caveolae, because caveolin-1-
null mice lack caveolar structures [3]. 
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Endocytosis inhibition results demonstrated that PcGal16 entered UM-UC-3 bladder 
cancer cells mainly through the clathrin-mediated endocytosis pathway, and that caveolae-
mediated endocytosis was involved to a small extent. In HT-1376 bladder cancer cells, both 
clathrin- and caveolae-mediated endocytosis were involved on the uptake of PcGal16. 
Interestingly, knockdown of caveolin-1 protein in HT-1376 cells increased GLUT1 protein 
levels in the plasma membrane and increased the uptake and phototoxicity of PcGal16 (Figure 
4.1). 
 
Figure 4.1 Hypothetic illustration of endocytic internalization of PcGal16 in human bladder cancer cells. 
The accumulation of PcGal16 around cancer cell membranes is modulated by the presence of carbohydrate-
binding proteins such as GLUT1. The internalization of PcGal16 is an energy dependent process, which makes 
use of both clathrin- and caveolae-endocytic pathways. Knockdown of caveolin-1 protein increases the uptake of 
PcGal16 and GLUT1 protein levels at the cell surface.  
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4.1.1 Methods 
 
 The following experimental protocols (please see Methods and Materials chapter IX) 
were used to obtain the data presented in this chapter: 
 Biological models – Culture of HT-1376 and UM-UC-3 bladder cancer cells (9.3.8A) 
 Fluorescence spectroscopy – uptake of PcGal16 (9.3.8C,D) 
 PDT treatments – Photosensitizer PcGal16 (9.3.8F) 
 Cell viability assays – MTT assay (9.3.8G) 
 Transfection assays – knockdown of caveolin-1 using siRNA (9.3.8I) 
 Western blotting assays – EEA1, Clathrin HC, Flotillin-1, Caveolin-1, GLUT1, EGFR, 
β-actin (9.3.8L) 
 Endocytic inhibitors assays – NaN3, chlorpromazine, sucrose, dynasore, filipin, 
methyl-β-cyclodextrin, nystatin (9.3.8N) 
 Cell-surface biotinylation assays – GLUT1, EGFR (9.3.8O) 
 
4.1.2 Publication 
 
This chapter comprises the following publication: 
Patrícia M.R. Pereira, Teresa M. Ribeiro-Rodrigues, Sandrina Silva, Carlos A.F. 
Ribeiro, José A. S. Cavaleiro, Henrique Girão, João P.C. Tomé, Rosa Fernandes, Role of 
clathrin- and caveolae-mediated pathways in galactodendritic conjugated phthalocyanine 
uptake by bladder cancer cells, under final preparation. 
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4.2 Clathrin- and caveolae-mediated endocytic pathways are required for 
internalization of PcGal16 
 
PSs accumulation in cancer cells can occur through diffusion (few cases) or endocytosis 
[4-6]. Regarding endocytosis, PSs can enter via clathrin-dependent and -independent pathways 
(such as caveolae-mediated endocytosis). Previous studies using fluorescence microcopy 
demonstrated that PcGal16 is efficiently accumulated in UM-UC-3 and HT-1376 bladder 
cancer cells [7]. To understand the mechanisms of cellular internalization of PcGal16 in HT-
1376 and UM-UC-3 bladder cancer cells, we determined the expression of different proteins 
involved in endocytic pathways. Next, we studied the effects of various endocytic inhibitors 
on the uptake and further phototoxicity of PcGal16. 
The presence of endocytic proteins, EEA1 (early endosome antigen 1), clathrin heavy 
chain (HC), flotillin-1 and caveolin-1 was determined in whole cells lysates of HT-1376 and 
UM-UC-3 bladder cancer cells. EEA1 is a membrane-bound protein that is an effector of Rab5 
(a small GTPase) controlling early endosome fusion dynamics; flotillin-1 and caverolin-1 are 
integral membrane proteins and constituents of lipid rafts and clathrin is a major protein 
component of chlatrin-coated pits [1]. Western blot analysis of whole cell lysates revealed 
similar levels of EEA1, clathrin HC and flotillin-1 proteins in HT-1376 and UM-UC-3 bladder 
cancer cells (Figure 4.2). Additionally, the caveolin-1 protein levels were almost two times 
higher in HT-1376 cells than in UM-UC-3 cells (Figure 4.2). 
 
Figure 4.2 HT-1376 and UM-UC-3 bladder cancer cell lines express different endocytic uptake proteins. 
(A) Western blotting analysis of EEA1, clathrin heavy chain (HC), flotillin-1 and caveolin-1 proteins in UM-UC-
3 and HT-1376 bladder cancer cells. β-actin was used as a loading control. (B) Quantitative analysis of EEA1, 
clathrin HC, flotillin-1 and caveolin-1 (normalized to β -actin) proteins expressed as a ratio of the levels found in 
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UM-UC-3 cells. Data are the mean ± S.D. of at least five independent experiments. **P< 0.01 compared to UM-
UC-3 bladder cancer cells. 
 
Next, we examined whether PcGal16 uptake was an active or passive process. We 
performed uptake assays at 4 ºC, because at this temperature all energy dependent processes 
(including endocytosis) are inhibited. Additionally, we also performed uptake assays with 
NaN3 to inhibit ATP hydrolysis required for active transport [8]. Incubation of HT-1376 and 
UM-UC-3 bladder cancer cells with PcGal16 at 4 ºC and treatment with NaN3 resulted in a 
reduction of uptake by about 90% (Figures 4.3 and SI4.1, Tables SI4.1,SI4.2).  
 
Figure 4.3 Low temperature and pre-incubation of HT-1376 bladder cancer cells with NaN3 reduce the 
uptake and phototoxicity of PcGal16. Intracellular uptake and phototoxicity of PcGal16 in HT-1376 bladder 
cancer cells at 4 ºC (A); or after pre-incubation with 20 mM NaN3. Data are the mean ± S.D. of at least three 
independent experiments performed in triplicates. **P< 0.01, ***P< 0.001 compared to uptake or phototoxicity at 
37 ºC (A) or in the absence of NaN3 (B). 
 
Specific compounds known to affect endocytic processes were used to understand the 
uptake mechanisms of PcGal16 in HT-1376 and UM-UC-3 bladder cancer cells. Clathrin-
dependent endocytosis was inhibited with hypertonic sucrose and chlorpromazine [9]. 
Dynasore was used to inhibit dynamin-dependent endocytosis [10]. Filipin, methyl-β-
cyclodextrin and nystatin were used to inhibit caveolae-dependent endocytosis [9]. To 
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determine an optimal protocol for the use of endocytic inhibitors for a certain cell type, it is 
important to determine their in vitro cellular toxicity. We investigated the viability of HT-1376 
and UM-UC-3 cancer cells after exposure to different concentrations of sucrose, 
chlorpromazine, dynasore, filipin, methyl-β-cyclodextrin or nystatin. The inhibitor was diluted 
in PBS and incubated with the cells for 2 h and toxicity was determined using the MTT assay 
at 24 h after cells incubation with inhibitors (Figures SI4.2,SI4.3). Based on these results, we 
determined non-toxic concentrations of endocytic inhibitors to be used in further assays. To 
study the effect of endocytic inhibitors on the uptake and phototoxicity of PcGal16, cells were 
pre-incubated during 30 min with 0.45 mM sucrose, 5 µM chlorpromazine, 40 µM dynasore, 
2.5 µg/mL filipin, 5 mM methyl-β-cyclodextrin or 25 µM nystatin. Next, cells were incubated 
with 5 µM PcGal16 (in the continued presence of the respective inhibitor) for 1.5 h (Figures 
4.4-4.6, SI4.4-SI4.6) and the PDT assays were performed by irradiating cells with light at 2.5 
mW/cm2 for 40 min (6 J/cm2). As phototoxicity is higher in HT-1376 cancer cells at 72 h after 
PDT when compared with that at 24 h [7], the effect of endocytic inhibitors in this cell line 
were evaluated at 24 and 72 h after PDT. In UM-UC-3 bladder cancer cells, MTT assay was 
performed at 24 h after PDT. 
 
Figure 4.4 Pre-incubation of HT-1376 bladder cancer cells with chlorpromazine and sucrose reduce the 
uptake and phototoxicity of PcGal16. Intracellular uptake and phototoxicity of PcGal16 in HT-1376 bladder 
cancer cells pre-incubated with 5 µM chlorpromazine (A) or 0.45 mM sucrose (B). Data are the mean ± S.D. of at 
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least three independent experiments performed in triplicates.**P< 0.01, ***P< 0.001 compared to uptake or 
phototoxicity in the absence of endocytic inhibitor. 
 
Chlorpromazine and sucrose considerably decreased the PcGal16 uptake and 
phototoxicity in both HT-1376 (Figure 4.4, Table SI4.1) and UM-UC-3 (Figure SI4.4, Table 
SI4.2) bladder cancer cells, indicating the involvement of clathrin-mediated endocytosis in 
PcGal16 uptake. Dynasore decreased the uptake of PcGal16 by 66% and 21% in HT-1376 and 
UM-UC-3 cells, respectively (Figures 4.5, SI4.5 and Tables SI4.1,SI4.2).  
 
Figure 4.5 Pre-incubation of HT-1376 bladder cancer cells with dynasore reduces the uptake and 
phototoxicity of PcGal16. Intracellular uptake and phototoxicity of PcGal16 in HT-1376 bladder cancer cells pre-
incubated with 40 µM dynasore. Data are the mean ± S.D. of at least three independent experiments performed in 
triplicates. *P< 0.05, **P< 0.01 compared to uptake or phototoxicity in the absence of dynasore. 
 
Filipin, methyl-β-cyclodextrin and nystatin decreased the uptake and phototoxicity of 
PcGal16 in a higher extent in HT-1376 cells (Figure 4.6, Table SI4.1) than in UM-UC-3 cells 
(Figure SI4.6, Table SI4.2), indicating that caveolae-mediated endocytosis was more 
important for the uptake of PcGal16 in HT-1376 cells than in UM-UC-3 cells. 
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Figure 4.6 Pre-incubation of HT-1376 bladder cancer cells with filipin, methyl-β-cyclodextrin and nystatin 
reduce the uptake and phototoxicity of PcGal16. Intracellular uptake and phototoxicity of PcGal16 in HT-1376 
bladder cancer cells pre-incubated with 2.5 µg/mL filipin (A), 5 mM methyl-β-cyclodextrin (B) or 25 µM 
nystatin (C). Data are the mean ± S.D. of at least three independent experiments performed in triplicates. **P< 
0.01, ***P< 0.001 compared to uptake or phototoxicity in the absence of endocytic inhibitor. 
 
4.3 Knockdown of caveolin-1 protein increases uptake and phototoxicity of PDT 
with PcGal16 in HT-1376 cancer cells 
 
Previous studies demonstrated that HT-1376 bladder cancer cells induce an antioxidant 
response after PDT with PcGal16[7]. But MTT assays performed at 24 and 72 h after PDT 
demonstrated that these cells were unable to recover from the photo-effects for at least 72 h 
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after PDT [7]. On the other hand, UM-UC-3 cells were quite sensitive to PDT with PcGal16 
[7]. In an attempt to correlate PcGall6 internalization pathway with the resistance of HT-1376 
cancer cells to PDT, we decided to extend our study with this cell line. Incubation of HT-1376 
cancer cells with PcGal16 induced an increase in the phosphorylated form of caveolin-1 
(phospho-caveolin-1, Figure 4.7A) without alteration on the levels of caveolin-1 protein as 
observed by Western blotting.  
 
Figure 4.7 Caveolin-1 protein has a key role on the uptake of PcGal16 by HT-1376 bladder cancer cells. (A) 
Western blotting analysis of phospho-caveolin-1 and caveolin-1 proteins levels in HT-1376 cells after PcGal16 
uptake. β-actin was used as a loading control. (B) Intracellular uptake of PcGal16 by HT-1376 bladder cancer cells 
transfected with caveolin-1 siRNA. Cells were incubated with PcGal16 48 h post-transfection with caveolin-1 
siRNA. Data are the mean ± S.D. of at least three independent experiments performed in triplicates.**P< 0.01 
compared to uptake in non-transfected cells. (C) Photocytotoxic effects after PcGal16-PDT in HT-1376 cells 
transfected with caveolin-1 siRNA. Phototoxicity was evaluated 24, 48 and 72 h after PDT. Data are the mean ± 
S.D. of at least three independent experiments performed in triplicates. +++P< 0.001 compared to phototoxicity in 
transfected control cells. $$$P< 0.001 compared to phototoxicity in non-transfected cells. 
 
Having found that PcGal16 uptake increases the levels of phospho-caveolin-1 and that it 
is inhibited more significantly by caveolae-inhibitors in the cell line where caveolin-1 is more 
abundant (HT-1376), we investigated the role of caveolin-1 in PcGal16 internalization by HT-
1376 cells. To determine whether caveolin-1 plays a role in the uptake of PcGal16 by HT-1376 
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cancer cells, siRNA was used to knockdown caveolin-1 (Figure SI4.7). As shown in Figure 
4.7B,C, transfected cells displayed a markedly increased uptake and phototoxicity of PcGal16. 
 
4.4 Knockdown of caveolin-1 protein increases GLUT1 protein levels at the plasma 
membrane of HT-1376 cancer cells 
 
GLUT1 is a glucose transporter overexpressed in cancer cells [11] and it is able to bind 
glyco-PSs increasing their concentration in cancer cells [7]. Previous studies demonstrated that 
GLUT1 protein contributes to the uptake of PcGal16 in HT-1376 cancer cells, because 
knockdown of this protein was associated with a marked decrease of PcGal16 uptake and 
phototoxicity [7]. The increase in the uptake of PcGal16 after knockdown of caveolin-1 
prompted us to study whether knockdown of caveolin-1 protein induced changes on the levels 
of GLUT1 protein in HT-1376 cancer cells. Knockdown of caveolin-1 protein was specific for 
this endocytic protein, because it did not induce changes in the levels of other endocytic 
proteins (such as chlatrin HC, Figure 4.8A,B). Interestingly, an increase in the GLUT1 protein 
levels were observed after knockdown of caveolin-1 (Figure 4.8A,B). 
Having established that knockdown of caveolin-1 protein increases the uptake of 
PcGal16 and the expression levels of GLUT1, we hypothesized that caveolin-1 regulates in 
somehow the internalization of GLUT1. To address this question we used cell-surface 
biotinylation assays to follow GLUT1 at the plasma membrane before and after uptake of 
PcGal16 in HT-1376 cells expressing caveolin-1 and HT-1376 cells depleted of caveolin-1. 
The results presented in Figure 4.8C show that, the amount of GLUT1 at the plasma 
membrane (biotinylated fraction) increases in cells depleted of caveolin-1. After cells 
incubation with PcGal16 GLUT1 decreases in the plasma membrane of both HT-1376 cells 
expressing caveolin-1 and depleted of this protein. In agreement with the data presented 
above, uptake of PcGal16 by HT-1376 bladder cancer cells increased the intracellular levels of 
GLUT1 protein (non-biotinylated fraction).  
The clathrin-dependent endocytosis is the main pathway involved in the down-
regulation of cell-surface receptors such as epidermal growth factor receptor (EGFR) [12]. 
Interestingly, cell-surface biotinylation assays demonstrated that EGFR increases in the 
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plasma membrane of HT-1376 cells depleted of caveolin-1 and it is internalized after uptake 
of PcGal16 Figure 4.8C. 
 
Figure 4.8 Knockdown of caveolin-1 protein increases the expression of GLUT1 protein in the plasma 
membrane of HT-1376 bladder cancer cells. Western blotting analysis (A) of clathrin heavy chain (HC), 
GLUT 1 and caveolin-1 proteins in HT-1376 cells transfected with caveolin-1 siRNA. β-actin was used as a 
loading control. (B) Quantitative analysis of clathrin HC, GLUT 1 and caveolin-1 GLUT1 (normalized to β-actin) 
expressed as a ratio of the levels found in control non-transfected control cells. Data represents mean ± S.D. of 
five independent experiments. *P< 0.05, **P< 0.01 compared to non-transfected control cells. (C) Western 
blotting analysis of GLUT 1 and EGFR after PcGal16 uptake in HT-1376 cells transfected with caveolin-1 siRNA 
and subjected to cell surface protein biotinylation. Cells were incubated with PcGal16 48 h post-transfection with 
caveolin-1 siRNA. Cells were then subjeted to cell surface protein biotinylation, and the biotin-labeled and 
biotin-unlabeled proteins were separated using NeutrAvidin beads. NeutrAvidin supernatant (non-biotinylated 
proteins) and NeutrAvidin-bound proteins (biotinylated proteins) were then analyzed by Western blotting using 
antibodies against GLUT1 or EGFR. 
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4.5 Discussion 
 
The internalization of PSs in cells is modulated by their degree of lipophilicity and 
asymmetry in the molecular structure, type and number of neutral and charged peripheral 
groups [4]; and by cell type and cell-specific features. These factors generally determine the 
subcellular compartment in which the PS accumulates. Taking into account the limited 
lifetime of ROS generated with PDT, the subcellular localization of the PS determines the 
targets of the primary damages. A study regarding the analysis of the endocytic pathways 
through which a PS is internalized, is of great importance in the design of an effective PS. 
Quantitative insight into the contribution of different endocytic pathways to the cellular uptake 
of a PS can be very helpful to understand how cellular uptake influences phototoxicity of a 
certain PS.  
Previously, we demonstrated that the uptake of a phthalocyanine conjugated with 
dendritic units of galactose (PcGal16) is dependent on the presence of galactose-binding 
proteins overexpressed in cancer cells (such as galectin-1 and GLUT1) [7]. We hypothesized 
that noncovalent interactions between PcGal16 and galactose-binding proteins will increase the 
concentration of this PS around cancer cell membranes, and the PS is then internalized by 
endocytosis. In the present study we demonstrated that PcGal16 endocytosis is highly 
dependent on the cell line used and both clathrin- and caveolae-mediated pathways are 
involved. Additionally, we demonstrated that PcGal16 uptake and further phototoxicity can be 
improved, in HT-1376 cell line resistant at the first times after PDT, by interfering with the 
endocytic machinery.  
The internalization of a PS can be studied by different approaches but all have their 
limitations [9]. The use of inhibitors that affect a specific cellular uptake mechanism is a 
common approach. Additionally, knockdown of proteins required for specific endocytic 
pathways can also be used. In this study, we have focused on the use of chemical inhibitors 
and knockdown of caveolin-1 protein to investigate the endocytic internalization of PcGal16 
[7, 13]. Further studies must consider the effect of the PS on the activity of endocytic 
pathways. 
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Sucrose hypertonic solution inhibits endocytosis because it blocks clathrin-coated pit 
formation [14]. Chlorpromazine is a cationic amphiphilic molecule which inhibits Rho 
GTPase activity needed for several mechanisms including clathrin-dependent endocytosis [9]. 
Dynasore is a cell-permeable small molecule that inhibits dynamin GTPase and mitochondrial 
dynamin activities, blocking dynamin-dependent endocytosis and interfering with both 
clathrin- and caveolin-dependent endocytosis [10]. Filipin changes the properties of 
cholesterol-rich membrane domains, interfering with caveolae-mediated endocytosis [15]. 
Methyl-β-cyclodextrin induces depletion of cholesterol (the main component of lipid rafts) 
from the plasma membrane and it has been used to determine if endocytosis is dependent on 
the integrity of lipid rafts [9]. Nystatin is an inhibitor of caveolae-mediated endocytosis, which 
disrupts lipid-raft caveolae structure and function [16]. 
PcGal16 uptake was highly reduced when active processes were inhibited (studies at 4 
ºC or in the presence of NaN3), which indicates that PcGal16 uptake is energy-dependent. 
None of the pharmacological inhibitors could fully inhibit PcGal16 uptake indicating that cells 
use multiple pathways simultaneously to internalize the same PS. Nevertheless, some 
inhibitors inhibited more strongly in one cell type than others. For instance, filipin, methyl-b-
cyclodextrin and nystatin inhibited the PcGal16 uptake in HT-1376 cancer cells more strongly 
than in UM-UC-3 cancer cells. In spite of having high inhibitory effects in the phototoxicity of 
PcGal16, dynasore inhibited the uptake only about 66% and 21% in HT-1376 and UM-UC-3 
cells, respectively. The lack of correlation between reduction in phototoxicity and uptake 
when dynasore is used as endocytic inhibitor can be due to the fluorescent properties of 
dynasore, because it has emission bands in the same region of PcGal16[17]. The compounds 
used to inhibit clathrin-mediated endocytosis (chlorpromazine and sucrose) were able to 
inhibit uptake and phototoxicity of PcGal16 in both cell lines. 
Our data suggests that PcGal16 uptake in UM-UC-3 bladder cancer cells, which express 
caveolin-1 protein in lower levels when compared with HT-1376 cells, occurred mainly by 
clathrin internalization. Additionally, PcGal16 uptake in HT-1376 cells resulted on the 
stimulation of the phospho-caveolin-1. Phosphorylation of caveolin-1 has been indirectly 
related to the endocytic activity of caveolae [18]. For example, the addition of 
glycosphingolipids to cells resulted on the phosphorylation of caveolin-1 and increased 
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dynamics of caveolae [19]. It seems therefore evident that caveolin-1 protein has a role on the 
uptake of PcGal16 by HT-1376 bladder cancer cells. 
Previous studies have demonstrated that blocking one uptake pathway can lead to the 
upregulation of other endocytic mechanisms [20]. Therefore, the increase in the uptake of 
PcGal16 after knockdown of caveolin-1 protein in HT-1376 bladder cancer cells can be due to 
the activation of other endocytic pathways that results in even higher accumulation of 
PcGal16. Cell-surface biotinylation assays demonstrated an increase in the internalization of 
EGFR after uptake of PcGal16 in cells depleted of caveolin-1. An upregulation in clathrin-
mediated endocytosis is expected in HT-1376 cancer cells depleted of caveolin-1, because 
EGFR internalization is mainly mediated by clathrin-dependent endocytosis [12]. In this 
study, we used siRNA to inhibit caveolin-1 mediated endocytosis. Although this is a great 
methodology to inhibit protein expression, the knockdown is not 100% efficient. The small 
amount of caveolin-1 observed by Western blotting upon siRNA treatment might be also 
involved in the uptake of PcGal16. Importantly, studies have demonstrated that endocytic 
uptake of virus particles and exosomes is increased in caveolin-1 knock out cells suggesting 
that their uptake is negatively regulated by caveolin-1 [21, 22]. Somewhat unexpectedly, the 
increase in the uptake of PcGal16 after knockdown of caveolin-1 protein in HT-1376 bladder 
cancer cells also suggests a negative regulatory role of caveolin-1 in PcGal16 uptake. 
In a previous study, we demonstrated that PcGal16 phototoxicity is higher in UM-UC-3 
cells than in HT-1376 cells at 24 h after PDT [7]. The resistance of HT-1376 at the first 24 h 
after PDT was explained by the fact that an antioxidant response is developed after PDT in 
HT-1376 cancer cells [7]. Some studies have proposed that the acquisition of resistance to 
different compounds by cancer cells might be associated with high expression of caveolin-1 
[23]. Considering the role of caveolin-1 protein in the resistance of cancer cells to therapy, we 
hypothesize that knockdown of this protein will increase the sensitivity of HT-1376 cancer 
cells to PDT.  
The reduction of GLUT1 in the plasma membrane and its intracellular increase after 
PcGal16 uptake supports our previous study demonstrating that GLUT1 has a key role on the 
uptake of PcGal16 by HT-1376 bladder cancer cells [7]. Interestingly, knockdown of caveolin-
1 protein increases GLUT1 protein levels at the plasma membrane of HT-1376 cancer cells. 
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These results led us to hypothesize that knockdown of caveolin-1 protein increases PcGal16 
uptake and further phototoxicity through an increment of GLUT1 in the plasma membrane. 
Studies have demonstrated that the activity of GLUT1 is sensitive to changes in the lipid 
environment of the transporter, such as changes in phospholipids and cholesterol composing 
the membrane [24]. Although the mechanism by which depletion of caveolin-1 increases 
GLUT1 at the plasma membrane is not clear, studies have reported that GLUT1 protein is 
distributed in caveolin-rich membrane fractions [24-26]. Mechanisms of plasma membrane 
protein degradation (endocytic recycling) can also explain these results. 
The accumulation of PcGal16 is not only dependent on the presence of galactose-binding 
proteins (as we have previously demonstrated in another study [7]), but it is a complex 
mechanism which results from the interplay between the mechanisms by which cells are able 
to endocytose PSs. The data presented here also suggest that PcGal16 might be internalized via 
different pathways in different cell types.  
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4.7 Supporting Information 
 
 
Figure SI4.1 Intracellular uptake and phototoxicity of PcGal16 in UM-UC-3 bladder cancer cells at 4 ºC (A); or 
after pre-incubation with 20 mM NaN3. Data are the mean ± S.D. of at least three independent experiments 
performed in triplicates. **P< 0.01 compared to uptake or phototoxicity at 37 ºC (A) or in the absence of NaN3 
(B). 
 
 
Figure SI4.2 Cytotoxic effects after HT-1376 cancer cells incubation with different concentrations of endocytic 
inhibitors (NaN3, chlorpromazine, sucrose, dynasore, filipin, methyl-β-cyclodextrin and nystatin) was evaluated 
24 h after treatment using the MTT assay. The percentage of toxicity was calculated relatively to control cells 
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(cells incubated with PBS). Data are the mean ± S.D. of at least three independent experiments performed in 
triplicates. *P< 0.05 compared to control cells. 
 
 
Figure SI4.3 Cytotoxic effects after UM-UC-3 cancer cells incubation with different concentrations of endocytic 
inhibitors (NaN3, chlorpromazine, sucrose, dynasore, filipin, methyl-β-cyclodextrin and nystatin) was evaluated 
24 h after treatment using the MTT assay. The percentage of toxicity was calculated relatively to control cells 
(cells incubated with PBS). Data are the mean ± S.D. of at least three independent experiments performed in 
triplicates. *P< 0.05 compared to control cells. 
 
 
Figure SI4.4 Intracellular uptake and phototoxicity of PcGal16 in UM-UC-3 bladder cancer cells pre-incubated 
with 5 µM chlorpromazine (A) or 0.45 mM sucrose (B). Data are the mean ± S.D. of at least three independent 
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experiments performed in triplicates.**P< 0.01 compared to uptake or phototoxicity in the absence of endocytic 
inhibitor. 
 
 
Figure SI4.5 Intracellular uptake and phototoxicity of PcGal16 in UM-UC-3 bladder cancer cells pre-incubated 
with 40 µM dynasore. Data are the mean ± S.D. of at least three independent experiments performed in 
triplicates. *P< 0.05 to phototoxicity in the absence of endocytic inhibitor. 
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Figure SI4.6 Intracellular uptake and phototoxicity of PcGal16 in UM-UC-3 bladder cancer cells pre-incubated 
with 2.5 µg/mL filipin (A), 5 mM methyl-β-cyclodextrin (B) or 25 µM nystatin (C). Data are the mean ± S.D. of 
at least three independent experiments performed in triplicates.*P< 0.05 compared to uptake or phototoxicity in 
the absence of endocytic inhibitor. 
 
 
Figure SI4.7 Knockdown of caveolin-1 in HT-1376 bladder cancer cells as determined by Western blotting 24, 
48 and 72 h post-transfection. β-actin was used as a loading control. 
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Table SI4.2 Analysis of the different endocytic inhibitors in UM-UC-3 bladder cancer cells, regarding PcGal16 
uptake and phototoxicity. 
Condition Inhibitor concentration 
Uptake 
(nmol PcGal16/mg protein) 
MTT reduction at 24 h after 
PDT 
(% from control) 
No inhibitor, 37 ºC ___ 3047 24.68 
4 ºC ___ 16.41 93.01 
NaN3 20 mM 29.70 78.41 
Sucrose 0.45 mM 295.7 89.13 
Chlorpromazine 5 µM 424.3 64.19 
Dynasore 40 µM 2397 60.44 
Filipin 2.5 µg/mL 2881 35.97 
Methyl-β-Cyclodextrin 5 mM 1560 44.62 
Nystatin 25 µM 2308 36.40 
Table SI4.1 Analysis of the different endocytic inhibitors in HT-1376 bladder cancer cells, regarding PcGal16 
uptake and phototoxicity, before and after transfection with caveolin 1 siRNA. 
Condition 
Inhibitor 
concentration 
Uptake 
(nmol PcGal16/mg protein) 
MTT reduction 
(% from control) 
Non-
transfected 
cells 
Transfected 
cells 
Non-transfected cells 
Transfected 
cells 
24 h 
after 
PDT 
72 h 
after 
PDT 
24 h 
after 
PDT 
72 after PDT 
No inhibitor, 37 ºC ___ 3433 6274 65.07 23.46 28.38 16.53 
4 ºC ___ 14.51 ___ 99.3 98.59 ___ ___ 
NaN3 20 mM 23.42 ___ 91.4 88.32 ___ ___ 
Sucrose 0.45 mM 225.2 7662 93.2 78.29 5.6 5.7 
Chlorpromazine 5 µM 295.9 8309 96.0 83.61 3.1 4.8 
Dynasore 40 µM 1170 ___ 96.2 59.79 ___ ___ 
Filipin 2.5 µg/mL 102.3 6444 93.0 98.23 14.1 13.9 
Methyl-β-
Cyclodextrin 
5 mM 149.6 5837 84.7 91.98 17.1 16.5 
Nystatin 25 µM 101 6464 92.1 91 13.0 13.8 
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Chapter V The role of galectin-1 in in vitro and in vivo photodynamic 
therapy with a galactodendritic porphyrin 
 
5.1 General overview 
 
Most of the clinically-approved agents used in PDT for cancer treatment are porphyrin-
based photosensitizers (e.g. Photofrin, ALA/PpIX, BPD-MA). Several porphyrin-based PSs 
have been synthesized through conjugation with biomolecules in order to influence their 
water/lipid solubility, amphiphilicity, pKa, stability, intracellular localization and 
pharmacokinetics [1-7]. The conjugation of galactose targeting moieties with a porphyrinoid is 
a valuable approach to achieve a high local concentration of PSs in tumor tissues, since certain 
galactose-binding proteins are overexpressed on cancer tissues [8, 9] increasing their tumor 
selectivity/uptake and reducing the unwanted phototoxicity in the surrounding healthy tissues. 
Galectin-1, the first discovered galectin, exhibits extracellular and intracellular localization 
[10], being able to form homodimers that can cross-link ligands containing appropriate 
carbohydrate moieties. The overexpression of galectin-1 has been described for several tumor 
types (namely bladder tumors) [11-13] and this has been associated with low prognosis and 
high metastatic potential [13]. This protein abundantly expressed in tumor environments can 
modulate several functions such as angiogenesis, cell migration adhesion and tumor-immune 
escape [11-13].  
We previously reported PorGal8, a porphyrin conjugated with dendritic units of 
galactose (Figure SI5.1), as a new water soluble PS able to generate ROS after photoactivation 
[14]. In the present chapter, we validated PorGal8 as a novel therapeutic agent in PDT for the 
treatment of tumors containing high levels of galectin-1 (Figure 5.1). We showed a specific 
uptake of PorGal8 and induction of apoptotic cell death by generating oxidative stress and 
alterations in the cytoskeleton of bladder cancer cells overexpressing galectin-1. We further 
validated the photodynamic efficiency of PorGal8 in athymic nude mice (Balb/c nu/nu) 
bearing subcutaneously implanted luciferase-positive bladder cancer xenografts, 
overexpressing galectin-1 protein. PorGal8 (5 µmol/kg, i.p.), injected 24 h before light 
delivery (50.4 J/cm2), inhibited tumor growth. We conclude that the use of PorGal8 enables 
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selective target and cytotoxicity by PDT in cancer cells overexpressing galectin-1, preventing 
undesired phototoxicity in the surrounding healthy tissues. 
 
Figure 5.1 Hypothetic illustration of phototoxicity of PorGal8 in in vitro and in vivo biological models 
containing high levels of galectin-1 protein. 
 
5.1.1 Methods 
 
 The following experimental protocols (please see Methods and Materials chapter IX) 
were used to obtain the data presented in this chapter: 
 Protein interaction assays – galectin-1 (9.2.2E) 
 Biological models – Culture of HT-1376 and UM-UC-3 bladder cancer cells (9.3.8A) 
 Fluorescence spectroscopy and microscopy – uptake of PorGal8 (9.3.8C-E) 
 PDT treatments – Photosensitizer PorGal8 (9.3.8F) 
 Cell viability assays – MTT, Trypan blue and TUNEL assays (9.3.8G) 
 Transfection assays – knockdown of galectin-1 using siRNA (9.3.8I) 
 Intracellular levels of Reactive Oxygen Species (9.3.8J) 
 Redox quenching assays (9.3.8K) 
 Western blotting assays – galectin-1, E-cadherin, β-actin (9.3.8L) 
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 Immunocytochemistry assays – E-cadherin (9.3.8M) 
 In vivo assays (9.4.8A) 
 Immunohistochemistry assays – E-cadherin, Ki-67, Phalloidin-TRICT, galectin-1 
(9.3.8C) 
 
5.1.2 Publication 
 
This chapter comprises the following publication: 
Patrícia M. R. Pereira, Sandrina Silva, José S. Ramalho, Célia M. Gomes, Henrique 
Girão, José A. S. Cavaleiro, Carlos A. F. Ribeiro, João P. C. Tomé, Rosa Fernandes,The role 
of galectin-1 in in vitro and in vivo photodynamic therapy with a galactodendritic porphyrin, 
accepted European Journal of Cancer. 
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5.2 PorGal8 interacts with galectin-1 and its accumulation in bladder cancer cells is 
dependent on the expression of this protein 
 
Porphyrin conjugated with four dendritic units of galactose (PorGal8) showed a high 
binding affinity to human galectin-1, as assessed by fluorescence quenching on the tryptophan 
residue of the protein (Figure 5.2A, Figure SI5.1B). The values determined for affinity 
constant (Ka) and the number of binding sites (n) for PorGal8 with galectin-1 were 1.27 x 10
7 
M-1 and 1.40, respectively. A strong interaction between PorGal8 and lectin-recombinant 
human galectin-1 was also confirmed by the measured apparent dissociation constant (KD), of 
1.44 ± 0.062 µM (mean ± s.d.), see Figure 5.2A. We assessed the cellular uptake of PorGal8 
in two bladder cancer cell lines derived from transitional cell carcinoma, HT-1376 and UM-
UC-3, (Figure SI5.1C), which have different galectin-1 protein levels. The uptake of PorGal8 
was both concentration- and time-dependent, reaching a plateau in less than 2 h (Figure 5.2B). 
Moreover, cellular uptake of PorGal8 was higher in UM-UC-3 cells that express higher levels 
of galectin-1 protein than HT-1376 cells (Figure 5.2C) [15]. A stronger fluorescence of 
PorGal8 (with occasional bright spots in the perinuclear region) was observed in UM-UC-3 
cells when compared with HT-1376 cells (Figure SI5.2). Knockdown of galectin-1 via siRNA 
in UM-UC-3 cells (Figure 5.2D) clearly showed a decreased uptake of PorGal8 (P < 0.01, 
Figure 5.2E). 
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Figure 5.2 Galectin-1 plays a role in the uptake of PorGal8 by HT-1376 and UM-UC-3 bladder cancer cells. 
(A) Fluorescence variation on the emission spectra of galectin-1 after addition of PorGal8. Data are means ± 
s.e.m. of two independent experiments. (B) Intracellular uptake of PorGal8 by HT-1376 and UM-UC-3 bladder 
cancer cells. Data are means ± s.e.m. of at least three independent experiments performed in triplicates. (C) 
Western blotting analysis of galectin-1 protein in HT-1376 and UM-UC-3 bladder cancer cells. β-actin was used 
as a loading control. (D) Knockdown of galectin-1 in UM-UC-3 bladder cancer cells as determined by Western 
blotting 48 h post-transfection. (E) Intracellular uptake of PorGal8 by UM-UC-3 bladder cancer cells transfected 
with galectin-1 siRNA. ** P < 0.01 compared to non-transfected control cells using a Student´s t test. Data are 
means ± s.e.m. of at least three independent experiments performed in triplicates. 
 
5.3 PorGal8 induces cytotoxicity after photodynamic activation 
 
Although PorGal8 is non toxic in the dark (at concentrations up to 12.5 µM and 
exposure times up to 4 h, Figure SI5.3A), it causes phototoxicity against bladder cancer cells. 
In fact, when HT-1376 and UM-UC-3 cells were incubated with PorGal8 and then irradiated 
(with a LEDs array system emitting white light, delivered at 8.4 mW/cm2), there was an 
increased phototoxicity in a concentration- and uptake time-dependent manner (Figure 
SI5.3B). No cytotoxicity was observed in the untreated sham irradiated cells (Figure SI5.3B) 
Chapter V. The role of galectin-1 in in vitro and in vivo photodynamic therapy with a galactodendritic porphyrin 
 
144 
 
or untreated irradiated cells in the presence of 0.45% (v/v) or less DMSO in PBS (data not 
shown). PorGal8 led to a significantly higher phototoxicity on UM-UC-3 cells compared to 
HT-1376 cells (Figure 5.3A).  
 
Figure 5.3 PDT with PorGal8 induces cytotoxicity in HT-1376 and UM-UC-3 bladder cancer cells. (A) and 
(B) Cytotoxicity 24 h after PDT with PorGal8 was determined using the MTT and trypan blue staining assays, 
respectively. * P < 0.05, **P < 0.01, ***P < 0.001 compared to MTT reduction (%) or excluded trypan blue (%) 
at 24 h after PDT for the respective control using a Student´s t test. Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates. (C) Photocytotoxic effects after PDT with PorGal8 in UM-UC-
3 cells transfected with galectin-1 siRNA. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to MTT reduction 
(%) at 24 h after PDT for the respective non-transfected cells using a Student´s t test. Data are means ± s.e.m. of 
at least three independent experiments performed in triplicates. (D) Quantification of TUNEL-positive cells at 24 
h after PDT with PorGal8 obtained from counts of randomly chosen microscopic fields.** P < 0.01 compared to 
control cells, $P < 0.05 compared to TUNEL-positive HT-1376 cells at 24 h after PDT using the multiple 
pairwise Kurskal-Wallis ANOVA. 
 
The percentage of cell death in treated cells compared to untreated controls was also 
significantly influenced by the dose of light (2.52, 5.04, 10.08 and 20.16 J/cm2). Based on the 
MTT data (Figure SI5.3B), we estimated the light dose necessary to induce significant 
phototoxicity in both cell lines. In subsequent experiments, a light dose of 8.4 mW/cm2 for 40 
min (i.e. 20.16 J/cm2, Figure 5.3A) was used to perform the PDT assays. Trypan blue viability 
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assay (cell membrane activity) confirmed that, compared to control cells, phototoxicity was 
higher in UM-UC-3 than in HT-1376 cells (Figure 5.3B). Additional studies indicated that in 
UM-UC-3 transfected cells with galectin-1 siRNA (Figure 5.3C) there was a decrease in 
cytotoxicity induced by PDT with PorGal8. Moreover, although increased apoptotic responses 
were observed in both cell lines (Figure 5.3D and Figure SI5.4A), 24 h after PDT with 
PorGal8, as assessed by the Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay, UM-UC-3 cell line was markedly more sensitive than HT-1376 cell line (P < 
0.05). Additional MTT and TUNEL assays demonstrated that a certain percentage of HT-1376 
cancer cells are able to recover from the photodynamic effect between 24 to 72 h after 
treatment (Figure SI5.4B). In UM-UC-3 cancer cells, a stronger phototoxic effect was 
observed at 72 h after treatment. 
 
5.4 Photodynamic therapy with PorGal8 induces ROS-mediated cytotoxicity 
 
ROS production in cancer cells after PDT can be determined using specific solid traps or 
fluorescent probes such as 2´,7´-dichlorodihydrofluorescein diacetate (H2DCFDA) and 
dihydroethidium (DHE).The H2DCFDA and DHE, two oxidation-sensitive fluorescent dyes, 
demonstrated the production of ROS immediately after PDT 20.16 J/cm2 in bladder cancer 
cells previously treated with 10 µM PorGal8 for 1.5 h (Figure 5.4A,B and Figure SI5.4C). 
Although both cell lines showed almost similar anion superoxide generation after PDT with 
PorGal8 (Figure SI5.4C), ROS generation detected with H2DCFDA in UM-UC-3 cells was 
almost twice of the HT-1376 cells (Figure 5.4A,B).  
PDT assays in bladder cancer cells incubated with non-toxic concentrations of ROS 
quenchers (histidine, sodium azideand cysteine) demonstrated that sodium azide (a quencher 
of 1O2) significantly decreased the percentage of cell death (P < 0.001, Figure 5.4C). Histidine 
and cysteine at the employed concentrations were also able to decrease the cytotoxicity 
induced by PDT with PorGal8 in UM-UC-3 cells (Figure 5.4C). Additionally, the oxygen 
levels in the medium of both cancer cell lines gradually decreased due to PDT-induced 
photochemical oxygen consumption (Figure 5.4D). Furthermore, the oxygen consumption was 
higher in UM-UC-3 cells when compared to HT-1376 cells.  
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Figure 5.4 PorGal8 generates ROS after PDT. (A) Quantification and (B) representative fluorescence images 
of DCF fluorescence increase (as a measure of ROS production) in HT-1376 and UM-UC-3, after PDT with 
PorGal8. Scale bars 20 µm. ** P < 0.01 compared to control cells using a Student´s t test. Data are means ± 
s.e.m. of at least three independent experiments performed in triplicates. (C) Phototoxicity after PDT with 
PorGal8 in the presence of 50 nM of ROS quenchers (sodium azide, histidine and cysteine) in HT-1376 and UM-
UC-3 cells. Cytotoxicity was assessed 24 h after treatment using the MTT assay. The percentage of cytotoxicity 
was calculated relatively to control cells (untreated cells). *** P < 0.001 compared to MTT reduction (%) 24 h 
after PDT with PorGal8 using a Student´s t test. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates. (D) Oxygen consumption in HT-1376 and UM-UC-3 cells after PDT with 
PorGal8. *P < 0.05, $$P < 0.01compared to control cells and HT-1376 cells after PDT, respectively, using the 
multiple pairwise Kurskal-Wallis ANOVA. Data are means ± s.e.m. of at least three independent experiments 
performed in triplicates. 
 
5.5 Photodynamic therapy with PorGal8 induces tumor shrinkage 
 
To examine the effectiveness of PorGal8 in vivo, we developed a xenograft tumor model 
that included mice with UM-UC-3luc+ cells (containing high levels of galectin-1 protein) in 
the dorsum (Figure SI5.5, Figure 5.5A).  
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Human UM-UC-3 bladder cancer cells were transduced by the lentiviral vector 
containing the firefly reporter gene pCMVLuc (pVR1216) and stable clones were selected 
using blasticidin (Figure SI5.5A). Human UM-UC-3luc+ bladder cancer cells were generated 
from clones (clone B6, Figure SI5.5A) that stably expressed luciferase protein. A cell titration 
curve with UM-UC-3luc+ cells demonstrated an elevated expression of luciferase expression 
over the background level in UM-UC-3 cells (Figure SI5.5B). To confirm that no alterations 
of cellular physiology occurred during the cloning process, we compared the UM-UC-3luc+ 
clones to the original UM-UC-3 cells and we found that they had similar growth patterns and 
cytotoxicity after PDT (Figure SI5.5C). 
A xenograft tumor model prepared by subcutaneous inoculation of 2 x 106 UM-UC-
3luc+ cancer cells in the dorsum of immunocompromised nude (Balb/c nu/nu) mice was 
followed continuously from the time of implantation by non-invasive bioluminescent imaging 
(Figure SI5.5D,E). Although non-invasive bioluminescent imaging allowed us to detect tumor 
burdens from the time of implantation of 2 x 106 UM-UC-3luc+ cancer cells, the tumors could 
not be detected with the caliper before day 9. 
 
Figure 5.5 PorGal8 accumulated in tumors expressing galectin-1 protein. (A) Representative fluorescence 
images of galectin-1 protein (green) in UM-UC-3luc+ tumors, with DAPI staining the nucleus (blue). Scale 
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bars20 µm. (B) Representative fluorescence images and quantification of PorGal8 in dissected organs (skeletal 
muscle, tumor, kidney, heart, lung and liver) obtained 24 h post intraperitoneal injection of PorGal8. Data are 
means ± s.e.m. (n = 3 mice). 
The strongest fluorescence intensity of PorGal8 was observed in the tumor at 24 h after 
injection (Figure 5.5B). At this time point, PorGal8 fluorescence is almost absent in the 
skeletal muscle and heart; and it could be also detected in the primary routes of drug excretion 
and metabolism, such as the lung, kidney and liver (Figure 5.5B). One day post-injection of 
PorGal8 was chosen as the optimal time to perform the PDT studies once at this time point, 
the tumor-to-background ratio (TBR) was about 2.0. 
After confirming the preferential accumulation of PorGal8 in the UM-UC-3luc+ tumors 
(24 h after intraperitoneal injection of 5 µmol/kg, Figure 5.5B), PDT was performed with a 
single dose of light (white light 400–800 nm of a LumaCare irradiation system, with a fluence 
rate of 28 mW/cm2 for 30 min, i.e. 50.4 J/cm2). 
The tumor growth and volume were significantly reduced in UM-UC-3luc+ tumors after 
PDT with PorGal8 when compared to control groups (Figure SI5.6A and Figure 5.6A,B). 
Immunohistochemical analysis of Ki-67 nuclear protein in tumors revealed that Ki-67-positive 
UM-UC-3luc+ cells were rare after PDT with PorGal8 (Figure 5.6C), presumably because of 
the paucity of residual viable cells. Immunohistochemical analysis of E-cadherin demonstrated 
a well organized distribution of this protein in tumors of control animals and its 
disorganization in the tumors of animals treated with PDT (Figure SI5.6B). Western blot 
analysis demonstrated a decrease of both full-length E-cadherin (E-cadherin/FL) and its 
fragments 120 kDa after PDT with PorGal8 (Figure 5.6D). Furthermore, staining with 
Phalloidin-TRICT showed a reorganization of filamentous actin (F-actin) in the tumors of the 
animals treated with PDT (Figure 5.6E). 
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Figure 5.6 PorGal8 has an anticancer photodynamic effect on UM-UC-3luc+ tumors inoculated in nude 
mice. (A) Tumor growth inhibition by PDT with PorGal8 in UM-UC-3luc+ tumors. * P < 0.05, ** P < 0.01 
compared to the control group using a Student´s t test. Data are means ± s.e.m. (n ≥ 6 mice in each group). (B) 
Representative photographs of dissected tumors in control group and animals treated with PDT. Scale bars 5 mm. 
Tumor volumes in untreated mice and mice treated with PDT at 12 days post PDT with PorGal8. ** P < 0.01 
compared to the control group using a Student´s t test. (C) Representative fluorescence images of Ki-67 protein 
(red) in UM-UC-3luc+ tumors of control and treated group, with DAPI staining the nucleus (blue). Scale bars 20 
µm. (D) Western blotting analysis of E-cadherin protein in UM-UC-3luc+ tumors in control and treated group. 
GAPDH was blotted as loading control. (E) Representative fluorescence images of Phalloidin-TRICT in control 
and treated group. Scale bars 20 µm. 
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5.6 Discussion 
 
Many existing PSs used in clinic lack tumor selectivity which leads to undesired damage 
in normal tissues. Thus, there have been many attempts to develop new PSs, that show specific 
accumulation within the target tumor tissue, through conjugation with various active targeting 
approaches, such as conjugation with carbohydrates [1-3], peptides or antibodies [4-7], 
incorporation within liposomes [16], and encapsulation within polymeric nanoparticles [17]. 
Among carbohydrates, the galactose one in the form of dendritic units could have potential in 
the development of new PSs since it improves the solubility of the PSs and it is able to 
promote multivalent interactions with galectins (namely galectin-1 [12]) overexpressed in 
many cancers [8]. In this study, PorGal8 was developed by linking four dendritic units of 
galactose to the photosensitizer porphyrin [14]. PorGal8, has several advantages in PDT, 
including improved water-solubility, photostability, high ability to generate ROS (namely 1O2) 
[14] and selectivity to cancer cells. The selectivity of PorGal8 is derived from its 
phototoxicity after preferential accumulation in cancer cells overexpressing galectin-1; the 
accumulation of this PS and its further phototoxicity is reduced in cancer cells containing low 
levels of galectin-1. 
In vitro studies indicated that PorGal8 binds to galectin-1 with relative high affinity (KD 
of 1.435±0.06175 µM and Ka of 1.27 x 10
7 M-1). Human lectins are involved not only in 
carbohydrate interactions [18, 19], but they are also enrolled in protein-protein/lipid 
interactions via a hydrophobic binding site [20], different from the CRD. The tryptophan 
residue Trp68 has been determined as the one responsible for the fluorescence emission of 
galectin-1 protein [21]. This residue is found on the CRD [21] and it is important in the 
binding of lactose with galectin-1 [22], which is shown by the decrease of the Trp 
fluorescence intensity. Therefore, we can speculate that the molecules of galactose around the 
macrocycle of the porphyrin can promote the binding of PorGal8 with galectin-1 via a 
carbohydrate interaction with the CRD. In addition to the CRD, galectin-1 protein has also a 
well-conserved hydrophobic core, which is responsible for the existence of dimeric galectin-1 
protein in solution due to hydrophobic interactions [21]. Therefore, we also hypothesize that, 
in addition to the carbohydrate interaction between PorGal8 and galectin-1, the spatial 
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clustering of hydrophobic amino acid side chains in human galectin-1 might hold the 
hydrophobic porphyrinic macrocycle. Previous studies have demonstrated that porphyrins (not 
conjugated with sugar moieties) interact with galectin-1 via hydrophobic binding sites [22]. 
Furthermore, the role of galectin-1 in PorGal8 selectivity was also shown when galectin-1 was 
knockdown in UM-UC-3 bladder cancer cells, which was associated with a marked decrease 
of PS uptake and phototoxicity. 
In vivo studies performed in a xenograft tumor model which includes mice with UM-
UC-3luc+ cells (containing high levels of galectin-1) in the dorsum, validated the ability of 
PorGal8 to be accumulated in the tumor tissue. Based on previous data of the lactose-
mediated liver-targeting effect [23], the strong fluorescence intensities of PorGal8 in the mice 
were obtained from 12 h to 24 h. PorGal8 fluorescence was found in the whole body with no 
selectivity at initial several hours and the strongest fluorescence in the tumor site was found at 
24 h after intraperitoneal injection. At this time point, PorGal8 could be detected clearly also 
in the main excretory organs, such as kidney, liver and lung. Together, these data indicate that 
the linkage of dendritic units of galactose may be a useful tool for PS delivery in cancer 
tissues overexpressing galectin-1. In addition to being overexpressed in a spectrum of cancers, 
galectin-1 expression is also heightened in the tumor-associated stroma or neovascular 
endothelium where it contributes to tumor immune escape, metastasis and angiogenesis [11]. 
Even being PDT with PorGal8 twice selective (first PorGal8 is accumulated in the tumor and 
second only the tumor is light irradiated), this strategy can also result in indirect PDT effects 
on the cellular and molecular components of the tumor microenvironment.  
PDT with PorGal8 in the xenograft tumor model demonstrated efficient tumor shrinkage 
with a single administration of PorGal8 followed by a single exposure of light. In a group of 
six animals, we detected complete elimination of the tumor in one of them. Previous PDT 
experiments with the PSs photofrin and/or talaporfin used irradiation doses superior to 100 
J/cm2 in carcinoma xenograft models [24, 25]. In our study, PDT with PorGal8 showed 
antitumor effects in vivo with a relatively low irradiation dose 50.4 J/cm2. This indicates that 
the high cancer cell selectivity and specificity of PorGal8 could reduce the total energy of 
light irradiation needed in PDT treatment. This reduction may further reduce the risk or 
severity of side effects of PSs related to the damage to adjacent normal tissue. 
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The cytoskeleton components (actin microfilaments, microtubules and intermediate 
filaments) are potential targets in the development of new anti-cancer drugs, due to its role in 
cell morphology and membrane integrity. Cytoskeletal structures as well as cell adhesion 
proteins have been shown to be affected by PDT [26]. Our previous unpublished in vitro 
studies demonstrated that PDT with PorGal8 induces alterations of F-actin organization [27]. 
In the present study we observed that PDT with PorGal8 was also able to induce in vivo 
changes in the distribution pattern of the cell adhesion protein E-cadherin. E-cadherin, the 
prototypic member of the classic cadherin family, mediates cell–cell adhesion in epithelia and 
to function, the cytoplasmic domain of cadherins must bind to the actin cytoskeleton via 
proteins called catenins [28]. It is tempting to speculate that rearrangements of the actin 
cytoskeleton and of E-cadherin observed in the present study may play an important role in 
regulating cell death triggered by PDT with PorGal8. Knowing that galectin-1 is also involved 
in cell motility and reorganization of the actin cytoskeleton in cells with increased expression 
of RhoA [29] (a protein involved in actin polymerization and depolymerisation processes), 
further assays are warranted to determine whether RhoA protein is involved in the 
photodamage induced by PDT with PorGal8 in the cytoskeleton of bladder cancer cells. 
In the present study, we used a porphyrin conjugated with dendritic units of galactose as 
an agent of PDT in vitro and in vivo. The potential of PDT with PorGal8 seems to be 
primarily dependent on the expression of galectin-1 in bladder cancer cells and, then on ROS 
formation and alterations on the cytoskeleton of cancer cells. PDT with PorGal8 led to 
successful shrinkage of subcutaneously xenografted tumors after only a single administration 
of PorGal8 followed by a single exposure of light. Thus, we believe that our present study is 
the first to provide the in vivo potential of PSs conjugated with dendritic units of galactose in 
PDT of tumors overexpressing galectin-1. 
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5.8 Supporting Information 
 
 
Figure SI5.1 (A) Chemical structure of porphyrin conjugated with four dendritic units of galactose (PorGal8). 
(B) Linear plot obtained by plotting the changes in the fluorescence of human galectin-1, log((F0-F)/F)vs. log(PS 
concentration) where log(Ka) and n are the ordinate at the origin and slope, respectively. (C) Bright field images 
of monolayer culture of HT-1376 and UM-UC-3 human bladder cancer cell lines. Scale bars 20 µm. 
 
 
 
Figure SI5.2 Representative fluorescence images of bladder cancer cells incubated with PorGal8 (red) in 
darkness and cell nucleus stained with DAPI (blue). Scale bars 20 µm. 
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Figure SI5.3 (A) Non-dark toxicity of PorGal8 determined 24 h after treatment using the MTT assay. The 
percentage of cytotoxicity was calculated relatively to control cells (untreated cells). Data are means ± s.e.m. of 
at least three independent experiments performed in triplicates. (B)Irradiation dose-dependent cell death in 
response to PDT with PorGal8. Cytotoxicity was assessed 24 h after treatment using the MTT assay. The 
percentage of cytotoxicity was calculated relatively to control cells (untreated cells). Data are means ± s.e.m. of 
at least three independent experiments performed in triplicates. * P < 0.05, ** P < 0.01, *** P < 0.001 compared 
to MTT reduction (%) or excluded trypan blue (%) at 24 h after PDT for the respective control using a Student´s t 
test. 
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Figure SI5.4 (A) Representative fluorescence images of apoptotic cell death using TUNEL assay in HT-1376 
and UM-UC-3 cells at 24 and 72 h after PDT with PorGal8. DAPI was used for nuclear region staining (blue) 
and TUNEL staining was used to visualize dead cells (green). Scale bars 20 µm. (B) Phototoxicity at 24 and 72 h 
after treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to control cells 
(untreated cells). Data are means ± s.e.m. of at least three independent experiments performed in triplicates. ++P < 
0.01, +++P < 0.001 compared to MTT reduction (%) in control cells 24 or 72h after PDT using a Student´s t test. * 
P < 0.05, compared to MTT reduction at 24 h for the respective treated cells. (C) Quantification and 
representative fluorescence images of DHE fluorescence increase (as a measure of ROS production) in HT-1376 
and UM-UC-3 cancer cells, after PDT with PorGal8. Scale bars 20 µm. Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates. ** P < 0.01 compared to control cells using a Student´s t test. 
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Figure SI5.5 (A) Bioluminescent signal of blasticidin-resistant clones isolated from UM-UC-3 bladder cancer 
cells transduced with the pLenti6 lentiviral vector containing the firefly reporter gene. Data are means ± s.e.m. of 
one independent experiment performed in duplicates. (B) In vitro correlation between the bioluminescent signal 
of clone B6 and the cell number. Data are means ± s.e.m. of one independent experiment performed in triplicates. 
(C) Phototoxicity after PDT with PorGal8 in UM-UC-3 and UM-UC-3luc+ bladder cancer cells. Cytotoxicity was 
assessed 24 h after treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to 
control cells (untreated cells).Data are means ± s.e.m. of at least three independent experiments performed in 
triplicates. (D) and (E) Bioluminescent signals at 4, 7, 9, 14, 18 and 21 days post-implantation of UM-UC-3luc+ 
cancer cells into the flanks of athymic nude mice. Data are means ± s.e.m. (n = 6 mice). 
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Figure SI5.6 (A) Representative bioluminescent images of mice at 2, 5, 7 and 12 days post PDT with PorGal8. 
PDT 50.4 J/cm2 was performed 24 h after intraperitoneal injection with 5 µmol/kg of PorGal8. (B) 
Representative fluorescence images of E-cadherin protein (red) in UM-UC-3luc+ tumors of control and treated 
group, with DAPI staining the nucleus (blue). Scale bars 20 µm. 
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Chapter VI Mitochondria-targeted photodynamic therapy with a 
galactodendritic chlorin to enhance cell death in resistant human bladder 
cancer cells 
 
6.1 General overview 
 
The photodynamic efficiency could be improved when PS reach and accumulate in 
hypersensitive subcellular sites [1]. The physicochemical properties of the PSs such as 
chemical structure, lipophilicity and charge have a key role on their accumulation in cell 
structures or organelles such as plasma membranes, lysossomes and mitochondria [2]. The 
mitochondrion is an attractive target for PDT due to its central role in energy metabolism and 
regulation of apoptosis [3, 4]. PSs able to target primarily mitochondria, such as cationic 
compounds or agents containing a mitochondrial localization peptide sequence have 
demonstrated enhanced phototoxicity, through mitochondria-mediated apoptosis [5-7]. 
However, a major limitation of the existing PS is the lack of high selectivity for cancer cells. 
In the design of new PSs for cancer treatment, reduction of porphyrins to Chls results on 
an increase in the extinction coefficient of the last Q band [8, 9]. Particularly, 
perfluorophenylchlorin (ChlF20) has demonstrated to be a useful core platform in the 
development of new PSs [10]. Based on our recent research, we envisaged that the conjugation 
of ChlF20 with dendritic units of galactose could improve not only the solubility of the PS in 
an aqueous medium [11] but also increase its specificity for tumor tissues [12]. The high local 
concentration of galactodendritic PSs in the tumor tissues is due to the possible interaction of 
galactose molecules with galactose-binding proteins (such as galectin-1 and glucose 
transporter 1 GLUT1) overexpressed in these tissues [13].  
Here we report the rational design of a new third-generation PS, a chlorin conjugated 
with galactodendritic units, ChlGal8, to improve the effectiveness of bladder cancer treatment. 
ChlGal8 shows better photo-chemical and -physical properties than the homologous 
porphyrin, PorGal8. In addition to inheriting excellent photostability, ability to generate 1O2 
and to interact with the proteins galectin-1 and HSA, ChlGal8 exhibits high absorption in the 
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red region of the electromagnetic spectrum. In vitro studies of anticancer activity of ChlGal8 
revealed that once this PS is taken up by UM-UC-3 bladder cancer cells, induces high 
cytotoxicity after a single dose of light irradiation. In HT-1376 bladder cancer cells resistant to 
therapy, enhanced photodynamic efficacy both in vitro and in vivo was achieved after a second 
light irradiation. The enhanced phototoxicity in HT-1376 cancer cells seems to be due to 
ChlGal8 ability to accumulate in the mitochondria, via GLUT1, in the period of time between 
single and repeated irradiation. A PDT regimen by using an extra dose of light irradiation and 
ChlGal8 as PS, represents a promising strategy in treating resistant cancers in clinic (Figure 
6.1). 
 
Figure 6.1 Hypothetic illustration of phototoxicity of ChlGal8 in in vitro and in vivo biological 
models.ChlGal8 is accumulated in bladder cancer cells. After single PDT, ChlGal8 generates ROS which induce 
high cell death in bladder cancer cells sensitive to PDT. Before repeated PDT, ChlGal8 is preferentially 
accumulated in the mitochondria (as well as GLUT1 protein) and induces high phototoxicity in bladder cancer 
cells resistant to PDT. As the animal model is the essential link between cell-based experiments and translational 
of this new PS into patients with bladder cancer, we have established a xenograft tumor model by subcutaneous 
injection of HT-1376 human bladder cancer cells in the dorsum of immunocompromised nude mice. A significant 
inhibition in the tumor growth was observed after repeated PDT with ChlGal8. 
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6.1.1 Methods 
 
 The following experimental protocols (please see Methods and Materials chapter IX) 
were used to obtain the data presented in this chapter: 
 Aggregation assays (9.2.2A) 
 Fluorescence assays (9.2.2B) 
 Photostability assays (9.2.2C) 
 Singlet oxygen assays (9.2.2D) 
 Protein interaction assays – galectin-1 and HSA (9.2.2E) 
 Partition coefficients (9.2.2F) 
 Biological models – Culture of HT-1376 and UM-UC-3 bladder cancer cells (9.3.8A) 
 Fluorescence spectroscopy – uptake of ChlGal8 (9.3.8C-E) 
 PDT treatments – Photosensitizer ChlGal8 (9.3.8F) 
 Cell viability assays – MTT assays (9.3.8G) 
 Transfection assays – knockdown of GLUT1 using siRNA (9.3.8I) 
 Intracellular levels of Reactive Oxygen Species (9.3.8J) 
 Redox quenching assays (9.3.8K) 
 Western blotting assays – Lamin B, GLUT1, β-actin, Tom20, ZO-1 (9.3.8L) 
 Cellular fractionation (9.3.8P) 
 In vivo assays (9.4.8B) 
 
6.1.2 Publication 
 
This chapter comprises the following publication: 
Patrícia M. R. Pereira, Sandrina Silva, Mafalda Bispo, Mónica Zuzarte, Célia Gomes, 
Henrique Girão, José A. S. Cavaleiro, Carlos A. F. Ribeiro, João P. C. Tomé, Rosa Fernandes, 
Mitochondria-targeted photodynamic therapy with a galactodendritic chlorin to enhance cell 
death in resistant bladder cancer cells, submitted.  
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6.2 ChlGal8 exhibits excellent photo-physical and -chemical properties for PDT 
 
ChlGal8 (Figure 6.2A) was synthesized as described in chapter II. The steady-state 
fluorescence emission spectrum of ChlGal8 was acquired in dimethylformamide (DMF) and 
the fluorescence quantum yield (ΦF) was determined (Table 6.1). These studies demonstrated 
that ChlGal8 has emission bands in the red spectral region at 653 nm and 714 nm. The 
electronic absorption spectra of ChlGal8 were measured in DMSO and their extinction 
coefficients (ɛ) in this solvent are summarized in Table 6.1. ChlGal8 at 4 µM (in DMSO) 
exhibit a very sharp Soret (around 410 nm) and Q bands (around 650 nm), which are typical of 
non-aggregated PSs (Figure 6.2B).  
 
Table 6.1 UV-Visible and fluorescence data of the galactose-conjugate ChlGal8. 
Galactose-conjugate Solvent λabsorption bands[nm] (log ε)a λemission (nm) ФF 
ChlGal8 
DMF 411 (4.5), 651 (3.80) 653, 714 0.60b 
DMSO 411 (4.41), 650 (3.83) ___ ___ 
PBS 416 (4.35), 652 (3.78) ___ ___ 
alogε M-1cm-1, bReference: 5,10,15,20-tetraphenylporphyrin (TPP) in DMF ФF = 0.11 [14] excitation 
at 601 nm. 
 
To determine the solubility of ChlGal8 in aqueous buffered solution, their absorption 
spectra were also acquired in PBS. In this solvent, ChlGal8 demonstrated a lowering intensity 
and a broadening of the Soret and Q bands, which are related with reasonable water solubility 
(Figure 6.2B). The galactose-conjugate strictly follows the Beer-Lambert law at 
concentrations between 0 to 10 µM suggesting no aggregation in PBS at concentrations below 
10 µM (Figure SI6.1A,B). To predict a priori the ability of ChlGal8 to diffuse across cancer 
cell membranes and to reach the inside of cancer cells, the partition coefficient value (log P, 
which is the log of the concentration of compounds in n-octanol/PBS system) was determined 
using the classic shake flask method [10]. Data show that the values of log P are higher for 
PorGal8 when compared with ChlGal8 (Table 6.2), indicating that ChlGal8 has less water 
solubility when compared with the corresponding porphyrin PorGal8. 
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Table 6.2 Partition coefficient (log P in n-octanol/PBS system) values of the galactose-conjugates PorGal8 and 
ChlGal8. 
Compound log P 
PorGal8 -4.00 
ChlGal8 -2.65 
 
The photostability of ChlGal8 was evaluated, by monitoring the intensity of Soret band 
of a PBS solution containing 4 µM ChlGal8, after irradiation with red light (>500 nm) at a 
fluence rate of 150 mW/cm2 (Table SI6.1). The results demonstrate that this galactose-
conjugate is photostable when exposed to strong light power over the investigated irradiation 
period (30 min). The generation of 1O2 by ChlGal8 was determined in DMF:H2O (9:1, v:v) 
using DPBF as 1O2 scavenger. The well known 
1O2 generator, TPPF20, was used as reference 
[15]. The ability of ChlGal8 to generate 1O2 was also compared with the corresponding 
porphyrin PorGal8. ChlGal8, PorGal8 and TPPF20 (both at 0.67 µM) were able to photo-
oxidize DPBF (at 16.15 µM, Figure 6.2C). Under the conditions of the assay, ChlGal8 
demonstrated higher ability to photo-oxidize DPBF when compared to the corresponding 
porphyrin PorGal8.  
 
Figure 6.2 ChlGal8 exhibits excellent photo-chemical and -physical properties. (A) Chemical structure of 
ChlGal8. (B) Electronic absorption spectra of ChlGal8 at 4 μM in DMSO and PBS. (C) Photo-oxidation of DPBF 
(16.15 µM) with or without ChlGal8, PorGal8 or TPPF20 at 0.67 µM, after irradiation with red light (λ > 500 
nm, 14 mW/cm2). The DPBF absorbance was recorded at 415 nm. Data are means ± s.e.m. of at least two 
independent experiments. 
 
 
Chapter VI. Mitochondria-targeted photodynamic therapy with a galactodendritic chlorin to enhance cell death 
in resistant human bladder cancer cells 
 
168 
 
6.3 ChlGal8 interacts with human serum albumin and galectin-1 proteins 
 
To predict the in vivo pharmacokinetics and pharmacological properties of ChlGal8, its 
interaction with the most abundant plasma protein (HSA) was studied by fluorescence 
spectroscopy [11, 16]. A quenching on the fluorescence emission (Figure SI6.1C) of the single 
tryptophan residue present in the protein (Trp214 [17] located in subdomain IIA of site I) 
occurred after addition of ChlGal8 (0 to 40 µM) to HSA samples (2 µM). Ka and n for 
ChlGal8 were 3.28 x 104 M-1 and 1.0, respectively. The value of n equal to 1 indicates that 
ChlGal8 binds HSA in the molar ratio of 1:1. 
We previously reported that the galactose binding proteins overexpressed in bladder 
cancer cells, galectin-1 and GLUT1, have a key role on the uptake of galactodendritic PSs 
[12]. The addition of ChlGal8 (0 to 4 µM) to recombinant human galectin-1 (2 µM) produced 
fluorescence quenching (Figure 6.3A) of the tryptophan residue (Trp68 [18, 19] present on the 
carbohydrate-recognition domain of the protein). The values of Ka and n equal to 1.76 x 107 
M-1 and 1.5, respectively, as well as the KDequal to 3.79 ± 2.22 µM indicate that ChlGal8 has 
high interaction for galectin-1.  
 
6.4 ChlGal8 accumulates and induces phototoxicity in bladder cancer cells 
 
Encouraged by the excellent photo-physical and -chemical properties of ChlGal8, we 
tested the PDT efficacy of ChlGal8 in two bladder cancer cell lines derived from transitional 
cell carcinoma, HT-1376 and UM-UC-3. Bladder cancer is a especially well suited for PDT 
since bladder is an easily accessible organ for both intravesical instillation and illumination 
[20]. Cancer cell uptake of ChlGal8 (0.5 to 10 µM) for up to 4 h was evaluated by 
fluorescence spectroscopy. Both HT-1376 and UM-UC-3 cells took up ChlGal8 quite readily 
with similar uptake profile and a slower steady increase was observed after 1.5 h (Figure 
6.3B). 
To evaluate the efficacy of PDT by ChlGal8 in bladder cancer cells, UM-UC-3 and HT-
1376 were treated with ChlGal8 at various concentrations, and cells were then irradiated with 
red light (> 500 nm) at 2.5 mW/cm2 for 40 min (i.e. 6 J/cm2). No cytotoxicity was observed in 
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cells incubated with ChlGal8 in the dark (Figure SI6.2) for at least 72 h after treatment. 
However, when UM-UC-3 and HT-1376 bladder cancer cells were incubated with ChlGal8 
and then irradiated there was an increased phototoxicity in a concentration-dependent manner 
(Figure 6.3C).  
 
Figure 6.3 ChlGal8 interacts with galectin-1 protein, accumulates and induces phototoxicity in bladder 
cancer cells. (A) Fluorescence variation on the emission spectrum of 2 µM galectin-1 protein after addition of 
ChlGal8 (0-4 µM). Data are means ± s.e.m. of at least two independent experiments. (B) Intracellular uptake of 
ChlGal8 by HT-1376 and UM-UC-3 bladder cancer cells. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicate. (C) Cytotoxicity 24, 48 and 72 h after PDT with ChlGal8, determined using 
the MTT assay. Data are means ± s.e.m. of at least three independent experiments performed in triplicate. *P< 
0.05, **P< 0.01, ***P< 0.001 compared to MTT reduction (%) of control cells (untreated cells) using a Student´s t 
test. 
 
Although PDT with ChlGal8 is more active against UM-UC-3 cells than HT-1376 cells, 
both cell lines were unable to recover from the PDT-induced damage effects (up to 72 h). The 
degree of cytotoxic effect of PDT with ChlGal8 in the two cell lines can be partially explained 
by the different intracellular amount of ROS produced immediately after irradiation, as 
detected with the oxidation-sensitive fluorescent dye 2´,7´-dichlorohydrofluorescin 
(H2DCFDA, Figure 6.4A).  
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6.5 A second light irradiation enhances photodynamic efficacy of ChlGal8 in 
bladder cancer cells 
 
The resistance of HT-1376 cancer cells to PDT with ChlGal8 prompted us to investigate 
the optimization of treatment regimens by repeated dose of light irradiation in order to 
enhance the effectiveness of PDT (Figure 6.4A). Cells were subjected to two irradiations for 
40 min at 2.5 mW/cm2 (6 J/cm2) with a time interval of 1.5 h. The phototoxicity was 
determined 24 h after treatment. Data show that the repeated PDT treatment was similar to the 
single PDT in UM-UC-3 bladder cancer cells (Figure 6.4B). In HT-1376 bladder cancer cells, 
the repeated PDT was shown to be more effective (Figure 6.4B).  
 
Figure 6.4 A second irradiation improves PDT efficacy in bladder cancer cells resistant to therapy. (A) 
Schematic illustration of single and repeated PDT experiments performed with ChlGal8 in bladder cancer cells. 
(B) Cytotoxicity 24 h after single and repeated PDT with ChlGal8, in HT-1376 and UM-UC-3 cancer cells, was 
evaluated using the MTT assay. Data are means ± s.e.m. of at least three independent experiments performed in 
triplicate. *P< 0.05, **P< 0.01, ***P< 0.001 compared to MTT reduction (%) at 24 h after PDT for control cells 
(untreated cells) using a Student´s t test. $P< 0.05, $$P<0.01 compared to MTT reduction (%) at 24 h after PDT 
for single PDT at the respective concentration of ChlGal8 using a Student´s t test. (C) Quantification of oxidized 
H2DCFDA (DCF) fluorescence increase (as a measure of ROS production) in HT-1376 and UM-UC-3 cancer 
cells, after single and repeated PDT with ChlGal8. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicate. **P< 0.01 compared to control cells (untreated cells) using a Student´s t test. 
$P< 0.05, $$P< 0.01 compared to single PDT using a Student´s t test. 
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The concentrations of ChlGal8 necessary to inhibit the metabolic activity of UM-UC-3 
and HT-1376 bladder cancer cells in 50% (IC50), after single and repeated light irradiation, 
were estimated from Figure 6.3C and Figure 6.4B. IC50 value is higher for HT-1376 cells 
treated with single PDT when compared with these cells treated with repeated PDT (Table 
6.3).  
 
Table 6.3 Values for photocytotoxic concentration (IC50, µM) of photoactivatedChlGal8 after single and repeated 
PDT on human bladder cancer cell lines, HT-1376 and UM-UC-3.  
 
IC50 (µM), CI95% 
 UM-UC-3 HT-1376 
Single PDT  1.4 [0.83; 2.3] 4.0 [0.93;17.4] 
Repeated PDT 1.3 [0.58;3.1] 1.3 [0.84;1.9] 
IC
50
 is the incubation concentration that inhibits the metabolic activity of cancer cells in 50%, after single and 
repeated PDT with ChlGal8. IC
50
values were calculated using the MTT dose response curves (24 h after 
treatment).CI
95%
: 95% Confidence interval. 
 
We further showed that the increased phototoxicity after repeated PDT with ChlGal8 in 
resistant HT-1376 bladder cancer cells was accompanied by increased ROS production 
(Figure 6.4C). Additional studies performed with the corresponding porphyrin PorGal8 
demonstrated that the high phototoxicity induced after repeated PDT, in resistant HT-1376 
cancer cells, is a specific characteristic of ChlGal8 (Figure SI6.3).  
 
6.6 ChlGal8 accumulation in mitochondrial fraction is enhanced after a single 
irradiation 
 
The improved efficacy of ChlGal8 after repeated PDT in resistant HT-1376 bladder 
cancer cells, prompted us to study the intracellular localization of ChlGal8 before single and 
repeated treatment. Subcellular fractions were prepared by the differential centrifugation 
method [21] and the amount of ChlGal8 in such fractions was determined by fluorescence 
spectroscopy. To ensure proper fraction enrichment, the subcellular fractions were also tested 
by western blot for specific markers, such as lamin B (nuclear marker), β-actin (cytosol 
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marker), Tom20 (mitochondrial marker) and ZO-1 (membrane marker). After ChlGal8 uptake 
(before single PDT), the intracellular concentration of this PS in the subcellular fractions of 
UM-UC-3 and HT-1376 bladder cancer cells decreased in the following order: nuclei plus cell 
debris (intact cells and large membranes) > mitochondria > plasma membrane > cytosol 
(Figure SI6.4 and Figure 6.5). The distribution of ChlGal8 was similar in the subcellular 
fractions obtained before first and repeated PDT (Figure SI6.4) in UM-UC-3 bladder cancer 
cells. In HT-1376 bladder cancer cells, there was an increase of ChlGal8 in the mitochondrial 
fraction obtained before repeated PDT (Figure 6.5A). The increase of ChlGal8 in the 
mitochondrial fraction of HT-1376 cells was accompanied with a decrease of this PS in the 
“nucleus plus cell debris” fraction. Interestingly, Western blot analysis of GLUT1 
demonstrated that in the period of time between single and repeated PDT there is an increase 
of GLUT1 protein in the mitochondrial fraction of HT-1376 cells (Figure 6.5B,C). In control 
experiments where HT-1376 bladder cancer cells were incubated with PBS and then repeated 
PDT was performed, no changes were observed in GLUT1present in the mitochondria-
enriched fraction (Figure SI6.5). 
 
Figure 6.5 ChlGal8 promotes translocation of GLUT1 to the mitochondria after a single irradiation. (A) 
Distribution of ChlGal8 in the subcellular fractions “nucleus (N) plus cell debris”, mitochondria (MT), plasma 
membrane (PM) and cytosol (Cy) of HT-1376 cancer cells, obtained before single and repeated PDT. Data are 
means ± s.e.m. of at least three independent experiments performed in triplicates. *P< 0.05, **P< 0.01 compared 
to uptake (nmol PS/mg protein) of ChlGal8 before single PDT for the respective subcellular fraction using a 
Student´s t test. (B,C) Western blot analysis of lamin B (nuclear marker), GLUT1, β-actin (cytosol marker), 
Tom20 (mitochondrial marker) and ZO-1 (plasma membrane marker) in the subcellular fractions of HT-1376 
bladder cancer cells, obtained before (B) single and (C) repeated PDT. 
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To determine whether the preferential accumulation of ChlGal8 in the mitochondria 
before repeated PDT is involved on the increment of mitochondrial ROS production and 
further enhancement of phototoxicity, additional experiments were performed with the 
mitochondria-targeted superoxide scavenger (MitoTEMPO) and with the fluorescent 
mitochondrial probe for highly reactive species, the mitochondria peroxy yellow 1 (MitoPY1) 
[22]. Overall, we found that phototoxicity was attenuated when PDT assays were performed in 
HT-1376 cells incubated with MitoTEMPO (Figure 6.6A). Additionally, the increase in 
phototoxicity after repeated PDT with ChlGal8 in HT-1376 cells demonstrated to be 
dependent on the production of mitochondrial ROS (namely hydrogen peroxide), as detected 
with MitoPY1 (Figure 6.6B).  
 
Figure 6.6 ChlGal8 induces higher mitochondrial ROS production after repeated irradiation. (A) 
Phototoxicity 24 h after single and repeated PDT in the presence of 10 µM MitoTEMPO (a specific scavenger of 
mitochondrial hydrogen superoxide) in HT-1376 cancer cells, determined using the MTT assay. Data are means 
± s.e.m. of at least three independent experiments performed in triplicate. *P<0.05, $$$P< 0.001 compared to MTT 
reduction (%) at 24 h after single and repeated PDT, respectively, using a Student´s t test. +P< 0.05 compared to 
MTT reduction (%) at 24 h after repeated PDT in the presence of 10 µM MitoTEMPO (added before single PDT) 
using a Student´s t test. (B) Quantification of MitoPY1 fluorescence increase (as a measure of hydrogen peroxide 
production in mitochondria) in HT-1376 cells in the absence and presence of MitoTEMPO, after single and 
repeated PDT with ChlGal8. Data are means ± s.e.m. of at least three independent experiments performed in 
triplicate. ***P< 0.001 compared to control cells (untreated cells) using a Student´s t test. $$$P< 0.001 compared to 
repeated PDT using a Student´s t test. 
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6.7 ChlGal8 promotes translocation of GLUT1 to the mitochondria after a single 
irradiation and induces high phototoxicity after repeated irradiation 
 
To determine whether GLUT1 plays a role in PDT efficacy with ChlGal8, siRNA was 
used to knockdown GLUT1 within HT-1376 cancer cells (Figure SI6.6A). No significant 
differences were detected on the uptake of ChlGal8 by HT-1376 cells after knockdown of 
GLUT1 protein (Figure SI6.6B). However, knockdown of GLUT1 significantly reduced ROS 
production and phototoxicity (Figure 6.7A,B). Furthermore, we showed that GLUT1 siRNA 
prevented the irradiation-induced increase of ChlGal8 in the mitochondrial fraction of HT-
1376 cells (Figure 6.7C).  
 
Figure 6.7 GLUT1 has a key role in increased ChlGal8-induced phototoxicity after repeated PDT. (A) 
Quantification of DCF fluorescence increase (as a measure of ROS production) in HT-1376 cells transfected with 
GLUT1 siRNA after single and repeated PDT with ChlGal8. Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates. *P< 0.05, $$P< 0.01 compared to single and repeated PDT, 
respectively, in non-transfected HT-1376 cells. ++P< 0.01 compared to single PDT in transfected HT-1376 cells. 
(B) Photocytotoxic effects after single and repeated PDT with ChlGal8 in HT-1376 cells transfected with GLUT1 
siRNA. Data are means ± s.e.m. of at least three independent experiments performed in triplicate. *P< 0.05, $$P< 
0.01 compared to MTT reduction (%) at 24 h after single and repeated PDT, respectively, using a Student´s t test. 
++P< 0.01 compared to MTT reduction (%) at 24 h after single PDT in HT-1376 cells transfected with GLUT1 
siRNA, using a Student´s t test. (C) Distribution of ChlGal8 in the subcellular fractions “nucleus (N) plus cell 
debris”, mitochondria (MT), plasma membrane (PM) and cytosol (Cy) of HT-1376 cells transfected with GLUT1 
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siRNA, obtained before single and repeated PDT. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicate. **P< 0.01, $$P< 0.01 compared to the respective subcellular fractions 
obtained before the first and second irradiation times, respectively, in non-transfected HT-1376 cells. 
 
6.8 Repeated PDT with ChlGal8 improves the in vivo photodynamic efficacy against 
HT-1376 tumors inoculated in nude mice 
 
Subcutaneous xenograft HT-1376 tumors were used to evaluate the PDT efficacy of 
ChlGal8 after single and repeated treatments (Figure 6.8A). In single PDT, the HT-1376 
tumors were treated with a single dose of light (>500 nm) with a fluence rate of 30 mW/cm2 
for 20 min, i.e. 36 J/cm2) at 1.5 h after intratumoral injection of ChlGal8 (3.33 µmol/kg). In 
repeated PDT, the tumors were irradiated for an additional time (36 J/cm2) at 40 min after the 
first PDT session. As illustrated in Figure 6.8B, a single intratumoral administration of 
ChlGal8 and exposure to repeated photo-irradiation was significantly more efficacious in the 
inhibition of tumor growth than single shot photo-irradiation. The tumor growth of mice 
treated with single treatment was slightly suppressed after PDT, however, accelerated after 6 
days and exhibited almost no difference to the control group at the endpoint.  
 
Figure 6.8 Repeated PDT with ChlGal8 improves the in vivo photodynamic efficacy against HT-1376 
tumors inoculated in nude mice. (A) Schematic illustration of single and repeated PDT experiments performed 
in vivo with ChlGal8. (B) Tumor volumes in control mice, mice treated with single and repeated PDT at days 1-
15 after treatment. Values are means ± s.e.m. (n = 6 mice per group).  
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6.9 Discussion 
 
ChlGal8 is an interesting third generation PS for PDT of bladder cancer because 
dendritic galactose molecules around chlorin macrocycle can be recognized by galactose 
binding proteins (such as galectin-1 and GLUT1) overexpressed in cancer cells. The synthesis 
of ChlGal8 was motivated by the interesting in vitro and in vivo results of PorGal8 (please see 
Chapter V).  
ChlGal8 has a more than 50-fold higher extinction coefficient (6800 M-1.cm-1) at the 
absorption maximum of 650 nm than the corresponding previously reported porphyrin 
PorGal8 in the previous chapter, 100 M-1.cm-1 at 655 nm) [11]. Due to its higher absorption at 
650 nm, where tissue light penetration is rather high [23], ChlGal8 could be advantageous for 
PDT when compared with the corresponding PorGal8.  
In addition to water solubility, 1O2 generation and photostability, ChlGal8 also 
demonstrated interaction with HSA and galectin-1 proteins. HSA is able to bind and transport 
anticancer drugs. Moreover, increased vascular permeability exhibited in solid tumors, leads to 
the accumulation of drug albumin conjugates in the tumor interstitium, affecting the unbound 
(free) drug quantity in the circulation, its distribution, metabolism, elimination and biological 
activity [24]. The interaction of ChlGal8 with galectin-1 can be explained by carbohydrate 
interactions of the galactose units with the carbohydrate-recognition domain of the protein 
[19], and hydrophobic interactions between the chlorin macrocycle and the well-conserved 
hydrophobic core of the protein [18, 25, 26].  
We have previously reported that HT-1376 and UM-UC-3 bladder cancer cells express 
high levels of the galactose binding proteins GLUT1 and galectin-1 (chapter III), respectively 
[12]. Therefore, it is envisaged that specific domains, enriched in these proteins, at the cell 
surface can promote the interaction with the galactodendritic units on the chlorin macrocycle 
of ChlGal8, enhancing somehow its cellular uptake. The association of ChlGal8 with 
galactose binding proteins promotes high local concentration of the PS around cancer cell 
membrane, which induces PS macrocycle partition into the membrane. Thus, uptake of 
ChlGal8 is also dependent on its relative hydrophobicity [27]. 
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When compared with PorGal8 data (chapter V), the uptake of ChlGal8 was lower which 
can be due to its higher partition coefficient value. Although the lower uptake of ChlGal8 by 
bladder cancer cells when compared with PorGal8, the photoxicity induced 24 h after PDT 
was higher with ChlGal8 than with PorGal8 in UM-UC-3 bladder cancer cells. Another 
interesting result was that although the similar uptake of ChlGal8 by UM-UC-3 and HT-1376 
bladder cancer cells, the phototoxicity induced by ChlGal8 was higher in UM-UC-3 than in 
HT-1376 cells. Previous studies have demonstrated that HT-1376 cells exhibit a protective 
mechanism after PDT by inducing an antioxidant response [12]. The key role of 
microenvironment-related molecules, particularly the extracellular matrix-metalloproteinase 
inducer CD147 on the resistance of HT-1376 cancer cells to cisplatin-based chemotherapy has 
also been reported [28]. 
In this study, we demonstrated that a repeated PDT was more effective in inducing cell 
death in resistant HT-1376 cancer cells when compared with single PDT. These results can be 
explained by disaggregation of ChlGal8 molecules between the first and second light 
irradiation steps. Interestingly, after a single irradiation both ChlGal8 and GLUT1 are 
localized in the mitochondrial fraction. GLUT1 is ubiquitously expressed in most mammalian 
cells [29]. Although the role of GLUT1 in the mitochondria is not completely clear, it is 
speculated that GLUT1 is mostly involved on the transport of the oxidized form of vitamin C, 
the dehydroascorbic acid [30]. Once inside mitochondria, dehydroascorbic acid is reduced to 
ascorbic acid [29] that quenches ROS, inhibits mitochondrial membrane depolarization and 
protects mitochondria from oxidative injury [30]. Our results collectively point to an 
antioxidant response of HT-1376 cancer cells after single PDT, which stimulates the 
translocation of GLUT1 to the mitochondria. As a first stage, it is expected that GLUT1 
translocation to the mitochondria contributes to a protective response against ROS-mediated 
damage. However, upon accumulation of ChlGal8 in mitochondria, if a repeated PDT occurs, 
this PS is highly efficient in inducing phototoxicity. 
Mitochondria have been recognized as a key target for the initiation of apoptosis in PDT. 
ChlGal8 bound to mitochondria can generate large amounts of ROS after irradiation, which 
can lead to mitochondrial damage triggering cell death signaling cascades and the 
mitochondria-dependent apoptosis [31].  
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Given that ChlGal8 was demonstrated to be a powerful PS in in vitro assays, we next 
conducted a proof-of-concept study to demonstrate its increased efficacy after a repeated 
irradiation treatment in a xenograft tumor. A single administration of ChlGal8 followed by a 
repeated PDT demonstrated to be more effective than the conventional single treatment. 
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6.11 Supporting information 
 
 
Figure SI6.1 (A) UV-Visible spectra of ChlGal8 in PBS at different concentrations (0 µM to 10 µM). (B) Linear 
plot obtained by plotting ChlGal8-Soret band at 416 nm vs. concentration of the galactose-conjugate in PBS. 
Data are means ± s.e.m. of at least two independent experiments. (C) Fluorescence quenching curves of 2 µM of 
HSA, after addition of ChlGal8 at several concentrations (between 0 µM to 40.4 µM). Quenching (%)=(F0-
F)/F0, where F0 and F are the HSA fluorescence intensities in the absence and presence of ChlGal8 (λexcitation 
at 280 nm and wavelength emission range between 300 nm to 400 nm). Data are means ± s.e.m. of at least two 
independent experiments.  
 
 
Figure SI6.2 Non-dark toxicity of ChlGal8 determined 24, 48 and 72 h after treatment using the MTT assay. The 
percentage of cytotoxicity was calculated relatively to control cells (untreated cells). Data are means ± s.e.m. of 
at least three independent experiments performed in triplicate.  
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Figure SI6.3 Irradiation dose-dependent cell death in response to single and repeated PDT with PorGal8. 
Cytotoxicity was assessed 24 h after treatment using the MTT assay. The percentage of cytotoxicity was 
calculated relatively to control cells (untreated cells). Data are means ± s.e.m. of at least three independent 
experiments performed in triplicate. *P< 0.05, **P< 0.01, ***P< 0.001 compared to control cells (untreated cells) 
using a Student´s t test.  
 
 
Figure SI6.4 (A) Distribution of ChlGal8 in the subcellular fractions “nucleus (N) plus cell debris”, 
mitochondria (MT), plasma membrane (PM) and cytosol (Cy) of UM-UC-3 cancer cells, obtained before single 
and repeated PDT. Data are means ± s.e.m. of at least three independent experiments performed in triplicate. 
(B,C) Western blot analysis of lamin B (nuclear marker), GLUT1, β-actin (cytosol marker) and Tom20 
(mitochondrial marker) in the subcellular fractions of UM-UC-3 bladder cancer cells, obtained before (B) single 
and (C) repeated PDT. 
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Figure SI6.5 Western blot analysis of lamin B (nuclear marker), GLUT1, β-actin (cytosol marker), Tom20 
(mitochondrial marker) and ZO-1 (plasma membrane marker) in the subcellular fractions “nucleus (N) plus cell 
debris”, mitochondria (MT), plasma membrane (PM) and cytosol (Cy), of HT-1376 bladder cancer cells, obtained 
before single and repeated PDT in control cells (untreated cells). 
 
 
 
Figure SI6.6 (A) Knockdown of GLUT1 in HT-1376 bladder cancer cells as determined by Western blot 24 h 
post-transfection. (B) Intracellular uptake of ChlGal8 by HT-1376 bladder cancer cells transfected with GLUT1 
siRNA. Data are means ± s.e.m. of at least three independent experiments performed in triplicate.  
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Table SI6.1 Photostability of ChlGal8 at 4 µM in PBS, after irradiation with red light (620-750 nm) at a fluence 
rate of 150 mW/cm2 for different periods of time (0-30 min). The results are presented in percentage calculated 
by the ratio of residual absorbance (at 416 nm) at different periods of time and absorbance before irradiation. 
Data are means ± s.e.m. of at least two independent experiments. 
Galactose-conjugate 
Irradiation time (min) 
0 1 3 4 5 10 15 20 25 30 
ChlGal8 100 100 100 99 99 99 99 98 98 98 
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Chapter VII Establishment and characterization of tumor spheroids 
for evaluating photodynamic efficacy of a porphyrin attached to the carbon-
3 of galactose 
 
7.1 General overview 
 
Galactosylated photosensitizers have been developed viaN-, S-, C- and O-galactosylation 
by attaching the anomeric carbon or carbon-6 of the sugar to the macrocycle of the 
porphyrinoid [1]. To gain affinity for galactose-binding proteins, the galactosylated 
porphyrinoids have been also developed by using galactose sugar in a multivalent format [2, 
3]. Besides this, optimization of monovalent galactose by derivatization of the galactose 
carbon-3 yielded compounds with high affinity to galectin-1 [4].  
Most work on PDT has been done on either in vivo animal models or in vitro two-
dimensional monolayers. Monolayer culture of cancer cells are easily handled and offer some 
information about cellular processes at a much lower cost than animal studies. However, 
monolayers represent a highly artificial cellular environment and lack the three-dimensional 
aspects of a tumor [5-8]. Therefore, they are less reliable in predicting effectiveness of 
treatments in vivo. Moreover, tumors are known to have a necrotic core [9] characterized by 
hypoxia at its center. This necrotic core has been shown to make cancer cells more resistant to 
ROS-dependent radiation [10], and chemotherapy [7]. Because PDT relies on the availability 
of oxygen to cells for generation of ROS, a monolayer model is not sufficient to understand 
what happens in vivo.  
To address this issue, researchers have turned to a more complex model using spheroids 
[11-13]. To a certain degree, spheroids with specific size can mimic the behavior of tumors 
because they are likewise three-dimensional cell aggregates with a necrotic core at the center 
and healthy cells at the surface. This is particularly important because it allows for the 
formation of a gradient of nutrients, such as oxygen which can influence PDT efficacy. Both 
the three-dimensional structure and the oxygen gradient make spheroids a better model to 
predict photodynamic efficiency of a new galactose-PS. 
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In an attempt to increase the affinity of porphyrinoids to galectin-1 protein, we have 
attached galactose units through carbon-3 to a porphyrin by click conjugation (Por-C3-Gal4). 
Furthermore, to validate the potential of Por-C3-Gal4,the same tetrapyrrolic macrocycle was 
also attached to the carbon-1 of galactose sugar (Por-C1-Gal4). The aim of the present study 
was to investigate the photophysical properties, uptake and photodynamic efficiency of Por-
C3-Gal4 and Por-C1-Gal4 in in vitro cancer models. In vitro studies were performed in 
monolayers of cancer cells (HCT-116 colon cancer cells, MCF-7 breast cancer cells, UM-UC-
3 bladder cancer cells and HeLa cervical cancer cells) expressing different levels of galectin-1 
protein. Attempting to mimic the several heterogeneous treatment effects found in vivo, in 
vitro studies were also performed in the corresponding three-dimensional spheroid cancer cell 
cultures. Using agarose-coated plates, we obtained viable spheroids from human tumor cell 
lines from different origins (HCT-116, MCF-7, UM-UC-3 and HELA cells) with appropriate 
size (volume of approximately 0.05 mm3 and diameter of approximately 443µm) for screening 
PDT agents. We observed that detachment from monolayer culture and growth as tumor 
spheroids was accompanied by changes in both glucose metabolism, endogenous ROS levels 
and galectin-1 and GLUT1 protein levels.  
 The uptake and phototoxocity of the new galactose-Pors are dependent on the galactose 
moiety (C1 vs. C3), partition coefficient, levels of galectin-1 in cancer cells and on the in vitro 
(monolayer or spheroid cultures) model used. Porphyrin attached to the carbon-3 of galactose 
sugar exhibits higher potodynamic activity in bladder cancer cells expressing galectin-1 
protein, than the corresponding porphyrin attached to the carbon-1 of galactose sugar (Figure 
7.1).  
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Figure 7.1 Illustration of spheroids formation with HCT-116, MCF-7, UM-UC-3 and HeLa cancer cells; 
and phototoxicity with Por-C3-Gal4 and Por-C1-Gal4. The initial aggregation of monolayer cancer cells plated 
for spheroid formation lasted for 24 h. Within 48-72 h the small clumps were replaced by compact spheroids. The 
glycolotic status (glucose usage and lactate production), endogenous levels of ROS and expression of the proteins 
galectin-1 and GLUT1 are altered during spheroids formation. Por-C3-Gal4 and Por-C1-Gal4 are non toxic 
compounds per se and have high toxicity after PDT.  
 
7.1.1 Methods 
 
The following experimental protocols (please see Methods and Materials chapter IX) 
were used to obtain the data presented in this chapter: 
 Partition coefficients (9.2.2F) 
 Biological models – Culture of HCT-116 colon cancer cells, MCF-7 breast cancer 
cells, UM-UC-3 bladder cancer cells and HeLa cervical cancer cells as monolayers and 
spheroids (9.3.8A,B) 
 Fluorescence spectroscopy – uptake of Por-C3-Gal4 and Por-C1-Gal4 (9.3.8C-E) 
 PDT treatments – Photosensitizer Por-C3-Gal4 and Por-C1-Gal4 (9.3.8F) 
 Cell viability assays – MTT and LDH assays (9.3.8G) 
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 Intracellular levels of Reactive Oxygen Species (9.3.8J) 
 Western blotting assays – galectin-1, GLUT1, β-actin (9.3.8L) 
 
7.1.2 Publication 
 
This chapter comprises the following publications: 
Patrícia M.R. Pereira, N. V. S. Dinesh K. Bhupathiraju, Naxhije Berisha, Rosa 
Fernandes, João P.C. Tomé, Charles M. Drain, Application of Cancer Cell Spheroids to 
Screen Photodynamic Efficiency of Glyco-Photosensitizers, under final preparation.  
 
Patrícia M.R. Pereira, N. V. S. Dinesh K. Bhupathiraju, Waqar Rizvi, Rosa Fernandes, 
João P.C. Tomé, Charles M. Drain, Comparative studies of porphyrin C3-galactose and 
porphyrin C1-galactose conjugates for enhanced photodynamic therapy, under final 
preparation.   
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7.2 Kinetics of spheroids growth 
 
The culture of certain type of cells on surfaces not favourable for cell attachment led to 
enhancement of homotypic cell-cell interactions, resulting in formation of three-dimensional 
structures (spheroids, Figure 7.2A) [8]. In our study, five different types of cells were tested 
for spheroid formation in agarose-coated wells of a 96-well plate (Table 7.1). The HCT-116 
colon cancer cells, MCF-7 and MDA-MB-231 breast cancer cells, UM-UC-3 bladder cancer 
cells and HeLa cervical cancer cells were cultured in suspension on agarose bed which forms a 
thin non-adherent film and prevents cell attachment. Agarose is one of the most efficient 
substrates to prevent cell attachment to the plate and has been used in several studies regarding 
spheroid cultures [7, 14-17].  
 
Table 7.1 Human cell lines tested for spheroids formation and their respective doubling times (h). 
 
 
 
 
 
 
 
After seeding on the agarose-coated wells, cells started to cluster, and the first loose 
aggregates were already seen after 2 h of incubation. During the first 24 h of incubation, the 
cells formed aggregates which were easily dissociated by mechanical force. Most of the tumor 
cells tested (HCT-116, MCF-7, UM-UC-3 and HeLa) gave rise to compact, rigid and 
spherically-shaped spheroids (Figures 7.2 and 7.3) by 48 h after cell plating. When spheroid 
cultures were observed under phase contrast microscope, a multilayer cell assembly was 
observed. The absence of necrotic core formation within spheroids was evident at all time 
points examined, indicative of cell viability in the interior of the spherical structures. Besides, 
these cultures were resistant to gentle agitation or physical transfer and only enzymatic 
digestion could separate these three-dimensional structures into single cells. MDA-MB-231 
Cell line Origin 
Doubling time (h) 
Monolayers [Reference] Spheroids 
HCT-116 Colon Cancer 17 [18] 19 
MCF-7 Breast Cancer 25 [18] 38 
UM-UC-3 Bladder Cancer 20 [19] 23 
HeLa Cervival Cancer 19 [18] 23 
MDA-MB-231 Breast Cancer 42 [18] N.D. 
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breast cancer cells remained as single suspended cells forming aggregates which were not 
stable enough for harvest and further experiments.  
 
Figure 7.2 Spheroid size is dependent on cell seeding number. (A) Spheroid plating scheme: one spheroid per 
well was formed in agarose-coated 96-well plates. (B,C)Volume (mm3) and number of cells of HCT-116, MCF-
7, UM-UC-3 and HeLa cancer cells at 48 h after plating with seeding densities of 2,500- 20,000 cells per well for 
HCT-116, UM-UC-3 and HeLa cancer cells and 5,000-20,000 cells per well for MCF-7 cancer cells. Data are 
mean ± S.D. of at least 30 spheroids. (D)representative brightfield images of spheroids at 48 h after plating with 
seeding densities of 2,500- 20,000 cells per well for HCT-116, UM-UC-3 and HeLa cancer cells and 5,000-
20,000 cells per well for MCF-7 cancer cells. Scale bars 100 µm. 
 
We analysed the growth kinetic of spheroid HCT-116, MCF-7, UM-UC-3 and HeLa 
cancer cells (Figures 7.2 and 7.3, Tables SI7.1-SI7.4). Figure 7.2D shows representative 
optical images of spheroids with different initial cell seeding density (2,500 – 20,000 cells per 
well). A higher cell density in the initial suspension gave rise to spheroids with bigger volume 
and number of cells per spheroid than lower cell densities (Figures 7.2B-D). HCT-116, MCF-
7, UM-UC-3 and HeLa spheroids showed similar growth pattern, i.e. the volume decreased 
significantly until 48 h in culture, then maintaining until 72 h with small fluctuations (Figures 
7.3A,C). Between 48 to 72 h after cell plating, the border of the spheroids became ruffled, 
indicating proliferation at the spheroid periphery (Figure 7.3C). The number of viable cells per 
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spheroid increased with time after cell seeding (Figure 7.3B) with doubling times lower when 
compared with monolayer cultures (Table 7.1).  
In an attempt to use spheroids with similar volume in our studies to guarantee the 
homogeneity of our three-dimensional populations, we determined the cell seeding densities 
by which spheroids of different cell lines can be obtained with similar size after 48 h in culture 
(Tables SI7.1-SI7.4, Figure 7.3A). The culture of 5,000 HCT-116 cells per well, 15,000 MCF-
7 cells per well, 20,000 UM-UC-3 cells per well, 20,000 HeLa cells per well gave rise to 
spheroids with volume and average size of approximately 0.05 mm3 and 443 µm, respectively.  
 
Figure 7.3 Spheroid size is dependent on time after cell seeding. (A, B)Volume (mm3) and number of cells of 
HCT-116, MCF-7, UM-UC-3 and HeLa cancer cells at 24, 48 and 72 h after plating with seeding densities of 
5,000 HCT-116 cells per well, 15,000 MCF-7 cells per well, 20,000 UM-UC-3 cells per well and 20,000 HeLa 
cells per well. Data are mean ± S.D. of at least 30 spheroids. (C) representative brightfield images of spheroids at 
24, 48 and 72 h after plating with seeding densities of 5,000 HCT-116 cells per well, 15,000 MCF-7 cells per 
well, 20,000 UM-UC-3 cells per well and 20,000 HeLa cells per well. Scale bars 100 µm. 
 
7.3 Cells of resulting spheroids are viable and have altered pattern of metabolism 
 
To assess cellular viability of spheroid cultures, the MTT assay (which measures cell 
metabolic activity) was performed in intact or dissociated spheroids [9, 20]. Unlike other 
studies reporting the use of MTT to study spheroids viability, the MTT assay could not be 
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applied on the evaluation of spheroids viability since this assay did not result in reproducible 
and constant results (data not shown). The determination of cell death via measurement of 
molecules released from membrane-defective cells into the extracellular medium 
demonstrated be preferable in the evaluation of spheroids viability. Therefore, culture media 
from monolayer or spheroid cultures were used for estimation of lactate dehydrogenase (LDH) 
release by cells that have membrane damaged due to necrosis or apoptosis [20]. The amounts 
of LDH release by spheroids at 48 and 72 h were similar to those at 24 h after cell plating 
(Figure 7.4A). LHD release by spheroids was similar to those by the respective monolayer 
cultures (Figure 7.4B), which demonstrates that the generated spheroids are viable structures 
for at least 72 h after cell plating. 
Spheroids, which are high cell-density and closely packed three-dimensional-tumor like 
structures, closely simulate conditions existing in the under-perfused solid tumors, wherein 
hypoxia and related alterations in cellular metabolism occur due to increasing distances from 
the nourishing blood capillaries. In fact, the diffusion of small molecules such as glucose and 
oxygen can be limited, leading to low concentrations of glucose and oxygen in the inner 
regions of spheroids [10, 21]. The glycolytic flux of cells in culture can be determined by 
measuring glucose consumption and lactate excretion [22]. To determine the glucose 
consumption by cells, we used the fluorescent glucose analog (2-deoxy-2-[(7-nitro-2,1,3-
benzoxadiazol-4-yl)amino]-D-glucose (2-NBDG), which was added to the cells during 1 h of 
incubation and its intracellular accumulation was measured by fluorescence spectroscopy. The 
glucose utilization (nmol per mg of protein) in monolayer cultures decreased in the following 
order HeLa > HCT-116 >UM-UC-3 > MCF-7 (Figure SI7.1). The glucose consumption by 
MCF-7 and UM-UC-3 spheroids was higher than the corresponding cells growing in 
monolayers (Figure 7.4C). On the other hand, spheroids of HCT-116 and HeLa demonstrated 
lower glucose consumption than monolayer cultures. Lactate production (nmol/mg of protein) 
was determined in the culture medium using a commercially available colorimetric kit. The 
lactate production in monolayer cultures decreased in the following order: HeLa > HCT-116 ≈ 
MCF-7 >UM-UC-3 (Figure SI7.2). A significant increment in lactate production was observed 
during the formation of UM-UC-3 and HeLa spheroids (Figure 7.4D). Interestingly, no 
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alterations in lactate production were observed during HCT-116 and MCF-7 spheroid 
development. 
 
Figure 7.4 Cells of resulting spheroids are viable and have altered pattern of metabolism. (A, B)Spheroids 
viability at 24, 48 and 72 h after plating with seeding densities of 5,000 HCT-116 cells per well, 15,000 MCF-7 
cells per well, 20,000 UM-UC-3 cells per well and 20,000 HeLa cells per well. Viability was determined using 
the lactate dehydrogenase (LDH) assay. LDH activity was measured in the culture supernatant and data were 
normalized to LDH activity of spheroids at 24 h after cell plating (A) or LDH activity of cells growing in 
monolayers (B). Data are means ± S.D. of at least three independent experiments performed in triplicate. C, 
DGlucose utilization and lactate production of cancer cells growing in monolayers and in spheroids at 48 h after 
plating with seeding densities of 5,000 HCT-116 cells per well, 15,000 MCF-7 cells per well, 20,000 UM-UC-3 
cells per well and 20,000 HeLa cells per well. The amount of glucose (nmol, C) and lactate (nmol, D) were 
estimated using enzymatic assays and the results were normalized for mg of protein. Data are means ± S.D. of at 
least three independent experiments performed in triplicate. **P< 0.01, ***P< 0.001 compared to glucose 
utilization or lactate production of the respective cancer cell line growing in monolayers, using a Student´s t test. 
 
7.4 Expression of galectin-1 and GLUT1 proteins; and endogenous ROS are altered 
during spheroids formation 
 
In our research related with the development of new PSs to be used in cancer PDT, we 
are particularly interested in porphyrinoids conjugated with sugars such as glucose and 
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galactose [1-3, 23]. Galectin-1 and GLUT1 are glyco-binding proteins overexpressed in cancer 
cells [24, 25] with a key role in the uptake and further phototoxicity of glyco-PSs [2, 26, 27]. 
Therefore we have evaluated the protein levels of galectin-1 and GLUT1 in monolayers of 
HCT-116, MCF-7, UM-UC-3 and HeLa cancer cells, by Western Blotting (Figure 7.5A,B). To 
determine whether the expression of these proteins is altered during spheroids development, 
we have also performed Western Blotting in cellular extracts of spheroid cultures (Figures 
7.5C,D). Galectin-1 and GLUT1 expression was higher in MCF-7 spheroids when compared 
with monolayer cultures. No alterations in galectin-1 expression occurred during growth of 
HeLa and UM-UC-3 spheroids. Galectin-1 protein levels were lower in spheroids of HCT-116 
and GLUT1 protein levels were lower in spheroids of HCT-116 and HELA. The expression of 
galectin-1 spheroids decreased in the following order: UM-UC-3 > HeLa > MCF-7 > HCT-
116 (Figure SI7.3). Additionally GLUT1 protein levels in spheroids decreased in the following 
order: MCF-7 > UM-UC-3 > HeLa ≈ HCT-116 (Figure SI7.4). 
Previous studies have reported alterations in endogenous ROS during spheroid 
development [10]. To determine endogenous levels of ROS in monolayer and spheroids, these 
cultures were stained with the redox sensitive dye H2DCFDA and the fluorescence of ROS 
converted into DCF (oxidized H2DCFDA) was monitored by fluorescence spectroscopy. 
Endogenous levels were similar in monolayers and spheroids of MCF-7 and UM-UC-3 cancer 
cells (Figure SI7.5). In HCT-116 and HELA spheroids there was an increase in endogenous 
ROS generation during spheroid formation. 
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Figure 7.5 Cells of resulting spheroids have altered expression of galectin-1 and GLUT1 proteins. (A, 
C)Western blotting analysis and quantification of galectin-1 protein levels in monolayers of HCT-116, MCF-7, 
UM-UC-3 and HeLa cancer cells growing in monolayers (A) or in spheroids (C). M means monolayer and S, 
spheroid. Quantitative analysis of galectin-1 (normalized to β-actin) expressed as a ratio of the levels found in 
HeLa cells (A) or in cancer monolayers (C). Data are means ± S.D. of at least five independent experiments. 
***P< 0.001 compared to galectin-1 protein levels in HeLa cells (A) or in respective cancer cell line growing in 
monolayers (C), using a Student´s t test. (B, D)Western blotting analysis and quantification of GLUT1 protein 
levels in monolayers of HCT-116, MCF-7, UM-UC-3 and HeLa cancer cells growing in monolayers (B) or in 
spheroids (D). M means monolayer and S, spheroid. Quantitative analysis of GLUT1 (normalized to β-actin) 
expressed as a ratio of the levels found in HeLa cells (B) or in cancer monolayers (D). Data are means ± S.D. of 
at least five independent experiments. *P< 0.05, **P< 0.01 compared to GLUT1 protein levels in HeLa cells (B) 
or in respective cancer cell line growing in monolayers (D), using a Student´s t test. 
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7.5 Por-C3-Gal4 and Por-C1-Gal4 accumulate in cancer cells growing as monolayer 
and spheroid cultures and are non-toxic in darkness 
 
Resistance of cancer cells to PDT agents arises not only due to decreased PS 
photoactivity in vivo, but also due to PS delivery barriers and penetration kinetics. The three-
dimensional structure of spheroidsmimics some of the physical and physiological barriers 
found in vivo [7, 8, 13]. To validate the use of HCT-116, MCF-7, UM-UC-3 and HeLa 
spheroid cultures in the screening of galactose-PSs we performed uptake and PDT studies 
(Figure 7.6A) with new porphyrin containing galactose units attached through carbon-3 (Por-
C3-Gal4). It is expected that Por-C3-Gal4 will have increased affinity to galactin-1 protein 
[4]. Furthermore, to validate the potential of Por-C3-Gal4, the same tetrapyrrolic macrocycle 
was also attached to the carbon-1 of galactose sugar (Por-C1-Gal4). (Figure SI7.6) [23]. 
Octanol-PBS partition coefficient values were determined for Por-C3-Gal4 and Por-C1-
Gal4 using the classic shake flask method [28]. Data show that the values of log P are higher 
for Por-C3-Gal4 when compared with Por-C1-Gal4 (Table 7.1), indicating that Por-C1-Gal4 
has less water solubility when compared with the corresponding porphyrin Por-C3-Gal4. 
 
Table 7.1 Partition coefficient (log P in n-octanol/PBS system) values of the galactose-conjugates Por-C3-Gal4 
and Por-C1-Gal4. 
Compound logP 
Por-C1-Gal4 -1.36 
Por-C3-Gal4 -1.50 
 
Monolayer cultures of cancer cells were incubated with increasing concentrations (2.25, 
4.5 and 9 µM) of Por-C3-Gal4 and Por-C1-Gal4 in PBS (containing a maximum of 0.5% v/v 
DMSO) for up to 4 h. No toxicity was observed in untreated cells (up to 4 h) in the presence of 
0.5% (v/v) DMSO in the incubation medium (Figure SI7.7). 
Moreover, Por-C3-Gal4 and Por-C1-Gal4 showed no significant dark cytotoxicity in 
monolayer and spheroid cultures at concentrations up to 9 µM (Figures SI7.8 and Figure 
SI7.9). We evaluated Por-C3-Gal4 and Por-C1-Gal4 accumulation in monolayer and spheroid 
cultures using fluorescence spectroscopy (Figure 7.6).  
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Figure 7.6 Por-C3-Gal4 and Por-C1-Gal4 accumulate in cancer cells growing as monolayer and spheroid 
cultures. (A) Uptake and PDT studies scheme. Intracellular uptake of Por-C3-Gal4 and Por-C1-Gal4 by HCT-
116, MCF-7, UM-UC-3 and HeLa cancer cells growing as monolayers (B) or spheroids (C). The concentration of 
PSs was determined by fluorescence spectroscopy (λexcitation at 410 nm and λemission at 702 nm) after incubation of 
cancer cells with 9 µM of PSs during 4 h and the results were normalized to protein quantity. Data are means ± 
S.D. of at least three independent experiments performed in triplicate. ***P< 0.001 compared uptake of Por-C3-
Gal4 in the respective cell line, using a Student´s t test. (D)Por-C3-Gal4 and (E) Por-C1-Gal4 uptake in cancer 
cells growing as monolayers and spheroids. Data are means ± S.D. of at least three independent experiments 
performed in triplicate. ***P< 0.001 compared uptake by cancer cells growing as monolayers, using a Student´s t 
test. 
 
The uptake by HCT-116, UM-UC-3 and HeLa cancer cells growing as monolayers or 
spheroids was higher for Por-C3-Gal4 when compared withPor-C1-Gal4 (Figures 7.6B,C). A 
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decrease in the uptake of Por-C3-Gal4 and Por-C1-Gal4 by monolayer cultures was observed 
in the following order: HCT-116 > HeLa ≈ UM-UC-3 > MCF-7 (Figures 7.6B). When 
spheroids were used as cell culture model, a decrease in the uptake of Por-C3-Gal4 and Por-
C1-Gal4 was observed in the following order: UM-UC-3 > HCT-116 > HeLa > MCF-7 
(Figures 7.6C). 
We compared the uptake of Por-C3-Gal4 and Por-C1-Gal4 into monolayer cultures vs. 
spheroids. Spheroid structures of HCT-116, MCF-7 and HeLa cells did not alter the extent of 
uptake of Por-C3-Gal4 and Por-C1-Gal4 (Figures 7.6D,E). Interestingly, an increase in the 
uptake of Por-C3-Gal4 and Por-C1-Gal4 was observed when UM-UC-3 cancer cells were 
culture in three-dimensional structures.  
 
7.6 Por-C3-Gal4 and Por-C1-Gal4 induce cytotoxicity in monolayer and spheroid 
cultures after photodynamic activation 
 
After characterization of spheroids formation and uptake assays, we investigated the 
effect of Por-C3-Gal4 and Por-C1-Gal4 mediated PDT efficacy in monolayer and spheroid 
cultures (Figure 7.6A). For these studies, we used spheroids with volume and average size of 
approximately 0.05 mm3 and 443 µm, respectively, which were obtained from the human 
cancer cell lines, as previously described.  
The cells were treated 48 h after plating, with 9 µM of Por-C3-Gal4 and Por-C1-Gal4 
for 4 h, and then exposed to light (420-700 nm) delivered at 0.44 mW/cm2 during 30 min 
(0.792 J/cm2). The 48 h time point following cell seeding was chosen based on the time 
needed for spheroids of the different cell lines to form and achieve reproducible and similar 
compactness (based on spheroid volume and shape) in each well. In all monolayer cultures, 
the light activation of Por-C3-Gal4 and Por-C1-Gal4 induced reduction of cells viability 
(Figure 7.7A).  
As shown in Figure 7.7A, the phototoxicity of Por-C3-Gal4 and Por-C1-Gal4 was 
higher in cell monolayers of HCT-116, UM-UC-3 and HELA when compared with that in 
MCF-7 cells. When PDT was performed in spheroid cultures, the release of LDH into the 
culture medium was increased when compared with control cells (Figure 7.7B). After PDT, 
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LDH released by HCT-166, UM-UC-3 and HELA spheroids was higher than that by MCF-7 
spheroid cultures. However, the amount of LDH leakage into the extracellular medium was 
lower for all cancer spheroid cultures when compared to their monolayer counterparts (Figure 
7.7C,D). 
 
Figure 7.7 Por-C3-Gal4 and Por-C1-Gal4 produces toxicity after PDT in cancer cells growing as monolayers 
or spheroids. (A) Cytotoxicity at 24 h after PDT with Por-C3-Gal4 and Por-C1-Gal4 in cancer cells growing in 
monolayers, determined using the MTT assay. Cells were incubated with 9 µM PS for 4 h and PDT was 
performed during 30 min at 0.44 mW/cm2. Data are means ± S.D. of at least three independent experiments 
performed in triplicate. **P< 0.01, ***P< 0.001 compared to phototoxicity with Por-C3-Gal4. (B) Cytotoxicity at 
24 h after PDT with Por-C3-Gal4 and Por-C1-Gal4 in cancer cells growing in spheroids, determined using the 
LDH assay. Spheroids were incubated with 9 µM PS for 4 h and PDT was performed during 30 min at 0.44 
mW/cm2. Data are means ± S.D. of at least three independent experiments performed in triplicate. *P< 0.05, ***P< 
0.001 compared to phototoxicity with Por-C3-Gal4, using a Student´s t test. (C,D) Cytotoxicity at 24 h after PDT 
with (C) Por-C3-Gal4 and (D) Por-C1-Gal4 in cancer cells growing in monolayers or spheroids, determined 
using the LDH assay. ***P< 0.001 compared to phototoxicity in monolayers, using a Student´s t test.  
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7.7 Discussion 
 
The development of reliable in vitro models for the screening of anticancer agents plays 
a key role in extracting biologically relevant knowledge. Tumor spheroid cultures with 
appropriate size and shape simulate the three-dimensional tumor micro-milieu and in vivo 
environment in which cancer cells reside [7, 8], namely the physic-chemical conditions 
(oxygen, pH and nutrient gradients). The advantage of using spheroid cultures in PS screening 
has been previously reported [5, 12, 29-33]. However, a high throughput screening that 
involves the use of different cancer cell lines is limiting due to the difficulty to obtain 
homogeneous spheroid cultures. To analyze uptake and cytotoxicity of an anticancer 
compound, in in vitro three-dimensional tumor structure, it is necessary to obtain spheroids 
with a compact structure and reproducible diameters. Of the five tested tumor cells, HCT-116 
colon cancer cells, MCF-7 breast cancer cells, UM-UC-3 bladder cancer cells and HeLa 
cervical cancer cells grew as viable, stable, structurally and functionally mature spheroids by 
48 h after cell seeding. MDA-MB-231 breast cancer cells failed to form spheroids in agarose-
coated 96-well plates, instead, formed loose aggregates, which may be attributed to weak cell-
cell aggregation. 
HCT-116, MCF-7, UM-UC-3 and HeLa spheroids formed 48 h after cell plating showed 
appropriate size (approximately 0.05 mm3 in volume and 443 µm in average cellular diameter) 
for use in the screening of PDT agents. Spheroids with a size lower than 200 µm may be 
sufficient to mimic three-dimensional cell-cell and cell-matrix interactions but they are 
inappropriate to reflect pathophysiological conditions with hypoxic areas in the spheroid 
center or to mimic proliferation gradients [6]. Spheroids with diameter starting from 200 µm 
mimic the chemical gradients (oxygen, nutrients or catabolites) found in vivo [13]. Cells 
cultured in spheroids with sizes beyond 500 µm may become quiescent with formation of a 
necrotic core and undergo cell death due to limited diffusion of oxygen and nutrients inside 
spheroids [34, 35]. Studies have demonstrated that not only spheroid volume, but also 
spheroid shape may be a source of variability when these three-dimensional structures are 
used on the evaluation of a new anticancer compound [13]. In spheroids with an irregular 
shape it is usually observed the formation of two necrotic cores instead of only one which 
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results in inconsistent viability in these cells. In our study, we optimized conditions to obtain 
spherically-shaped spheroids of homogenous size and preserved cell viability for at least 72 h 
after cell seeding. 
Glycolysis is the process characterized by conversion of glucose into pyruvate and then 
to lactic acid. In the presence of oxygen, most of the mitochondria of mammalian cells oxidize 
pyruvate to carbon dioxide and water, inhibiting glycolysis [21]. On the other hand, cancer 
cells have increased glycolysis (in which glucose is converted to lactic acid) even if oxygen is 
available [36, 37]. The high glucose consumption is a unique property of cancer cells and 
might have a key role in promoting tumor development [21]. When compared with tumors 
under "normal" oxygen levels, hypoxic tumors require increased glycolysis to survive [21]. 
The development of hypoxic regions in three-dimensional cultures will increase glycolysis 
which will result in an increase in glucose utilization and lactate production [38].  
In our study we observed alterations in glucose metabolism during spheroid formation. 
Glucose utilization by cancer cells was measured using the fluorescent glucose analog 2-
NBDG which is taken into cells through glucose transporters [22, 39]. We observed an 
increase in glucose utilization by MCF-7 and UM-UC-3 cancer cells during spheroid 
development when compared with the respective monolayer cultures. These results suggest 
that, concomitant to the development of MCF-7 and UM-UC-3 spheroid structures, there is 
alteration in the pattern of metabolism with increase in glucose dependence. As the uptake of 
glucose by cancer cells is dependent on the expression of glucose transporters (such as 
GLUT1) [21]; increased GLUT1 protein levels can explain the increased glucose consumption 
by MCF-7 and UM-UC-3 spheroid cancer cells. Interestingly, HCT-116 and HeLa spheroids 
demonstrated a decrease in the consumption of glucose as well as a decrease in GLUT1 
expression levels. Previous studies have also demonstrated that dephosphorylation of 2-NBDG 
by hexokinase can result in efflux from cells [39]. Additionally, alterations in hexokinase 
expression have been observed during spheroids development [38]. Therefore, alterations in 
hexokinase expression during HCT-116 and HeLa spheroids can result in dephosphorylation 
and efflux of 2-NBDG which lead to decreased glucose consumption.  
Lactate production was measured enzimatically in the culture cell media of monolayers 
or spheroids cultures by using an appropriate commercial kit [22]. The development of UM-
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UC-3 and HeLa spheroids resulted in an increment of lactate production, while no alterations 
were detected during the development of HCT-116 and MCF-7 spheroids. The increment in 
the production of lactate by UM-UC-3 spheroids can be due to increased glycolysis in these 
cells. Previous studies have demonstrated that lactate production and utilization (oxidation for 
energetic purposes, amino acid production or shuttles for anabolic purposes) can occur 
simultaneously and these processes are highly dependent on the external lactate concentrations 
[40]. Therefore, the increase in lactate in the culture medium of HeLa spheroids (in spite of 
decrease in glucose utilization by these cells) can be due to alterations in lactate efflux [41]. 
The breakdown of cellular macromolecules or the catabolism of other fuels (besides glucose) 
can also justify the increase of lactate levels found in HeLa spheroids [38]. As lactate efflux is 
dependent on monocarboxylate transporter 1 (MCT 1) at the cell membrane [41], alterations in 
the expression of MCT 1 during spheroids development can explain the alterations in lactate 
production. 
The oxygen sensor transcription factor hypoxia-inducible factor-1α (HIF1α) has a key 
role in the glycolytic response [42]. Under hypoxic stress, the upregulation of HF1α induces 
the expression of survival genes such as glucose transporters [43], haematopoeitic factors (e.g. 
transferrin and erythropoietin) [44], hexokinase II [45], angiogenic growth factors (vascular 
endothelial growth factor, VEGF). Additionally, HIF1α overexpression increases galectin-1 
expression and its inhibition attenuates hypoxia induction of galectin-1 [46].  
In our research we are particularly interested in the screening of new galactose-PSs to be 
used in cancer PDT [1, 3, 47], since this type of compounds can interact in somehow with 
proteins able to bind galactose (such as galectin-1 and GLUT1) overexpressed in cancer cells 
improving the selectivity of the PS for cancer cells. In both MCF-7 and UM-UC-3 cancer 
cells, galectin-1 and GLUT1 protein levels were found to be increased in spheroids compared 
to the respective monolayers. In HCT-116 spheroids the expression of these proteins was 
lower when compared with monolayer cultures. Galectin-1 expression was unaltered in HeLa 
spheroids, while GLUT1 protein expression was reduced. The precise changes in the spheroids 
setting underlying these alterations require further investigation, yet it is well known that the 
expression of both galectin-1 and GLUT1 is altered during hypoxic conditions due to 
upregulation of HIF1α [43, 46].  
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Herein we used cell lines growing in monolayer and spheroid cultures which express 
galectin-1 and GLUT1 in different levels. Therefore, we could not only study how the 
expression of these proteins influences the uptake and further phototoxicity of galactose-PSs 
but also compare the in vitro PDT efficacy of a galactose-PS in monolayer vs. spheroid 
cultures.  
In an attempt to increase the affinity of galactose-PSs to galectin-1, a porphyrin was 
conjugated to the carbon-3 of galactose sugar (Por-C3-Gal4). To determine the in vitro 
photodynamic properties of Por-C3-Gal4 we used monolayer and spheroid cultures in our 
studies. Por-C3-Gal4 results were also compared to the results for the same porphyrin 
conjugated to carbon-1 of galactose sugar (Por-C1-Gal4). The uptake and phototoxicity 
induced by PDT with Por-C3-Gal4 and Por-C1-Gal4 were dependent on the cell line and on 
the in vitro model. The uptake of PSs was higher in cell lines containing high levels of 
galectin-1 and GLUT1 proteins than in cell lines containing low levels of these proteins. 
Additionally, the increment in the levels of galectin-1 and GLUT1 proteins during the 
development of UM-UC-3 spheroids resulted in an improvement of Por-C3-Gal4 and Por-
C1-Gal4 uptake. Porphyrin attached to the carbon-3 of galactose sugar exhibited higher 
potodynamic activity in cancer cells expressing galectin-1 protein, than the corresponding 
porphyrin attached to the carbon-1 of galactose sugar. However, the three-dimensional culture 
model demonstrated higher resistance to phototoxicity when compared with monolayer 
cultures which is consistent with previous studies [12].  
Many factors associated with PS accumulation in spheroids, hypoxia and related 
alterations in the metabolism have influence on the phototoxicity response of spheroids. 
Additionally, the slower proliferation of spheroids (characterized by increased doubling times) 
when compared with monolayer cultures can contribute to the lower phototoxicity in 
spheroids. In monolayer cultures, the cells are exposed to uniform Por-C3-Gal4 and Por-C1-
Gal4 and oxygen levels. On the other hand, Por-C3-Gal4 and Por-C1-Gal4 and oxygen need 
to diffuse to the center of spheroids which decreases PS and oxygen in the core of these three-
dimensional structures. As PDT is dependent not only on the photo-activation of the PS but 
also on the generation of ROS [48], the low concentration of PS and low levels of oxygen in 
the center of the spheroid can decrease the photodynamic efficacy. Previous studies have 
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reported the formation of a necrotic core during spheroid development due to lack of nutrition 
and oxygen in the middle of these three-dimensional structures [8]. In our study we did not 
observe that phenomenon (usually detected by observation of a darkest region in the spheroid 
core imaged in brightfield [13]), because we used spheroids with 443 µm size which were 
cultured during short time (72 h). 
Alteration in cell redox status, with increasing generation of ROS has been observed 
during spheroids development [10]. This is a biochemical property that can explain the 
resistance of spheroid cultures when compared with cells growing in monolayers. In our study, 
an increase in endogenous ROS generation was detected during the development of HCT-116 
and HeLa spheroids. GLUT1 protein has antioxidant functions in cells due to its ability to 
import the oxidized form of vitamin C (dehydroascorbic acid) [49] to the mitochondria. 
Therefore, it is expected that the decrease in GLUT1 protein expression in HCT-116 and HeLa 
spheroids will result in an increase of endogenous ROS.  
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7.9 Supporting information 
 
 
Figure SI7.1 Glucose utilization of cancer cells growing in monolayers at 48 h after plating with seeding 
densities of 5,000 HCT-116 cells per well, 15,000 MCF-7 cells per well, 20,000 UM-UC-3 cells per well and 
20,000 HeLa cells per well. The amount of glucose (nmol) was estimated using the fluorescent glucose analog 2-
NBDG and the results were normalized for mg of protein. Data are means ± S.D. of at least three independent 
experiments performed in triplicate. ***P< 0.001 compared to glucose utilization in HeLa cells, using a Student´s 
t test. 
 
 
Figure SI7.2 Lactate utilization of cancer cells growing in monolayers at 48 h after plating with seeding densities 
of 5,000 HCT-116 cells per well, 15,000 MCF-7 cells per well, 20,000 UM-UC-3 cells per well and 20,000 HeLa 
cells per well. The amount of lactate (nmol) was estimated using an enzymatic assay and the results were 
normalized for mg of protein. Data are means ± S.D. of at least three independent experiments performed in 
triplicate. ***P< 0.001 compared to glucose utilization in HeLa cells, using a Student´s t test. 
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Figure SI7.3 Quantitative analysis of galectin-1 (normalized to β-actin) in spheroid cultures expressed as a ratio 
of the levels found in HeLa spheroids. Data are means ± S.D. of at least five independent experiments. **P< 0.01, 
***P< 0.001 compared to galectin-1 protein levels in HeLa spheroids, using a Student´s t test. 
 
 
Figure SI7.4 Quantitative analysis of GLUT1 (normalized to β-actin) in spheroid cultures expressed as a ratio of 
the levels found in HeLa spheroids. Data are means ± S.D. of at least five independent experiments. *P< 0.05, 
***P< 0.001 compared to GLUT1 protein levels in HeLa spheroids, using a Student´s t test. 
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Figure SI7.5 Quantification of DCF fluorescence increase (as a measure of endogenous ROS) in cancer cells 
growing as monolayers or spheroids. ROS levels are expressed as a ratio of the levels found on the respective cell 
line growing in monolayers. Data are means ± S.D. of at least three independent experiments performed in 
triplicate. **P< 0.01, ***P< 0.001 compared to DCF fluorescence in the respective cell line growing in 
monolayers, using a Student´s t test. 
 
 
Figure SI7.6 Chemical structure of Por-C3-Gal4 and Por-C1-Gal4. 
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Figure SI7.7 Cytotoxicity of PBS solution containing 0.5% DMSO (v/v) in monolayer cultures at different 
incubation times (0.5, 1, 2 and 4 h). The percentage of cytotoxicity was calculated relatively to control cells (cells 
incubated with medium). Data are means ± S.D. of at least three independent experiments performed in triplicate. 
 
 
Figure SI7.8 Non-dark toxicity of Por-C3-Gal4 and Por-C1-Gal4 at different concentrations (0, 2.25, 4.5 and 9 
µM) and uptake time of 4 h, in monolayer cultures. The percentage of cytotoxicity was calculated relatively to 
control cells (untreated cells). Data are means ± S.D. of at least three independent experiments performed in 
triplicate. 
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Figure SI7.9 Non-dark toxicity of Por-C3-Gal4 and Por-C1-Gal4 at 9 µM and uptake time of 4 h, in spheroids 
cultures. The percentage of cytotoxicity was calculated relatively to control cells (untreated cells). Data are 
means ± S.D. of at least three independent experiments performed in triplicate. 
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Table SI7.1 HCT-116 spheroid size and cellular characteristics as a function of age (24, 48 and 72 h) and number 
of platted cells (2,500, 5,000, 10,000 and 20,000 cells per well). 
Number of platted 
cells/well 
Age of 
spheroids (h) 
Radius (µM) 
± S.D. 
Volume 
(mm3) 
Number of 
cells/spheroid 
Average cellular 
diameter (µm) ± S.D. 
2500 
24 193±16 0,03515 8177 387±32 
48 174±8 0,02497 15000 349±15 
72 142±9 0,01299 25083 285±17 
5000 
24 231±5 0,05360 7581 463±10 
48 216±9 0,04541 31944 433±19 
72 194±14 0,03675 42363 388±28 
10000 
24 304±7 0,12160 17839 608±4 
48 259±5 0,07360 41250 520±11 
72 198±8 0,03334 49322 396±16 
20000 
24 378±3 0,22630 65000 756±7 
48 323±5 0,14230 62500 648±10 
72 247±17 0,06809 135000 495±34 
 
Table SI7.2 MCF-7 spheroid size and cellular characteristics as a function of age (24, 48 and 72 h) and number 
of platted cells (5,000, 10,000, 15,000 and 20,000 cells per well). 
Number of platted 
cells/well 
Age of 
spheroids (h) 
Radius (µM) 
± S.D. 
Volume 
(mm3) 
Number of 
cells/spheroid 
Average cellular 
diameter (µm) ± S.D. 
5000 
24 151±3 0,01489 6625 304±6 
48 143±4 0,01292 9375 287±9 
72 138±6 0,01180 11250 276±12 
10000 
24 208±2 0,03816 14542 417±5 
48 188±4 0,02862 18750 378±8 
72 183±5 0,02706 30625 367±11 
15000 
24 236±4 0,05515 14000 467±3 
48 232±2 0,05198 23500 463±3 
72 206±8 0,03688 32500 412±17 
20000 
24 276±3 0,08893 25542 552±7 
48 253±3 0,06871 38125 507±6 
72 244±4 0,06180 38130 489±8 
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Table SI7.3 UM-UC-3 spheroid size and cellular characteristics as a function of age (24, 48 and 72 h) and 
number of platted cells (2,500, 5,000, 10,000 and 20,000 cells per well). 
Number of platted 
cells/well 
Age of 
spheroids (h) 
Radius (µM) 
± S.D. 
Volume 
(mm3) 
Number of 
cells/spheroid 
Average cellular 
diameter (µm) ± S.D. 
2500 
24 126±2 0,008440 4833 253±4 
48 99±1 0,004145 10000 199±2 
72 101±1 0,004405 13833 203±3 
5000 
24 171±2 0,021190 8458 343±3 
48 134±1 0,010000 18750 267±2 
72 126±1 0,008473 26833 253±3 
10000 
24 222±2 0,045640 13750 444±3 
48 167±3 0,019930 26875 335±6 
72 155±2 0,015680 40083 310±3 
20000 
24 288±1 0,099910 15000 576±3 
48 211±4 0,040230 40000 423±8 
72 193±3 0,030280 53875 386±6 
 
Table SI7.4 HeLa spheroid size and cellular characteristics as a function of age (24, 48 and 72 h) and number of 
platted cells (2,500, 5,000, 10,000 and 20,000 cells per well). 
Number of platted 
cells/well 
Age of 
spheroids (h) 
Radius (µM) 
± S.D. 
Volume 
(mm3) 
Number of 
cells/spheroid 
Average cellular 
diameter (µm) ± S.D. 
2500 
24 110±3 0,005588 6250 220±6 
48 98±3 0,003991 18750 196±7 
72 94±2 0,003491 21250 188±3 
5000 
24 147±4 0,013480 8750 295±8 
48 137±3 0,010860 31250 274±6 
72 126±2 0,008347 45000 252±3 
10000 
24 192±2 0,029870 17500 385±4 
48 167±2 0,019630 42500 335±4 
72 171±2 0,020810 52500 341±4 
20000 
24 260±2 0,073960 20000 521±5 
48 229±3 0,050690 56250 460±6 
72 231±2 0,051750 72500 463±4 
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Chapter VIII Conclusions and future perspectives 
 
8.1 Conclusions 
 
Porphyrinoids were successfully conjugated with dendritic units of galactose (PorGal8, 
ChlGal8 and PcGal16) and with galactose through carbon-3 (Por-C3-Gal4). Although 
structurally different, all of these bioconjugates have a common purpose – molecular targeted 
photodynamic therapy of cancer cells. PorGal8 and ChlGal8 contain in their structure a 
porphyrin and a chlorin, respectively, conjugated with eight galactose units distributed in a 
dendritic manner. PcGal16 is a phthalocyanine conjugated with sixteen galactose units 
distributed in a dendritic manner. Por-C3-Gal4 is a porphyrin conjugated with four galactose 
sugars through carbon-3. 
The new galactose-PSs exhibited excellent properties as PSs: i) water solubility, ii) 
interaction with galectin-1 protein which is overexpressed in many tumor types,iii) ability to 
generate 1O2, iv) photostability and v) interaction with the most abundant protein of blood 
plasma (HSA).  
PcGal16 demonstrated high absorption in the wavelength range between 650 and 850 nm 
and strong ROS production. Monolayers of UM-UC-3 and HT-1376 bladder cancer cells were 
used to evaluate the potential of PcGal16. In comparison with the non-conjugated Pc, PcGal16 
readily accumulated in bladder cancer cells. PcGal16 was accumulated by UM-UC-3 and HT-
1376 cells expressing high levels of galectin-1 and GLUT1 proteins, respectively. We 
conclude that galectin-1 and GLUT1 proteins are essential in the uptake of PcGal16 by bladder 
cancer cells based on the observations that i) knockdown of these proteins significantly 
decreased the uptake of PcGal16 and ii) PcGal16 colocalizes with galectin-1 and GLUT1 
proteins. The intracellular uptake of the photosensitizers studied in this work was determined 
by fluorescence spectroscopy and validated using fluorescence microscopy.  
Temperature-dependent studies suggested the contribution of an energy-dependent 
process to PcGal16 transport across UM-UC-3 and HT-1376 cells. Studies with inhibitors of 
clathrin-mediated endocytosis revealed an impeded uptake of PcGal16 by UM-UC-3 cells. The 
uptake of PcGal16 in HT-1376 cells was inhibited after depletion of cholesterol in the plasma 
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membrane (preventing caveolin-mediated endocytosis) and inhibition of clathrin-coated 
vesicles (preventing clathrin-mediated endocytosis). UM-UC-3 cells express lower levels of 
caveolin-1 (a protein involved in the formation of caveolae during endocytosis) when 
compared with HT-1376 cells. Interestingly, knockdown of caveolin-1 protein in HT-1376 
cells significantly increased the uptake of PcGal16 and the expression of GLUT1 protein at the 
plasma membrane. We conclude that uptake of PcGal16 is a complex process that i) is 
dependent on the cell line used, ii) requires the expression of galactose-binding proteins 
present at the plasma membrane of cancer cells and iii) occurs through a combination of 
specific endocytic uptake mechanisms. In vitro PDT studies with PcGal16 demonstrated 
phototoxicity associated with increased levels of intracellular ROS. Phototoxicity was higher 
in UM-UC-3 cells than in HT-1376 cells at 24 h after treatment. In this study, we observed 
that HT-1376 cells generate an antioxidant response to counteract the effects of oxidative 
stress induced by PDT with PcGal16. The increase in the uptake of PcGal16 after knockdown 
of caveolin-1 protein decreased the resistance of HT-1376 cells to PDT. 
PorGal8 binds to galectin-1 protein with high affinity. The photodynamic efficiency of 
PorGal8 was evaluated in vitro using monolayers of UM-UC-3 and HT-1376 bladder cancer 
cells and in vivo in athymic nude mice (Balb/c nu/nu) bearing subcutaneously implanted 
luciferase-positive UM-UC-3 bladder cancer xenografts. The uptake of PorGal8 was higher in 
UM-UC-3 cells than in HT-1376 cells and it can be somehow related to the higher protein 
levels of galectin-1 in UM-UC-3 cell line. Galectin-1 knockdown reduces uptake of PorGal8 
by UM-UC-3 bladder cancer cells. PorGal8 was nontoxic to cancer cells until activated by 
light. The phototoxicity after PDT with PorGal8 was higher for the cell line UM-UC-3 than 
for the cell line HT-1376, being mediated by ROS production. PDT with PorGal8 induced 
apoptotic cell death and alterations in the cytoskeleton of UM-UC-3 bladder cancer cells. 
Biodistribution studies, at 24 h after intraperitoneal injection of PorGal8, revealed that this PS 
accumulates in the main excretory organs (e.g. kidney, liver and lung) and in the tumor. 
Highly efficient tumor ablation was achieved with a single intraperitoneal administration of 
PorGal8 followed by a single exposure of light. 
ChlGal8 exhibited a more than 50-fold increase in the extinction coefficient at the 
lowest-energy Q band relative to the porphyrin PorGal8. The photodynamic efficiency of 
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ChlGal8 was evaluated in vitro using monolayers of UM-UC-3 and HT-1376 bladder cancer 
cells and in vivo in athymic nude mice (Swiss nu/nu) bearing subcutaneously implanted HT-
1376 bladder cancer xenografts. In spite of better photo-chemical and –physical properties, 
ChlGal8 uptake by bladder cancer cells was lower when compared with PorGal8. In vitro, a 
single dose of ChlGal8 and irradiation induced high photosensitivity in UM-UC-3 bladder 
cancer cells sensitive to therapy. HT-1376 cells were resistant to PDT as previously observed 
for PDT with PcGal16 and PorGal8. Interestingly, both ChlGal8 and GLUT1 protein were 
localized in the mitochondrial fraction of HT-1376 cells after a single irradiation. We further 
demonstrated, using both in vitro and in vivo assays, that a repeated irradiation treatment 
(instead of the traditional single irradiation treatment) could improve phototoxicity with 
ChlGal8 in HT-1376 bladder cancer cells resistant to PDT. The particular ability of ChlGal8 
to be accumulated in the mitochondria in the period of time between single and repeated PDT 
provides new insights into the optimization of treatment regimens by fractionated dosing of 
light irradiation to achieve enhanced PDT efficacy. 
The attachment of porphyrin to C3-galactose (Por-C3-Gal4) demonstrated to be an 
effective way to increase the specificity of a PS to cancer cells overexpressing galectin-1 
protein. The uptake and phototoxicity of Por-C3-Gal4 were studied in monolayers and 
spheroid cultures of HCT-116 colon cancer cells, MCF-7 breast cancer cells, UM-UC-3 
bladder cancer cells and HeLa cervical cancer cells. Por-C3-Gal4 exhibited higher uptake by 
cancer cells expressing high levels of galectin-1 protein when compared with cells containing 
low levels of this protein. Additionally, PDT effects in cancer cells expressing galectin-1 were 
higher with Por-C3-Gal4 when compared with the same porphyrin attached to C1-galactose.  
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8.2 Future perspectives 
 
PDT is a clinically approved cancer therapy with unquestionable advantages when 
compared with conventional cancer therapies. It has intrinsic dual cancer cell selectivity due to 
the specificity of the PS and the precise light delivery in the target lesions. However, none of 
the clinically approved PSs fulfill all the criteria of an ideal one for cancer PDT. As light 
delivery technologies advance, the success of PDT seems to be highly dependent on the 
development of new PSs able to target selectively cancer cells. The conjugation of 
porphyrinoids (porphyrins, chlorins, phthalocyanines and others) with galactose molecules 
increases their water solubility and provides the possibility for specific (non-covalent) 
interaction with galactose-binding proteins overexpressed in cancer cells. A careful planning 
of the organic synthetic strategy, considering both galactose moieties and PSs suited for 
conjugation, should allow very efficient PDT treatments. In this work, the use of dendritic 
units of galactose and C3-galactose demonstrated to be promising strategies in the synthesis of 
new galactose-PSs.  
The synthesis of dendritic units of galactose through carbon-3 of the sugar seems indeed 
very promising in the development of new galactose-PSs. Our in vitro and in vivo data 
demonstrated that galectin-1 protein has a great potential in molecular-targeted PDT. We 
envisage that the conjugation of a porphyrinoid with an antibody recognizing this antigen 
could improve its targeting efficiency and further photoxicity. 
The photo-properties of new galactose-conjugated PSs are only one aspect among the 
many in vitro and in vivo steps that matter for their efficiency in cancer PDT. Photophysical 
and photochemical studies were performed prior to in vitro/in vivo studies. In our study, the 
production of 1O2 by galactose-PSs was determined before in vitro and in vivo studies by using 
a qualitatively methodology. A quantitative assay is necessary in further studies. Intracellular 
ROS were determined using ROS-sensitive fluorescent probes (i.e. H2DCFDA, DHE and 
MitoPY1) which are very useful for quick screening experiments and to measure general 
aspects of intracellular oxidative stress and redox status. However, these probes are often 
unspecific and the results obtained do not always correlate with the photocytotoxic effects. 
The use of new and more accurate techniques to determine in vitro and in vivo generation of 
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ROS will be helpful in further studies to gain insight into the contribution of specific ROS in 
galactose-PS-mediated cell death after PDT. 
In vitro studies demonstrated that galactose-PSs bind to galectin-1 protein. However, the 
molecular mechanisms of this interaction are still unknown and further studies should be 
performed to interpret these results. Further studies using immunoanalytical assays can be 
interesting to gain insight about PSs uptake through mediated interaction with specific 
galactose-binding proteins. 
  There is a lack of knowledge about the mechanisms by which a PS is accumulated 
inside cancer cells. Our data demonstrated that i) galactose-binding proteins overexpressed at 
the plasma membrane of cancer cells are important in the uptake of galactose-PSs and ii) 
caveolae- and clathrin-mediated endocytosis are involved in the internalization of galactose-
PSs. We demonstrated that interfering with endocytosis in vitro can lead to increased uptake 
and further phototoxicity of PcGal16.Although we provide convincing evidence that 
knockdown of caveolin-1 increases uptake and further phototoxicity of PcGal16 by increasing 
the amount of GLUT1 in the plasma membrane of cancer cells, our studies do not fully 
elucidate the mechanisms by which GLUT1 protein levels are increased in cells depleted of 
caveolin-1. Future studies should explore if after accumulation around cancer cell membranes, 
PcGal16 follows the same endocytic pathway as GLUT1. 
The in vitro studies with galactodendritic-PSs were based in two-dimensional monolayer 
cell culture systems, which are too simple to replicate the tumor heterogeneity present in vivo. 
Further studies using cancer cells growing in a three-dimensional environment (e.g. spheroid 
or organotypic cultures) will be helpful to investigate the selectivity and photototoxicity of 
galactose-PSs.  
In vivo studies with galactose-PSs were performed in xenograft tumor models. Further 
studies in orthotropic tumor models are needed to gain insight into the importance of tumor 
host environment in determining tumor response to PDT with a galactose-PS. Further 
investigations using repeated administrations of the therapy (galactose-PS plus light) must be 
considered in the treatment of cancer cells resistant to PDT. 
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Chapter IX Methods and Materials 
 
9.1 Synthesis of galactose-conjugates 
 
9.1.1 Equipment and reagents 
 
The starting reagents were commercially available and used without further purification.  
1H, 13C, and 19F Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker 
Avance-300 instrument at 300.13, 75.47 and 282.38 MHz, respectively. The deuterated 
solvents chloroform (CDCl3)and dimethyl sulfoxide (DMSO-d6) were used for the acquisition 
of NMR spectra. Tetramethylsilane (TMS) at  0 ppm was used as internal reference in 1H and 
13C NMR spectra. For 19F NMR spectra, hexafluorobenzene (C6F6) was used as internal 
standard at -163 ppm. The chemical shifts are expressed in  (ppm) and the coupling 
constants (J) in Hertz (Hz). Spin multiplicities are indicated by the following symbols: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Unequivocal 1H assignments were 
made with aid of 2D COSY (1H/1H), while 13C assignments were made on the basis of 2D 
HSQC (1H/13C). 
High Resolution Mass Spectrometric (HRMS) analysis was performed at the University 
of Vigo using a VG AutoSpec Q and M mass spectrometers, CHCl3 as solvent and nitrobenzyl 
alcohol (NBA) as matrix (unless otherwise stated). 
Column chromatography was carried out using silica gel (Merck, 35-70 mesh). Reverse 
phase column chromatography was carried out using Sep-Pak® Vac 35 cc (10 g) columns. 
Analytical TLC was carried out on precoated sheets with silica gel 60 F254 (0.2 mm thick, 
Merck). 
All chemicals were supplied by Sigma–Aldrich. Solvents were purified or dried 
according to the literature procedures. TPPF20 was commercially available. 
The UV-visible assays were performed on the UVIKON 922 spectrophotometer from 
Biotek Instruments.  
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9.1.2 Softwares 
 
ChemDraw Ultra 12.00 from CambridgeSoft was the software used to draw chemical 
structures. MestReNova LITE (version 5.2.5-5780) was used to analyze NMR spectra. 
 
9.1.3 Synthetic procedures 
 
A. Synthesis of galactodendritic-photosensitizers 
Synthesis of 2-chloro-4,6-di-O-isopropilidene-α-D-galactopyranose-1,3,5-triazine (1) 
The compound 1 (2-chloro-4,6-di-O-isopropilidene-α-D-
galactopyranose-1,3,5-triazine) was synthesized as previously 
described in the literature [1]. Under N2, 1,2:3,4-di-O-isopropylidene-
α-D-galactopyranose (4.0 g, 15.4 mmol) was dissolved in dry toluene 
(40 mL) and a large excess of N,N-diisopropylethylamine (DIPEA, 2.0 mL) was added. The 
reaction was then cooled at 0 ºC and 2,4,6-trichloro-1,3,5-triazine (1.4 g, 7.33 mmol) was 
joined to the mixture. The reaction mixture was stirred at 60 ºC during 48 h. After 
concentration under vacuum, the residue was purified by column chromatography (light 
petroleum/ethyl acetate, 8:2 to 2:1 v/v) to afford compound 1 (4.28 g, 80%) as a white solid.  
1H NMR (300 MHz, CDCl3): δ 1.27, 1.28, 1.39 and 1.45 (4s, 4 x 6H, CH3), 4.14 (ddd, 
J4’-5’= 1.7, J5’-6’a=6.5, J5’-6’b= 7.9, 2H, H-5’), 4.26-4.29 (m, 4H, H-2’, H-4’), 4.48-4.50 (m, 4H, 
H-6’a, H-6’b), 4.58 (dd, J2’-3’= 7.9, J3’-4’= 2.5, 2H, H-3’), 5.48 (d, J1’-2’= 5.0, 2H, H-1’).  
13C NMR (75 MHz, CDCl3): δ 24.4, 24.9, 25.9, 26.0 (Me-isop), 65.4 (C-5’), 67.4 (C-
6’), 70.4 (C-3’), 70.5 (C-2’, C-4’), 96.2 (C-1’), 108.8, 109.6 (Cq-isop), 171.9 (C-4, C-6), 172.6 
(C-2).  
HRMS-ESI:m/z calculated for C27H39ClN3O12 [M+H]
+: 632.2222, found: 632.2212. m/z 
calculated for C27H38ClN3O12Na [M+Na]
+: 654.2042, found: 654.2033. m/z calculated for 
C27H38ClN3O12K [M+K]
+: 670.1781, found: 670.1771. 
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Synthesis of 3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-galactopyran-6-yl)-1,3,5-
triazin-2-yl) thio]propane-1-thiol (2)  
The compound 2 (3-[(4,6-bis(1,2:3,4-di-O-isopropylidene-α-D-
galactopyran-6-yl)-1,3,5-triazin-2-yl) thio]propane-1-thiol) was 
synthesized as previously described in the literature [1]. Under N2, 
compound 1 (4.3 g, 6.8 mmol) was dissolved in dry toluene (40 mL). 
DIPEA (5.9 mL, 34 mmol) and 1,3-dimercaptopropane (2.7 mL, 27.2 
mmol) were then added and the mixture stirred at 70 ºC during 12 h. 
After concentration under vacuum, the residue was purified by column chromatography 
(hexane/ethyl acetate, 9:1 to 6.5:3.5 v/v) to afford compound 2 (4.2 g, 72%) as a viscous 
colorless oil.  
1H NMR (300 MHz, CDCl3): δ 1.33, 1.34, 1.45, 1.51 and 1.61 (4s, 4 x 6H, CH3), 1.97-
2.09 (m, 2H, CH2CH2CH2SH), 2.61-2.69 (m, 2H, CH2CH2CH2SH), 2.77–2.81 (m, 1H, SH), 
3.21-3.27 (m, 2H, CH2CH2CH2SH), 4.19 (ddd, J4’-5’= 1.7, J5’-6’a=6.5, J5’-6’b= 8.2, 2H, H-5’), 
4.32-4.36 (m, 4H, H-2’, H-4’), 4.50-4.52 (m, 4H, H-6’a, H-6’b), 4.63 (dd, J2’-3’= 7.9, J3’-4’= 
2.4, 2H, H-3’), 5.54 (d, J1’-2’= 5.0, 2H, H-1’).  
13C NMR (75 MHz, CDCl3): δ 23.5 (CH2CH2CH2SH), 24.6, 25.1, 26.1 and 26.2 (Me-
isop), 28.9 (CH2CH2CH2SH), 33.3 (CH2CH2CH2SH), 65.6 (C-5’), 66.5 (C-6’), 70.7 (C-3’, C-
2’), 70.8 (C-4’), 96.4 (C-1’), 108.9, 109.7 (Cq-isop), 170.6 (C-4, C-6), 185.0 (C-2).  
HRMS-ESI:m/z calculated for C30H46N3O12S2 [M+H]
+: 704.2523, found: 704.2510. m/z 
calculated for C30H45N3O12S2Na [M+Na]
+: 726.2342, found: 726.2333. 
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Synthesis of protected galactodendritic porphyrin (protectedPorGal8) 
The protectedPorGal8 
was synthesized as previously 
described in the literature [1]. 
Under N2, TPPF20 (50.0 mg, 
51.3 µmol) was dissolved in 
dimethylformamide (DMF). 
DIPEA (0.9 mL, 5.13 
mmol) and compound 2 (155.0 
mg, 0.22 mmol) were added 
and the mixture stirred at 40 ºC 
during 24 h.  
After co-evaporation of 
DMF with toluene, the residue was purified by column chromatography (light petroleum/ethyl 
acetate/dichloromethane (CH2Cl2)/acetone, 6:1:2:1 to 4:1:2:1 v/v). The eluent was evaporated 
to dryness under reduced pressure and the solid was dissolved in CH2Cl2and precipitated with 
light petroleum affording protectedPorGal8 (148.4 mg, 78%) as a red solid.  
1H NMR (300 MHz, CDCl3): δ -2.88 (brs, 2H, NH), 1.31 and 1.34 (2s, 2 x 24H, CH3), 
1.47 (m, 24H, CH3,), 1.52 (s, 24H, CH3), 2.30 (q, J= 6.9, 8H, SCH2CH2CH2SPor), 3.40-3.49 
(m, 16H, SCH2CH2CH2SPor), 4.23 (ddd, J4’-5’= 1.5, J5’-6’a= 6.4, J5’-6’b= 8.0, 8H, H-5’), 4.34 
(dd, J1’-2’= 5.0, J2’-3’= 2.4, 8H, H-2’), 4.37 (dd, J3’-4’= 7.9, J4’-5’= 1.5, 8H, H-4’), 4.56-4.58 (m, 
16H, H-6’a, H-6’b), 4.64 (dd, J2’-3’= 2.4, J3’-4’= 7.9, 8H, H-3’), 5.55 (d, J1’-2’= 5.0, 8H, H-1’), 
8.94 (brs, 8H, pyrrolic β-H).  
19F NMR (282 MHz, CDCl3): δ -160.2 (q, Jo-m= 12.5, 8F, F-ortho), -157.4 (q, Jo-m = 
12.5, 8F, F-meta).  
13C NMR (75 MHz, CDCl3): δ 24.6, 25.1, 26.1 and 26.2 (Me-isop), 29.0 
(SCH2CH2CH2SPor), 29.5 (SCH2CH2CH2SPor), 33.6 (SCH2CH2CH2SPor), 65.6 (C-5’), 66.6 
(C-6’), 70.7 (C-3’, C-2’), 70.8 (C-4’), 96.4 (C-1’), 108.9, 109.7 (Cq-isop), 119.9, 120.4 and 
134.7 (C-Por), 145.4, 148.3, 148.5 and 149.6 (C-Por, C-F), 155.1 (C-Por), 170.7 (C-4, C-6), 
184.8 (C-2).  
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HRMS-ESI:m/z calculated for C164H188F16N16O48S8 [M+2H]
2+: 1854.5103, found: 
1854.5131.  
UV-Vis in DMSO λmax(log ɛ): 412 (4.31), 508 (3.14), 582 (2.78), 656 (1.12). 
 
Synthesis of protected 
galactodendritic 
phthalocyanine 
(protectedPcGal16) 
The 
protectedPcGal16 was 
synthesized as previously 
described in the literature 
[1]. The synthesis and 
characterization of 
protectedPcGal16 were 
performed by Doctor 
Sandrina Silva, postdoc 
student, in the laboratory of 
Doctor João Tomé, 
Department of Chemistry – 
University of Aveiro, 
Aveiro, Portugal. 
 
 
 
 
Synthesis of ChlF20 
The ChlF20 was synthesized as previously described in the 
literature [2, 3]. Under N2, the commercially available TPPF20 (100 
mg, 102.6 µmol) was dissolved in dry toluene. N-methylglycine (20 
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mg, 224.5 µmol) and paraformaldehyde (17 mg, 566.1 µmol) were added and the mixture was 
heated at reflux for 5 h. After evaporation of toluene, the residue was purified by column 
chromatography (light petroleum/ethyl acetate, 9:1 to 7:3 v/v). The eluent was evaporated to 
dryness under reduced pressure and the solid was dissolved in CH2Cl2 and precipitated with 
hexane affording ChlF20 (74 mg, 70%) as a green solid.  
1H NMR (300 MHz, CDCl3): δ -1.82 (s, 2H, NH), 2.21 (s, 3H, N-CH3), 2.46-2.67 (m, 
2H, H-pyrrolidine), 3.06-3.22 (m, 2H, H-pyrrolidine), 5.16-5.33 (m, 2H, β-H [C (sp3)]), 8.39 
(d, 2H, J=4.9Hz, pyrrolic β-H), 8.48 (s, 2H, pyrrolic β-H), 8.71 (d, 2H, J=4.9Hz, pyrrolic β-
H). 
19F NMR (282 MHz, CDCl3): δ -161.39 to -161.78, -162.72 to -162.78 (2m, 8F, F-
meta), -152.66 to -153.01 (m, 4F, F-para), -136.62 to -138.17, -138.25 to -138.63 (2m, 8F, F-
ortho). 
 
Synthesis of protected galactodendritic chlorin (protectedChlGal8) 
The conjugation of ChlF20 with 
galactodendritic unit was performed as 
previously described for PorGal8 
described in the literature [1]. Under 
N2, ChlF20 (70.0 mg, 67.85 µmol) was 
dissolved in DMF. DIPEA (3.0 mL, 
166.9 mmol) and compound 2 (215.0 
mg, 0.304 mmol) were added and the 
mixture stirred at 40ºC during 44 h. 
After co-evaporation of DMF with 
toluene, the crude was dissolved in 
CH2Cl2, neutralized with an aqueous 
solution of sodium bicarbonate 
(NaHCO3) and the organic layer was washed with water (H2O) and dried under diminished 
pressure. Then, the mixture was concentrated and submitted to column chromatography 
(hexane/ethyl acetate/ CH2Cl2/acetone, 6:1:2:1 to 4:2:2:1 v/v). The eluent was evaporated to 
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dryness under reduced pressure and the solid was dissolved in CH2Cl2 and precipitated with 
light petroleum affording protected ChlGal8 (164.0 mg, 70%) as a dark-green solid.  
1H NMR (300 MHz, CDCl3): δ -1.78 (s, 2H, NH); 1.32 e 1.34 (2s, 2 x 24H, CH3); 1.46 
(s, 24H, CH3); 1.52 (s, 24H, CH3); 2.20 (s, 3H, N-CH3); 2.26 (q, J=6.2 Hz, 8H, 
SCH2CH2CH2SChl); 2.52-2.62 (m, 2H, H-pyrrolidine); 3.07-3.17 (m, 2H, H-pyrrolidine);3.34-
3.49 (m, 16H, SCH2CH2CH2SChl); 4.22 (td, J5’-6á= J5’-6’b= 6.5Hz, J5’-4’ = 1.6Hz, 8H, H-5´); 
4.33 (dd, J2’-3’ = 2.4 Hz, J2’-1’ = 5.0 Hz, 8H, H-2’); 4.37 (dd, J4’-3’ = 8.0 Hz, J4’-5’ = 1.6 Hz, 
8H, H-4’); 4.50-4.58 (m, 16 H, H-6´a and H-6´b); 4.64 (dd, J3’-2’ = 2.4 Hz, J3’-4’ = 8.0 Hz, 
8H, H-3´); 5.25-5.34 (m, 2H, β-H [C (sp3)]); 5.54 (d, J1´-2´= 5.0 Hz, 8H, H-1´); 8.41 (d, 2H, 
J=4.9Hz, pyrrolic β-H); 8.51 (s, 2H, pyrrolic β-H); 8.73 (d, 2H, J=4.9Hz, pyrrolic β-H). 
19F NMR (282 MHz, CDCl3): δ -156.1 to -156.2 and -156.6 to -156.7 (2m, 4F, F-meta); 
-157.4 to -157.6 (m, 4F, F-meta); -159.0 to -159.2 and -160.4 to -160.6 (2m, 6F, F-orto); -
161.0 to -161.1 (m, 2F, F-orto). 
13C NMR (75 MHz, CDCl3):δ 22.9,24.6, 25.1, 26.1, 26.2 , 29.0, 29.5,29.8; 32.1,33.6, 
65.6, 66.6, 70.6, 70.7, 70.8, 96.4, 108.9, 109.7, 128.2, 135.1, 140.1, 145.0, 146.0, 145.8, 
147.8,170.7, 184.7. 
HRMS-ESI:m/z calculated for C167H194F16N17O48S8/3 [M/3 + H]
+ 1256,36670, found 
1256.36755. m/z calculated for C167H194F16N17O48S8/2 [M/2 + H]
+ 1884.04605, found 
1884,05136. 
 
 General procedure for the cleavage of the isopropylidene acetals of the 
protectedPorGal8, protected PcGal16 and protected ChlGal8  
A suspension of galactose-conjugated porphyrinoids was stirred in a mixture of 
trifluoroacetic acid (TFA)/H2O (9:1 v/v) at room temperature during 5 h. The mixture was 
then neutralized with aqueous potassium carbonate (K2CO3) and the product was purified by 
reverse phase column chromatography using a gradient of H2O and tetrahydrofuran (THF) as 
eluent. The desired compound was precipitated, filtered, washed and dried under reduced 
pressure. 
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Synthesis of PorGal8 
PorGal16 was synthesized 
as previously described in the 
literature [1].According to the 
aforementioned general 
procedure, protected PorGal8 
(35.0 mg, 9.43 µmoL) was 
treated with 3 mL of TFA/H2O 
(9:1 v/v). After neutralization 
with the aqueous solution of 
K2CO3 and reverse phase 
column chromatography, 
PorGal8 was precipitated with 
CH2Cl2, filtered, washed, with acetone and dried under reduced pressure (23.2 mg, 80%).  
1H NMR (300 MHz, DMSO-d6):δ -3.20 (brs, 2H, NH), 2.19–2.32 (m, 8H, 
SCH2CH2CH2SPor), 3.64-3.92 (m, 16H, SCH2CH2CH2SPor), 4.17–4.51 (m, 24H, H-5’, H-2’, 
H-4’), 4.61-4.82 (m, 16H, H-6’a, H-6’b), 4.93–4.99 and 5.17 – 5.28 (2m, 8H, H-3’), 6.29–6.36 
(m, 4H, H-1’α), 6.65-6.76 (m, 4H, H-1’β), 9.41 (brs, 8H, pyrrolic β-H).  
19F NMR (282 MHz, DMSO-d6): δ -162.8 to -162.7 (m, 8F, F-ortho), -158.1 to -158.0 
(m, 8F, F-meta).  
HRMS-ESI:m/z calculated for C116H122F16N16O46S8 [M+2H-2OH]
2+: 1517.2605, found: 
1517.2562. m/z calculated for C116H123F16N16O47S8 [M+2H-OH]
2+: 1525.7618, found: 
1525.7622. m/z calculated for C116H124F16N16O48S8 [M+2H]
2+: 1534.2632, found: 1534.7648. 
m/z calculated for C116H123F16N16O48S8Na [M+H+Na]
2+: 1545.2542, found: 1545.2570. 
UV-Vis in DMSO λmax (log ɛ): 415 (5.24), 505 (4.20), 575 (3.80), 655 (2.00). 
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Synthesis of PcGal16 
PcGal16 was 
synthesized as previously 
described in the literature [1]. 
The synthesis and 
characterization were PcGal16 
was performed by Doctor 
Sandrina Silva, postdoc 
student, in the laboratory of 
Doctor João Tomé, 
Department of Chemistry – 
University of Aveiro, Aveiro, 
Portugal. 
 
 
 
 
 
 
Synthesis of ChlGal8 
According to the 
aforementioned general 
procedure, protected ChlGal8 
(103.1 mg, 27.37 µmoL) was 
treated with 10 mL of TFA/H2O 
(9:1 v/v). After neutralization 
with the aqueous solution of 
K2CO3 and reverse phase column 
chromatography, ChlGal8 was 
precipitated with 
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methanol/CH2Cl2, filtered, washed, with acetone and dried under reduced pressure (74.4 mg, 
87%). 
1H NMR (300 MHz, DMSO-d6):δ -2.01 (s, 2H, NH); 2.04 (s, 3H, N-CH3); 2.33-2.49 (m, 
8H, SCH2CH2CH2SChl); 2.70-2.76 (m, 2H,H-pyrrolidine); 3.04-3.14 (m, 2H, H-pyrrolidine); 
3.37-3.49 (m, 16H, SCH2CH2CH2SChl);3.50-4.13 (m, 16H, H-5’, H-2’); 4.31-4.57 (m, 8H, H-
4’); 4.62-5.14 (m, 16H, H-6’a, H-6’b); 5.16-5.63 (m, 8H, H-3’); (m, 8H, H-1’α, H-1’β); 8.75 
(d, 2H, J=4.0Hz, pyrrolic β-H); 8.82 (s, 2H, H pyrrolic β-H); 9.16 (d, 2H, J=4.0Hz, pyrrolic β-
H). 
1H NMR (300 MHz, DMSO-d6): δ-155.3 to -155.8 and -156.0 to -156.7 and -156.8 to -
157.2 and -157.7 to -158.3 (4m, 8F, F-meta); -160.4 to -161.1and -162.1 to -162.5 and -162.9 
to -163.3 (3m, 8F, F-orto). 
HRMS-ESI:m/z calculated for C119H130F16N17O48S8 [M/2 + H]
+ 1563.2938, found 
1563.2934. 
UV-Vis in DMSO λmax (log ɛ): 411 (4.41), 505 (3.14), 530 (2.32), 597 (2.75), 650 
(3.83). 
 
B. Synthesis of porphyrin C3-galactose and porphyrin C1-galactose 
Por-C3-Gal4 and Por-C1-Gal4 were 
synthesized and characterized by Doctor Dinesh 
Bhupathiraju (postdoc student) and Waqar Rizvi 
(PhD student) in the laboratory of Professor Charles 
Michael Drain, Department of Chemistry – Hunter 
College of CUNY, New York, United States. 
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9.2 Photo -physical and -chemical assays of galactose-conjugates 
 
9.2.1 Equipment and reagents 
 
A. General instrumentation 
Equipment and material for the UV-Visible absorbance and fluorescent measurements 
The fluorescence assays were performed on FluoroMax-3 spectrofluorimeter from 
Horiba Jobin Yvon.The data acquisition and post processing/analysis were performed using its 
software DataMax.The UV-visible assays were performed on the UVIKON 922 
spectrophotometer from Biotek Instruments.  
 
Equipment for irradiation assays 
The illumination system used to determine the photostability and 1O2 generation of PSs 
was the Light Source Model Lc-122 from Lumacare, equipped with a halogen/quartz 250 W 
lamp coupled to the selected interchangeable optic fiber probes (400-800 nm or 620-750 nm). 
The fluence rates were determined with the energy meter Coherent FieldMaxII-Top with a 
Coherent PowerSens PS19Q energy sensor. Alternatively, a LEDs array system emitting red 
light (600-800 nm with maximum emission at 700 nm) was also used in the determination of 
1O2 generation. 
 
Reagents, chemical products and buffers 
Dimethyl sulfoxide (DMSO), n-octanol, dimethylformamide (DMF), 1,3-
diphenylisobenzofuran (DPBF) were obtained from Sigma. Phosphate buffered saline (PBS) 
buffer was prepared in Milli-Q water at pH 7.60: 10 mM NaH2PO4, 70 mM Na2HPO4 and 145 
mM NaCl. 5,10,15,20-tetraphenylporphyrin (TPP) was from Sigma. 
The Human Serum Albumin (HSA) lyophilized powder, essentially protease free; ≥96% 
(agarose gel electrophoresis) was purchased from Sigma. The human galectin-1 lyophilized 
powder, recombinant, expressed in E. coli was obtained from Sigma. 
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B. Softwares 
GraphPad Prism (v.5.00, GraphPad Software) was used for most of the displayed graphs 
and ChemDraw Ultra 12.00 from CambridgeSoft was the software used to draw the chemical 
structures. DataMax software was used to acquire fluorescence emission spectra. 
 
9.2.2 Protocols 
 
A. Aggregation assays 
Principle 
The aggregation behaviour of PSs in PBS buffer is studied at different concentrations by 
Lambert-Beer´s law plots, where the relation of absorbance and concentration is linear: A = ɛ x 
b x c. A is the absorbance, ɛ is the molar absorptivity of the compound (L.mol-1.cm-1), b is the 
length of the light path (cm) and c is the concentration of the compound in solution (mol/L). 
 
Protocol 
Stock solutions of the galactose-conjugates at a concentration of 20 mM were prepared 
in DMSO and stored in the dark at room temperature. The working solutions were freshly 
prepared prior to use, by diluting the stock solutions in PBS buffer with the concentration of 
DMSO being always inferior to 1% (v/v). 
Two milliliters of working solutions (without air bubbles) was placed into quartz 
cuvettesand the absorbance was scanned for wavelengths between 300 to 900 nm.
2The 
wavelengths of maximum absorption were determined and the molar absorptivity of the 
compounds was calculated by Lambert-Beer´s law after plotting the absorbance against the 
respective concentration.3 
 
 
 
 
                                                          
2 The maximum absorbance was always inferior to 1.0, in all working solutions. 
3 It was considered that the length of the light path (b) is equal to 1 cm. 
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B. Fluorescence assays 
Principle 
The fluorescence quantum yields (ФF) of PSs can be calculated in DMF by comparison 
of the area below the corrected emission spectra (between 620 nm to 850 nm) using TPP as 
standard (λexcitation at 601 nm, Фf = 0.11 in DMF) [4]. For that, the following equation is used: 
PS = TPP(FPS/FTPP)(ATPP/APS)(n2PS/n2TPP); FPS and FTPP are the fluorescence integral areas 
(under the fluorescence emission curves) of PS and TPP reference, respectively. APS and ATPP 
are the absorbance of PS and TPP (near of 0.03 at 601 nm), respectively. nPS and nTPP are the 
refractive indices of solvents used for PS and TPP reference, respectively [5].  
 
Protocol 
PSs working solutions were freshly prepared in DMF to give absorbance near of 0.034 at 
601 nm. The fluorescence emission spectra of PSs were measured between 620 to 850 nm, 
after excitation at 601 nm. The excitation and emission slits width were set at 2.0 nm. Using 
the DataMax software, the emission spectra were corrected and the area under the 
fluorescence emission curves was calculated. 
 
C. Photostability assays 
Principle 
The photostability can be studied by monitoring the decrease of the absorbance of Soret 
and Q bands, after different times of irradiation with white light (400-800 nm) or red light 
(620-750 nm) delivered by an illumination system. 
 
Protocol 
Solutions of PSs were freshly prepared in PBS buffer (0.5% v/v DMSO) and kept in the 
dark at room temperature. The irradiation experiments were performed in magnetically stirred 
cuvette solutions (with 2 mL of sample) in a dark room, over a period of 30 min with white or 
red light (400-800 nm) at a fluence rate of 150 mW/cm2. The absorbance of PSs was 
                                                          
4 This condition minimizes reabsorption of radiation by the ground-state species. 
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determined before irradiation and at several periods of time after irradiation. The results were 
expressed as follows: Photostability (%) = (Abs at a given time of irradiation) / (Abs before 
irradiation. 
 
D. Singlet oxygen assays 
Principle 
Singlet oxygen (1O2) can be qualitatively determined by a chemical method using 1,3-
DPBF as 1O2 scavenger. The yellow-colored DPBF reacts specifically with 
1O2 in a [4+2] 
cycloaddition reaction, being oxidized to the colorless o-dibenzoylbenzene (Figure 9.1). DPBF 
has an absorption maximum at 415 nm, thus it is possible to follow the ability of the PSs to 
generate 1O2 by measuring the DPBF absorption decay, at this wavelength. 
 
 
 
 
Figure 9.1 Reaction of diphenylisobenzofuran (DPBF) with singlet oxygen (1O2) by a Diels Alder reaction. 
 
Protocol 
Freshly prepared stock solutions of 50 µM DPBF, 10 µM of galactose-conjugates 
(DMF:H2O; 9:1, v/v) were maintained in the dark at room temperature until use. Solutions 
containing DPBF with or without PSs were prepared in DMF:H2O (9:1, v/v) in a quartz 
cuvette. The solutions were irradiated at room temperature and under gentle magnetic stirring. 
The breakdown of DPBF was monitored by measuring the decrease in absorbance at 415 nm 
at pre-established irradiation intervals. The results were expressed by plotting the DPBF 
depletion against the irradiation time. The depletion of DPBF was calculated as follows: 
DPBF depletion = (Abst) / (Abs0); Abs0 and Abst are the absorbance values of DPBF at 415 nm 
before and after irradiation, respectively. 
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E. Human Serum Albumin and galectin-1 interaction assays 
Principle 
The interaction of the galactose-conjugates with HSA or galectin-1 proteins can be 
determined by measuring the intrinsic fluorescence quenching of tryptophan residues (excited 
at 280 nm) on the respective protein. If occurs interaction between conjugates and proteins, the 
binding constant (Ka) and the number of binding sites (n) can be determined by the following 
equation: Trypthophan residues quenching (%)=(F0 – F)/(F0)x100; F0 and F are fluorescent 
intensities of tryptophan residues before and after addition of PS, respectively. Ka (binding 
constant) and n (number of binding sites) values were determined by plotting the log((F0-
F)/F) against log(PS concentration), giving a linear plot, where log(Ka) and n are the ordinate 
at the origin and slope, respectively [6]. 
 
Protocol 
HSA was freshly prepared at a concentration of 2 µM in PBS buffer at room 
temperature. The concentration of galectin-1 was determined before the experiments by 
measuring the absorbance at 280 nm (ɛGal1 = 7 560 M-1 cm-1, M = 14,000 g/mol) [7]. 
Two mL of protein solution at 2 µM was titrated with increasing concentrations of 
galactose-conjugates, keeping always the final concentration of DMSO to no more than 0.15% 
(v/v).5 The fluorescence emission spectra of the protein´s tryptophan residues were acquired 
for the wavelength range between 300 nm to 450 nm upon excitation at 280 nm. The 
excitation and emission slits width were set at 2.0 nm. The fluorescence quenching curves 
were obtained by plotting the tryptophan residues quenching (in percentage) against 
conjugates concentration. The tryptophan residues quenching (in percentage) was calculated 
using the aforementioned equation. 
The dissociation constants (KD) of the galactose-conjugates to galectin-1 were calculated 
using the Boltzmann sigmoidal model of the program GraphPad Prism [8], according to the 
equation: △F=(Bmax[PS])/(KD+[PS]); Bmax is the maximal binding, and KD is the 
concentration of PS required to reach half-maximal binding. 
 
                                                          
5Over a concentration range of 0-0.5% (v/v), DMSO did not quench HSA fluorescence. 
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F. Partition coefficients 
Principle 
The hydrophobic character of a drug can be measured experimentally by testing the 
drug´s relative distribution in an n-octanol/water mixture. Hydrophobic molecules will prefer 
to dissolve in the n-octanol layer of this two-phase system, whereas hydrophilic molecules will 
prefer the aqueous layer. The relative distribution is known as the partition coefficient (P) and 
it is obtained from the following equation: P=(concentration of PS in octanol)/(concentration 
of PS in aqueous solution). Hydrophobic compounds have a high P value, whereas hydrophilic 
compounds have a low P value. 
 
Protocol 
The partition coefficient (P) of the galactose-conjugated PSs was measured in an n-
octanol/PBS solvent system. The PSs were dissolved in a mixture of n-octanol/PBS (1:1 v/v) 
at a concentration of 15 µM, and the solution was shaken at room temperature. The two 
different phases formed were then separated by centrifugation (3 min at 3,000 rpm). The 
absorbance of the PS in each phase was determined and the concentration was calculated using 
molar absorptivity values. The partition coefficient value was then determined using the 
aforementioned equation. 
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9.3 In vitro biological assays 
 
9.3.1 Equipment and common materials 
 
A. General equipment 
The centrifuge used was a SIGMA 2-16 and the microcentrifuge was a VWR MiniFuge 
Galaxy MiniStar C1413. The vortex was from VWR. The liquid aspirator system used was the 
Vacusip from Integra. The shaker used was a standard analog shaker from VWR. Dounce 
homogenizer was from Thomas Scientific. 
 
B. Equipment for the UV-visible absorbance and fluorescence measurements 
The UV-visible absorbance measurements were performed on a microplate reader 
Synergy™ HT (Biotek Instruments) controlled by BioTek's Gen5™ Data Analysis Software. 
For PorGal8 and ChlGal8, the fluorescence measurements were also performed on this 
equipment. For PcGal16, the fluorescence measurements were performed using the IVIS 
Lumina XR system (Caliper Life Sciences) in combination with its Living Image Software. 
For Por-C3-Gal4 and Por-C1-Gal4, the fluorescence measurements were performed using the 
microplate reader Gemini EM Microplate Spectrofluorometer. 
 
C. Equipment for the cells irradiation 
Studies with PorGal8 were performed using a LEDs array system. The LEDs were 
prepared by Mr. Cândido Casqueira, electromechanic technician of the Department of 
Chemistry of the University of Aveiro, and they were used in the irradiation assays. They were 
composed of a matrix of 24 x 16 LEDs which makes a total of 384 light sources emitting 
white light with two emission peaks (λ = 450 ± 20 and λ = 550 ± 50 nm). 
The illumination system used for PDT with PcGal16 and ChlGal8 was the Light Source 
Model Lc-122 from Lumacare, equipped with a halogen/quartz 250 W lamp coupled with the 
optic fiber probe (400-800 nm).  
For Por-C3-Gal4 and Por-C1-Gal4, the OLED Lumiblade Brite FL300 wm Level 4 
(OLEDWorks)emitting light 420-700 nm was used for the PDT experiments. 
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The fluence rates were determined with the energy meter Coherent FieldMaxII-Top with 
a Coherent PowerSens PS19Q energy sensor. 
 
D. Equipment for the Western blotting 
The Mini Protean electrophoresis system and the Mini Trans-Blot system were from 
Bio-Rad Laboratories. The tube roller SRT6D was from Stuart. The chemiluminescence 
detection system used was the Chemi DocTM XRS from Bio-Rad controlled by the software 
Quantity One. The fluorescence detection system was the Infrared Imaging System (LI-COR 
Biosciences).6 
 
E. Microscopes 
The fluorescence microscopes were purchased from Leica Microsystems (Model 
DFC350) or Nikon Eclipse Ti fluorescent microscope. Confocal microscopes were from Zeiss 
(LSM 710, Carl Zeiss) or Molecular Devices (Nikon Eclipse Ti With Ultra High Speed 
Wavelength Source).7 
 
F. Materials 
Canted neck cell culture flasks 75 cm2 with 0.2 µM vent cap were purchased from 
Corning. CyroPure tubes were purchased from SARSTEDT. The tissue culture testplates and 
the conical tubes of 15 mL or 50 mL were from Orange Scientific. Rubber spatulas, cell 
scrappers were purchased from Greiner Bio-One. The Coverslip Glasses with diameters of 5 
mm were purchased from Warner Instruments. The Neubauer chamber was from VWR. The 
Immun-Blot PVDF membranes were purchased from Bio-Rad. The plates used were 
transparent (Orange Scientific) and black (Greiner Bio-One) 96-wells microtiter plates for the 
absorbance and fluorescence studies, respectively.  
 
 
                                                          
6 Fluorescence detection was used to acquire data of Chapter VII. 
7 The fluorescence and confocal microscopes from Leica Microsystems and Zeiss, respectively, were used to 
acquire data of Chapters III and V. The fluorescence and confocal microscopes from Nikon Eclipse Ti and 
Molecular Devices, respectively, were used to acquire data of Chapter VII. 
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9.3.2 Cell culture and trypsins 
 
The cancer cells lines were from American Type Culture Collection (ATCC®). UM-UC-
3 (ATCC Number: CRL-1749TM) and HT-1376 (ATCC Number: CRL-1472TM), human 
bladder transitional cell carcinoma cell lines, have been isolated from urinary bladder of a 
male and a female Caucasian aged 58 years, respectively, with a grade 3 bladder carcinoma. 
HCT-116 (ATCC Number: CCL-247TM), colorectal carcinoma, have been isolated from colon 
of an adult male. MDA-MB-231 (ATCC Number: HTB-26TM) and MCF-7 (ATCC Number: 
HTB-22TM), adenocarcinoma, were obtained from mammary gland/breast (derived from 
metastatic site: pleural effusion) of females aged 51 and 69 years, respectively. HeLa (ATCC 
Number: CCL-2TM), adenocarcinoma, have been isolated from cervix of a female 31 years. 
All batches of culture media were supplemented with 10% (v/v) heat-inactivated Fetal 
Bovine Serum (FBS) from Gibco, 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 
µg/mL amphotericin B (Sigma). UM-UC-3 and HT-1376 bladder cancer cells were cultured in 
Eagle´s Minimum Essential Medium (EMEM; Corning) with 1.5 g/L sodium bicarbonate, 
non-essential amino acids, L-glutamine and sodium pyruvate. Alternatively, UM-UC-3 and 
HT-1376 cells were also cultured in Roswell Park Memorial Institute (RPMI)-1640 medium 
(Sigma) supplemented with 2 g/L sodium bicarbonate (Sigma), 2 mM L-glutamine (Sigma).8 
HCT-116 colon cancer cells, MCF-7 and MDA-MB-231 breast cancer cells were cultured in 
Dulbecco´s Modified Eagle´s Medium (DMEM, Sigma). HELA cervical cancer cells were 
cultured in DMEM (Corning) with 4.5 g/L glucose, and L-glutamine without sodium pyruvate. 
All cells were maintained at 37 ºC in a 5% CO2 humidified atmosphere. 
Trypsin-EDTA 0.25% (w/v) and Trypsin Tryple Express were purchased from Gibco.  
 
 
 
 
                                                          
8 Data demonstrated in Chapter VI was acquired using UM-UC-3 and HT-1376 cells growing in (RPMI)-1640 
medium. 
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9.3.3 Proteins, molecular weight marker, antibodies and hsiRNA 
 
Bovine Serum Albumin (BSA), the lyophilized albumin fraction V was purchased from 
Biochemical. The protein standard for the Western blotting assays was the Precision Plus 
ProteinTM Dual Color standard, containing ten protein bands (10, 15, 20, 25, 37, 50, 75, 100, 
150, and 250 kDa) from Bio-Rad. The pool of three target-specific 20-25 nt GLUT1 hsiRNA, 
galectin-1 hsiRNA or caveolin-1 hsiRNA, transfection medium, transfection reagent were 
obtained from Santa Cruz Biotechnology. 
 
Table 9.1 Primary antibodies used in the Western blotting and immunofluorescence assays. 
 
Antibody 
Antigen Molecular 
Weight (kDa) 
Dilution 
Supplier 
 
Western 
blotting 
(v/v) 
Immunofluorescence 
(v/v) 
Rabbit anti galectin-1 14 1:1,000 1:100 Abcam 
Mouse anti β-actin 43 1:20,000 ___ Sigma-Aldrich 
Mouse anti-Lamin B 68 1:100 ___ 
Oncogene Research 
Products 
Rabbit anti-GLUT1 50 1:1,000 1:250 Chemicon 
Rabbit anti-Tom20 20 1:1,000 ___ 
Santa Cruz 
Biotechnology 
Rabbit anti ZO-1 225 1:250 ___ 
Invitrogen Life 
Technologies 
Mouse anti E-cadherin 120 1:1,000 1:100 BD Biosciences 
Rabbit anti-phospho-
caveolin-1 
22 1:100 ___ Abcam 
Rabbit anti-caveolin-1 22 1:500 ___ Abcam 
Mouse anti-chathrin 
heavy chain 
180 1:1,000 ___ BD Biosciences 
Mouse anti-EEA1 180 1:1,000 ___ BD Biosciences 
Mouse anti-Flotillin-1 47 1:1,000 ___ BD Biosciences 
Mouse anti-Ki-67 359 ___ 1:100 
Santa Cruz 
Biotechnology 
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The horseradish peroxidase-conjugated secondary anti-rabbit (GAR-HRP) or anti-mouse 
(GAM-HRP) antibodies, used in the Western blotting assays (chemiluminescence detection), 
were purchased from Bio-Rad. The secondary anti-rabbit IRDye® 800CW (Western blot, 
fluorescence detection) was from LI-COR Biosciences. 
The secondary anti-rabbit or anti-mouse antibodies, used in the immunofluorescence 
assays, were the Alexa Fluor 488 Goat Anti-Rabbit and Alexa Fluor 568 Goat Anti-Mouse, 
purchased from Molecular Probes.  
 
9.3.4 KITS and probes 
 
The Immun-StarTM WesternCTM Chemiluminescent Kit (containing the 
chemiluminescent substrate: luminol/enhancer and peroxide solution) used in the Western 
blotting assays (chemiluminescence detection) was from Bio-Rad. 
The PierceBCA Protein Assay Kit-Reducing Agent Compatible (containing the BCA 
Protein Assay Reagent and BSA standards at 2 mg/mL) was purchased from Thermo 
Scientific.  
The 4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Enzo Life Sciences. 
The VectaSHIELD mounting medium with DAPI was purchased from VECTOR. 
The 2´,7´-dichlorohydrofluorescin (H2DCFDA) and dihydroethidium (DHE) were 
purchased from Life Sciences. MitoPY1 was from Sigma. 
TRITC (tetramethylrhodamine isothiocyanate)-conjugated phalloidin was purchased 
from Sigma. 
Glucose uptake cell-based assay kit was from Cayman Chemical and lactate assay kit 
(colorimetric) was from Sigma. CytoTox 96® Non-Radioactive Cytotoxicity Assay was from 
Promega. 
DeadEnd Fluorometric terminal deoxynucleotidyltransferasedUTP nick end-labeling 
(TUNEL) System was obtained from Promega. 
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9.3.5 Buffers, reagents and chemical products 
 
Sodium Chloride (NaCl), Triton X-100, formaldehyde (PFA) and sodium azide (NaN3) 
extra pure were from Merck. Tris Base ULTROL Grade was from CalbioChem. Protease 
inhibitor cocktail tablets were purchased from Complete Mini. 
Glycerol electrophoresis reagent, DL-dithiothreitol 99%, bromophenol blue salt solution, 
sodium dodecyl sulfate (SDS), ethylene glycol tetraacetic acid (EGTA), iodoacetamide (IAD), 
phenylmethanesulfonyl fluoride (PMSF), sodium deoxycholate (DOC), Tween 20, dimethyl 
sulfoxide (DMSO) Hybri-Max™, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT), ammonium persulfate, Tetramethylethylenediamine (TEMED) 
electrophoresis reagent, glycine, L-histidine, L-cysteine were purchased from Sigma. Agarose 
was obtained from MP Biomedicals. 
The trypan blue stain 0.4% was from BioWhittaker Reagents, Lonza. The 2-propanol 
was from J.T.Baker BAKER ANALYZED™ A.C.S reagents. The methanol (MeOH) was 
from EMSURE, Merck. The hydrochloric acid (HCl) 37% was from Panreac. 
The acrylamide/Bis 20% solution was from BIO-RAD. The ECL reagent was from 
Amersham Biosciences. The Glycergel was purchased from DAKO. Poly-L-lysine was from 
Sigma.  
Sucrose, chlorpromazine, dynasore filipin, methyl-β-cyclodextrin and nystatin were 
from Sigma. 
NADPH, cytochrome c, xanthine and xanthine oxidase were obtained from Merck. 
Glutathione-reduced form (GSH), glutathione reductase (GR), EDTA, tert-butyl 
hydroperoxide (t-BOOH), imidazole, glutathione-oxidised form, 1-chloro-2,4-dinitrobenzene 
(CDNB) were from Sigma. Sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate 
(Sulfo-NHS-SS-biotin) and NeutrAvidin beads were from Pierce. MitoTEMPO was from 
Sigma. 
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Table 9.2 Buffers used in the biological studies. All buffers were prepared in Milli-Q water unless other solvent 
is mentioned. 
 Buffer name Composition pH 
 
PBS buffer 
137 mM NaCl, 27 mM KCl, 81 mM Na2HPO4, 15 mM 
KH2PO4 
7.30 
1% SDS lysis 
buffer 
1% (w/v) SDS , Prepared in PBS buffer 7.00 
RIPA buffer 
150 mM NaCl, 50 mM Tris base, 5 mM EGTA, 1% (v/v) 
Triton X-100, 0.5% (w/v) DOC, 0.1% (w/v) SDS, 2 mM 
PMSF, 2 mM IAD, 1 tablet of protease inhibitor cocktail 
7.50 
6x Laemmli 
buffer 
350 mM Tris-HCl, pH 6.8, 30% (w/v) glycerol, 10% (w/v) 
SDS, 600 mM DTT, 0.012% (w/v) bromophenol blue 
6.80 
1.5 M Tris-HCl 
buffer 
1.5 M Tris base 8.80 
0.5 M Tris-HCl 
buffer 
0.5 M Tris base 6.80 
Fixation buffer 4% (v/v) PFA, Prepared in PBS buffer 7.30 
Hypotonic buffer 10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl 7.50 
Western blot 
Running buffer 25 mM Tris base, 192 mM Glicyine, 0.1% (w/v) SDS 8.80-8.50 
Transfer buffer 
25 mM Tris base, 192 mM Glycine, 20% (v/v) MeOH, 0.005% 
(w/v) SDS 
8.00-8.50 
Tris Buffer Saline 
Tween20 (TBST) 
buffer 
20 mM Tris base, 150 mM NaCl, 0.1% (v/v) Tween 20 7.60 
Blocking buffer 
5% (v/v) non-fat milk or 3% (v/v) BSA, Prepared in TBST 
buffer 
7.60 
Immunofluorescence 
Blocking buffer 5% (v/v) BSA or 1:10 (v/v) goat serum, Prepared in PBS buffer  
Permeabilization 
buffer 
1% (v/v) Triton X-100, 0.02% (w/v) BSA, 0.02% (w/v) NaN3, 
Prepared in PBS 
7.30 
PBS Triton X-100 
(PBST) buffer 
0.25% (v/v) Triton X-100, 1% (w/v) BSA, 0.02% (w/v) NaN3, 
Prepared in PBS 
7.3 
Washing buffer 0.02% (w/v) BSA, 0.02% (w/v) NaN3, Prepared in PBS 7.3 
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9.3.6 Softwares 
 
Paint Shop ProTM (v.6.00, Jasc Software) was used for the treatment of the images 
obtained in microscopy. 
ImageJ 1.42n (Wayne Rasband, National Institutes of Health, USA) was used for the 
quantification of the proteins expression on Western blotting assays. 
GraphPad Prism (v.5.00, GraphPad Software) was used for most of the displayed 
graphs, as well as for the statistical analysis.  
Optimas® image analysis software (Optimas, version 5.0) was used for spheroids 
characterization. 
 
9.3.7 Statistical Analysis 
 
The results are presented as mean ± standard deviation (S.D.) with n indicating the 
number of experiments. Statistical significance among two conditions was assessed using the 
nonparametric Mann-Whitney test. Statistical significance among three conditions was 
assessed by the nonparametric Kruskal-Wallis test. Statistical significance among several 
conditions was assessed with the Friedman test. P-value was considered at the 5% level of 
significance to deduce inference of the significance of the data. 
 
9.3.8 Protocols 
 
A. Monolayer cultures 
Principle 
Animal cell lines, obtained from certain cancer cells and from genetic engineering, 
under the appropriate nutrients and strict aseptic conditions grow and replicate in culture. 
 
Protocol: Defrosting Cells 
The human bladder carcinoma cell lines were frozen in 1 mL vials in liquid nitrogen. 
The vial content was thawed, as fast as possible, in 37 ºC water bath and transferred to 5 mL 
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of prewarmed cell culture medium. After centrifugation at 1,000 g during 5 min, appropriate 
aliquots of cell suspension were added to new 25 cm2 or 75 cm2 cell culture flasks. Cells 
grown in monolayer at 37 ºC in a humidified incubator gassed with 5% carbon dioxide (CO2) 
and 95% air. The cells were not cultured for more than three months following resuscitation. 
 
Protocol: Subculturing 
The cell culture medium was removed from culture flasks by aspiration and discarded. 
The cell layers were rinsed with 5 mL of warm sterile PBS, in order to remove traces of serum 
which would inhibit the action of the trypsin. Cells were treated with 0.033 mL/cm2 of trypsin. 
The trypsinization progress was monitored under an inverted microscope. Flasks were 
incubated at 37 ºC until the cells rounded up and the cell layer begun being dispersed.Cell 
culture medium (0.1 mL/cm2) was added to inhibit further trypsin activity and the cells were 
dispersed by repeated pippeting over the surface bearing the monolayer.The cells suspensions 
were then centrifuged at 1,000 g for 5 min. The supernatant was removed, the cells were re-
suspended in cell culture medium and appropriate aliquots of cells were added to new 25 cm2 
or 75 cm2 culture flasks. Cells were examined carefully every day by eye on an inverted 
microscope, for signs of contamination and the cell culture medium was changed two or three 
times per week.  
 
Protocol: Freezing Cells 
Cells were stored frozen as stocks in liquid nitrogen using cell culture medium 
containing 10% (v/v) DMSO at a density of 2-4 x 106 cells/mL. Cells were also frozen at -80 
ºC for short times. Cells were harvested in the same manner used for routine subculture. The 
cell pellet was re-suspended in cell culture medium to give a final concentration of about 3 x 
106 cells/mL and 900 µL were aliquot into each sterile vial containing 100 µL of sterile 
DMSO. The cells were frozen in a -80 ºC freezer prior to transfer to liquid nitrogen. 
 
 
 
Chapter IX. Methods and Materials 
 
256 
 
B. Spheroid cultures 
Principle 
Cells that usually grow as monolayers can be cultured in three-dimensional structures. 
Cells growing in three-dimensional structures mimic the physiological environment of living 
organisms compared to conventional monolayer culture systems. There are several methods 
available for the generation of spheroids. In this work, spheroids were generated by growing 
cancer cell suspensions in agarose-coated 96 well plates [9, 10]. The agarose prevents the cells 
from attaching to the bottom of the wells, thereby increasing interactions with neighboring 
cells (Figure 9.2). 
 
Figure 9.2 Schematic illustration of cells growing in monolayers or in spheroids. 
 
Protocol: Spheroids culture 
Spheroids culture were tried with HCT-116 colon cancer cells, MCF-7 and MDA-MB-
231 breast cancer cells, UM-UC-3 bladder cancer cells and HeLa cervix cancer cells.9 Agarose 
solution (1.5% w/v in PBS) was added to the wells of a 96-well microplate. Next, cells were 
seeded at densities ranging from 2,500 to 20,000 cells per well and the microplate was 
centrifuged for 15 min at 1,500 g. Clusters of cancer cells were observed after 24 h of seeding. 
For HCT-116, MCF-7, UM-UC-3 and HELA cancer cells, it took nearly 48 h for these clusters 
to form spheroids (i.e. clusters which are not dislodged by pipetting). MDA-MB-231 breast 
cancer cells did not form spheroids under these conditions for at least 72 h after cell seeding.  
 
                                                          
9 Spheroid cultures were performed in the laboratory of Professor Charles Michael Drain, Department of 
Chemistry – Hunter College of CUNY, New York, United States. 
Cells adhere to well
1 spheroid per well
2-D monolayer cancer 
cell cultures
96-well  round
bottom plate
3-D spheroid cancer 
cell cultures
96-well  round
bottom plate
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Protocol: Spheroids volume and surface area 
Images of spheroids were obtained at 24, 48 and 72 h after cell seeding using the image 
analysis system consisting of Nikon Eclipse Ti fluorescent microscope and an Andor iXon 
EMCCD camera. Volume and surface area were calculated using Optimas® image analysis 
software. The size of nearly 30 spheroids was calculated in each cell line [11] by measuring 
two orthogonal diameters (d1 and d2) using the line morphometry function. Volume was 
calculated using the formula Volume=4/3πr3, where r=1/2√d1d2 is the geometric mean radius. 
Spheroids with volume ≈0.05 mm3 were obtained 48 h after plating 5,000 HCT-116 cells per 
well, 15,000 MCF-7 cells per well, 20,000 UM-UC-3 cells per well and 20,000 HELA cells 
per well. These conditions were used to obtain spheroids for the determination of the doubling 
time, glucose utilization, lactate production, preparation of cells extracts, ROS determination, 
uptake and PDT assays. 
 
Protocol: Spheroids average cell number 
Average cell number per spheroid was determined at 24, 48 and 72 h after cell seeding 
by trypsinizing six spheroids, mixing the cell suspension with Trypan blue (Sigma) and 
counting the number of viable cells (details about trypan blue assay are described in cell 
viability assays section). The total number of cells obtained was divided by the number of 
spheroids trypsinized.  
 
Protocol: Spheroids doubling times 
The spheroid doubling times were determined by direct measurement of cell numbers, as 
described above. The spheroids were harvested at 24, 48 and 72 h after seeding cells in 
agarose-coated 96-well plate. Doubling times were determined using the formula: 
N/N0=e
kt[12], where N is the cell number for a spheroid at a certain time (t) and N0 is the 
corresponding cell number at time zero. The constant k was calculated for each spheroid by 
plotting ln(N/N0)vs.t, between 24 and 72 h the period of time in which the cell growth rate was 
linear. The doubling time was then determined using the above formula and N/N0=2. 
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Protocol: Spheroids glucose utilization and lactate production 
Glucose utilization in monolayer and spheroid cultures was determined using the 
glucose uptake cell-based assay kit. The spheroids were obtained 48 h after plating cells in 
agarose-coated black, clear bottom 96-well plate. Monolayer and spheroid cultures were 
incubated in PBS for 2 h. The cultures were then incubated with 100 µg/mL of fluorescently-
tagged glucose derivative 2-NBDG in PBS for 1 h. The supernatant was removed and cell 
cultures were washed with cell-based assay buffer. After removal of supernatant, 100 µL of 
cell-based assay buffer was added to each well and 2-NBDG taken up by cells was detected in 
a Gemini EM Microplate Spectrofluorometer with the excitation and emission filters set at 485 
nm and 535 nm, respectively.  
Lactate production in monolayer and spheroid cultures was determined using the lactate 
assay kit. The spheroids were obtained 48 h after plating cells in agarose-coated 96-well plate. 
After incubation of monolayer and spheroid cultures with PBS for 2 h, 50 µL of supernatant 
was collected to a new plate and mixed with 50 µL of master reaction mix (46 µL lactate assay 
buffer, 2 µL lactate enzyme mix, 2 µL lactate probe) during 30 min at room temperature. The 
lactate produced was detected by measuring the absorbance at 570 nm in a PowerWave HT 
Microplate Spectrophotometer. 
Cells were lysed in 1% (w/v) sodium dodecyl sulfate solution in PBS (pH 7.0) and the 
protein concentration was determined by bicinchoninic acid reagent. Glucose consumed or 
lactate produced was normalized to protein concentration (details about protein determination 
are described in determination of intracellular photosensitizer concentration by fluorimetry 
section). 
 
C. Preparation and treatment of cancer cells with photosensitizers 
Principle 
Cancer cells growing as monolayers of spheroids are treated with working sterile 
solutions of PSs.  
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Protocol: Preparing photosensitizers working solutions  
Stock solutions of the PSs at a concentration of 2 mM were prepared in DMSO and 
stored at 0-4 ºC in dark conditions. Freshly working solutionswere prepared from the 
respective stock solution in sterile PBS, accounting their water solubility range. The 
concentration of DMSO was always lower than 0.45% (v/v), in all working solutions. 
 
Protocol: Preparing cancer cell lines 
Adherent cancer cells were detached with trypsin as described before. Cell culture 
medium was then added to inhibit trypsin activity and cells were dispersed by repeated 
pippeting up and down for 4 min. The cells suspensions were then centrifuged at 1,000 g for 5 
min. For studies in monolayers, the cells were re-suspended in cell culture medium and seeded 
into cell culture plates (plates of 6, 12, 24, or 96-wells according to the experiment) at a 
density of 9.4 x 104 cells/cm2   10 and incubated overnight in an incubator at 37 ºC with 5% 
CO2 and 95% air to promote cell adhesion. For studies in spheroids, three-dimensional 
cultures were obtained 48 h after platting 5,000 HCT-116 cells per well, 15,000 MCF-7 cells 
per well, 20,000 UM-UC-3 cells per well and 20,000 HELA cells per well in agarose-coated 
96-well plates. 
 
Protocol: Treatment of cancer cells with photosensitizers 
After seeding the cells as monolayers or spheroids, the cell culture medium was 
removed and the cells were washed with PBS.11 The cells were incubated in dark conditions at 
various periods of time with increasing concentrations of PSs in sterile PBS. 
 
 
 
 
                                                          
10The concentration of viable cells per milliliter of cell supession was calculated using the Trypan Blue Staining. 
Only cells with viability above 90% were used in all experiments. Details about trypan blue assay are described 
in cell viability assays section 
11 This washing step allows the elimination of serum proteins that are able to interact with the PSs. 
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D. Determination of intracellular photosensitizer concentration by fluorimetry 
Principle 
Taking into account the fluorescence properties of the PSs, their concentration inside 
cancer cells can be determined by fluorimetry (after cell lysis) and normalized to total protein 
quantity. 
The concentration of proteins in a sample can be measured spectrophotometrically using 
the Bicinchoninic Acid Assay (BCA assay), also known as the Smith assay. The procedure 
involves two steps. The first is the biuret reaction, whose faint blue color results from the 
reduction of cupric ion (Cu2+) to cuprous ion (Cu+) by peptide bonds in protein, in an alkaline 
environment. Therefore, the amount of reduced Cu2+ is proportional to the amount of protein 
present in the solution. The second is the chelation of two molecules of BCA with one cuprous 
ion, resulting in an intense purple-colored product that strongly absorbs light at the wavelength 
of 562 nm. The BCA-copper complex exhibits a strong linear absorbance at 562 nm with 
increasing concentration of protein. The purple color can be measured at any wavelength 
between 550 and 570 nm with minimal loss of signal. 
 
Protocol: Determination of intracellular photosensitizer fluorescence by fluorimetry 
Cancer cells growing as monolayers or spheroids were incubated with PSs. After PSs 
uptake by cancer cells, cells were washed twice with PBS. Cells were mechanically scrapped 
in 130 µL of 1% (w/v) SDS solution in PBS (pH 7.0) and the plate was stirred on an automatic 
plate shaker in the dark at room temperature. One hundred µL of this cell suspension was 
transferred to 96-wells black plates and the intracellular fluorescence of the PSs was 
determined by ﬂuorometric measurement (Table 9.3), using standard PSs solutions for 
calibration.  
The PS concentration in the samples was directly obtained by plotting the average of the 
fluorescence for each PS standard in function of its concentration (µM). 
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Table 9.3 Equipments and filters used for determination of intracellular photosensitizer fluorescence by 
fluorimetry. 
Compound Equipment λexcitation (nm) λemission (nm) 
PorGal8 microplate reader Synergy™ HT 360/40  645/40  
ChlGal8 microplate reader Synergy™ HT 360/40 645/40  
PcGal16 IVIS Lumina XR system 675  695-770  
Por-C1-Gal4 Gemini EM Microplate Spectrofluorometer 410 702 
Por-C1-Gal4 Gemini EM Microplate Spectrofluorometer 410 702 
 
Protocol: Calculations 
The PS uptake curves were obtained by non linear regression analysis (using GraphPad), 
accordingly to the following equation: Uptake (nmol PS per mg of protein)= 
(Bmax[PS])/(Kd+[PS]). The Bmax is the maximum extrapoled value of the PS uptake (nmol of 
PS per mg of protein) and Kd is the PS concentration needed to achieve a half maximum 
uptake at equilibrium. 
 
Protocol: Determination of total protein 
In a 96-wells plate, the following solutions were pipetted into each well: 
- 25 µL of sample buffer: 1% (w/v) SDS in PBS (pH 7.0), 
- 25 µL of sample, blank (sample buffer), standard (prepared in the sample buffer at 
concentrations ranging from 12.5-800 µg/mL using the BSA standard at 2 mg/mL), 
- 200 µL of BCA working Reagent (50 parts of BCA reagent A mixed with one part of 
BCA reagent B). 
The plate was incubated at 37 ºC for 30 min. Then, the absorbance at 570 nm was 
measured in the plate reader spectrophotometer. The protein concentration in the samples was 
directly obtained by plotting the average of the absorbance at 570 nm for each BSA standard 
in function of its concentration (µg/mL). 
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E. Determination of intracellular photosensitizer fluorescence by fluorescence 
microscopy 
Principle 
Based on the fluorescence properties of the porphyrin and phthalocyanine based PSs, 
their distribution inside the cells can be evaluated by fluorescence microscopy. 
 
Protocol 
Coverslips (three coverslips per well in 12-wells culture plates) were coated with poly-
L-lysine (diluted 1:10, v/v, in sterile PBS) for 1 h at room temperature. The coverslips were 
allowed to dry completely at room temperature. The cells were plated for 24 h before 
treatment. After photosensitizer uptake and washing, cells were fixedwith 4% w/v PFA for 10 
min at room temperature. The samples were washed with PBS (3 x 5 min). The coverslips 
were mounted using the VectaSHIELD mounting medium,12 sealed with nail polish and stored 
at 4 ºC until visualization under the fluorescence microscope. 
 
F. Photodynamic assays 
Principle 
The excitation of a potential PS (previously accumulated in cancer cells) with light at a 
specific wavelength induces cell toxicity, which is mediated by ROS generation. It is expected 
that, besides the preferential accumulation of the PS in cancer cells, they produce toxicity just 
after activation by light. Thus, it is important to evaluate both the PS toxicity in the absence of 
light and after light irradiation. 
 
Protocol: Irradiation 
After PSs incubation, the cells were washed twice with PBSand covered with 100 µL of 
fresh medium. In a dark room, the cells were irradiated for variable times with the desired 
light irradiation time (Table 9.4). After irradiation, cells were incubated for selected time 
points in the humidified incubator gassed with 5% CO2 and 95% air. 
                                                          
12 The mounting medium is applied on a slide and the coverslip with cells on top is added. 
Chapter IX. Methods and Materials 
 
263 
 
With ChlGal8, a repeated PDT was performed 1.5 h after single photo-irradiation of the 
cells with red light at 2.5 mW/cm2 for 40 min  
 
Table 9.4 Light irradiation systems and conditions used during PDT assays. 
Compound Irradiation system 
Potency 
(mW/cm2) 
Irradiation time 
(min) 
PDT treatment 
PorGal8 
white light with two emission peaks  
(λ = 450 ± 20 and λ = 550 ± 50 nm) 
8.4 40 
Single 
ChlGal8 Lumacare (> 500 nm) 2.5 40 
Single 
Repetated (1.5 h dark period 
interval) 
PcGal16 Lumacare (620–750 nm 2.5 40 Single 
Por-C1-Gal4 OLED (420-700 nm) 0.44 30 Single 
Por-C1-Gal4 OLED (420-700 nm) 0.44 30 Single 
 
G. Cell viability assays 
 
 MTT colorimetric assay 
Principle 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT, yellow-colored) 
is added directly to the medium in the wells and incubated for 2-4 h. In living cells, MTT is 
reduced to an insoluble formazan (giving a blue purple colour), being this reduction 
proportional to the mitochondrial enzyme succinate dehydrogenase activity.  
 
Protocol  
The cells were treated with the photosensitizer and the photodynamic treatment was 
performed, as described before. Twenty four, 48, or 72 h after treatments, 50 µL of the 
medium was removed and 10 µL of MTT stock solution (3 mg/mL in PBS buffer) was added 
to each well at a final concentration of 0.5 mg/mL.The plates were thenwrapped in aluminium 
foil and incubated in the darkness at 37 ºC for 4 h. The resulting purple needle-shaped crystals 
were dissolved by the addition of 200 µL acidic isopropanol (0.04 M HCl in absolute 
isopropanol). To dissolve completely the converted dye, repetitive pipetting was applied and 
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the plate was stirred on an automatic plate shaker in the dark at room temperature. The 
absorbance was measured at 570 nm (using 620 nm as the background wavelength), in the 
plate reader spectrophotometer. The percentage of absorbance for each treated sample was 
normalized to that of the untreated control cells.  
 
Calculations 
For each well, the absorbance was expressed as: Absorbance 570 nm – Abosrbance 620 
nm. The results were expressed as percentage of MTT reduction: MTT reduction 
(%)=Absorbance treated wells/Absorbance control wells x 100. 
 
The IC50 values (i.e. concentration of PS that reduces cell survival by 50%) were 
calculated using non-linear regression analysis, sigmoidal dose-response curves (using 
GraphPad Prism) as shown in the equation below: MTT reduction (%)=Bottom+(Top-
Bottom)/(1+10(logIC50-log[PS])Hillslope). Bottom represents the maximum value of response 
(maximum percent of MTT reduction) and Top is the minimum value of response (minimum 
percent of MTT reduction). The log IC50 is the log of the PS concentration ([PS]) that 
responses midway between Top and Bottom. The Hillslope is the steepness of the curve. 
 
 Trypan blue assay 
Principle 
Trypan blue is an organic amine dye that is excluded by living cells with intact 
membranes, whereas dead or dying cells with compromised plasma membrane integrity take 
up the dye. Therefore, all the cells that exclude the dye are considered viable and appear 
brilliant under the microscope. By contrast, cells with damaged membranes appear with a 
distinctive blue color readily observed under the microscope. 
 
Protocol  
To check cell viability before plating the cells, they were trypsinized and resuspended in 
medium. Then, 20 µL of cell suspension and 20 µL of trypan blue stain were gently mixed, 
and the cells were counted using a haemocytometer. The percentage of viable cells and the 
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concentration of viable cells per milliliter of cell suspension were calculated. Only cells with 
viability above 90% were used in all experiments.  
To check cell viability after PDT experiments, the cells were plated in 48-wells culture 
plates for 24 h before treatment. Next, the cells were treated with the photosensitizer and the 
photodynamic treatment was performed. Twenty four, 48, or 72 h after treatments, the cell 
suspension was diluted in the trypan blue stain and the cells were counted. 
 
Calculations 
Viable (bright cells) and nonviable cells (cells stained in blue) were counted and 
summed for the total number of cells. The viability was calculated as follows: Viable 
cells(%)=Number of viable cells/Number of total cells x 100. The concentration of viable cells 
per milliliter in the cell suspension was calculated considering the average of viable cells 
(VCs) per each counting square, the dilution made and the volume of each counting 
square:13(Viable cells/mL)=(VCs x dilution factor)/(1 x10-4). 
 
 TUNEL assay 
Principle 
The photodynamic activation of PSs in cancer cells can trigger cell death pathways 
mediated by apoptosis. In many cell types, apoptosis is characterized by the generation of 
deoxyribonucleic acid (DNA) fragments through the activation of endogenous nucleases. The 
DeadEnd Fluorometric TUNEL System measures the fragmented DNA of apoptotic cells by 
catalytically incorporating fluorescein-12-dUTP and 3´-OH DNA ends using the Terminal 
Deoxynucleotidyl Transferase, Recombinant, enzyme (rTdT). The fluorescein-12-dUTP-
labeled DNA can then be visualized using fluorescence microscopy.  
 
Protocol 
Cell death was detected by TUNEL assay, using the DeadEnd Fluorometric TUNEL 
System, according to the manufacturer´s instructions. Briefly, 24 and 72 h after PDT 
                                                          
13 Considering the volume of each counting square to be 0.1 mm3, the same as 1 x 10-4 mL. 
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treatment, bladder cancer cells were fixed in 4% (w/v) PFA and permeabilized with 0.2% v/v 
Triton X-100 in PBS solution. Cells were stained with TdT reaction cocktail for 60 min at 37 
ºC. The nuclei were stained with DAPI and the cells were analyzed under a fluorescence 
microscope. TUNEL-positive DAPI-stained cells were counted in 10 randomly selected fields 
from three independent experiments. Percentage of dead cells was expressed as ratio of 
TUNEL-positive cell numbers to DAPI-stained cell numbers. 
 
 Lactate dehydrogenase assay 
Principle 
Lactate dehydrogenase (LDH) is a soluble cytosolic enzyme which is released to the cell 
culture medium upon cell death due to damage of plasma membrane. The increase of the LDH 
activity is proportional to the number of lysed cells. The CytoTox 96® Non-Radioactive 
Cytotoxicity Assay is a colorimetric enzymatic assay which measures the release of LDH from 
damaged cells by combining lactate, Nicotinamide Adenine Dinucleotide (NAD+) and a 
tetrazolium salt (iodonitrotetrazolium violet, INT) as substrates in the presence of diaphorase 
to measure the absorbance at 490 nm of a red formazan product (Figure 9.3). 
 
 
 
 
 
Figure 9.3 Schematic representation of Lactate dehydrogenase (LDH) activity assay using the CytoTox 96® Non-
Radioactive Cytotoxicity Assay. 
 
Protocol 
 The CytoTox 96® Non-Radioactive Cytotoxicity Assay measures LDH activity and it 
was used to determine cytotoxicity in spheroid cultures. Briefly, 50 µL of culture medium was 
collected from the 96-well plate containing cell spheroids and mixed with 50μl of the CytoTox 
96® Reagent in dark for 30 min at room temperature. After incubation, 50μl of stop solution 
was added to each well and the absorbance was recorded at 490 nm using a microplate reader. 
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The average values of the culture medium background were subtracted from all values of 
experimental wells. The protein concentration was determined by Bicinchoninic Acid 
Assay14after scrapping spheroid cultures in 1% (w/v) SDS solution in PBS (pH 7.0); and LDH 
activity was normalized to protein concentration. 
 
H. Antioxidant enzyme activities 
Principle 
As the induction of cell death by PDT is mediated by the production of ROS, the 
involvement of specific antioxidant enzymes in the detoxification of ROS and/or resulting 
toxic products can be measured by spectroscopy (Figure 9.4). Superoxide dismutase (SOD) 
catalyses the dismutation of superoxide radical anions into hydrogen peroxide and molecular 
oxygen. Hydrogen peroxide is then removed by catalase (CAT) when it is present at high 
concentrations or by glutathione peroxidase (GPox) when present at low concentrations. 
Glutathione reductase (GR) has an indirect antioxidant function of in the replenishment of 
gluthathione levels in reduced form (GSH) and glutathione S-transferase (GST) is involved in 
the elimination of reactive compounds through their conjugation with GSH. 
 
 
 
 
 
 
Figure 9.4 Schematic illustration of the involvement of specific antioxidant enzymes in the detoxification of 
ROS.  
 
Protocol 
Cell homogenates were obtained immediately after PDT and centrifuged at 10,000 g for 
10 min at 4 ºC. The supernatants were used for measurements of glutathione peroxidase 
                                                          
14Details about protein determination are described in determination of intracellular photosensitizer 
concentration by fluorimetry section. 
Chapter IX. Methods and Materials 
 
268 
 
(GPox), glutathione reductase (GR), glutathione S-transferase (GST), superoxide dismutase 
(SOD) and catalase (CAT) activities in 96-well plates using a Biotek Synergy HT 
spectrophotometer. The activity was expressed as nmol of substrate oxidized per minute per 
mg of protein (mU/mg). The protein concentration was determined by Bicinchoninic Acid 
Assay.15 
 
Glutathione peroxide (GPox) activity 
GPox activity was determined at 30 ºC, measuring the NADPH oxidation at 340 nm. 
Supernatants were mixed with 1 mM of glutathione-reduced form (GSH), 0.5 U/mL GR, 0.18 
mM NaDPH, 1 mM EDTA and 0.7 mM tert-butyl hydroperoxide (t-BOOH) in 50 mM 
imidazole at pH 7.4. The activity was calculated using the NADPH extinction coefficient of 
0.62 m2/mmoL. 
 
Glutathione reductase (GR) activity  
GR activity in cell supernatants was determined at 30 ºC by measuring the rate of 
NADPH oxidation at 340 nm in the presence of 3 mM glutathione-oxidised form, 0.12 mM 
NADPH, and 2.5 mM EDTA, in 50 mM Hepes (pH 7.4). The activity was calculated using the 
NADPH extinction coefficient of 0.62 m2/mmoL. 
 
Glutathione S-transferase (GST) activity  
GST activity was determined at 30 ºC by monitoring the formation of GSH conjugate 
with 1-chloro-2,4-dinitrobenzene (CDNB) at 340 nm in the presence of 1 mM GSH and 1 mM 
CDNB in 50 mM Hepes (pH 7.4). The activity was calculated using the conjugate extinction 
coefficient of 0.96 m2/mmoL. 
 
Superoxide dismutase (SOD) activity 
SOD activity was determined at 25 ºC measuring the cytochrome c reduction at 550 nm. 
The supernatants were mixed with 40 µM cytochrome c solution (0.05 M potassium 
                                                          
15Details about protein determination are described in determination of intracellular photosensitizer 
concentration by fluorimetry section. 
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phosphate, 0.5 mM EDTA, pH 7.8) containing 80 µM xanthine. To initiate the reaction, 2 
U/mL xanthine oxidase was added. The increase in cytochrome c absorbance at 550 nm was 
recorded. SOD activity was calculated considering that one unit of SOD activity represents the 
inhibition of 50% in the rate of increase in absorbance at 550 nm when compared with control 
(sample without SOD under the conditions of the assay).  
 
Catalase (CAT) activity 
CAT activity was determined at 25 ºC by monitoring the rate of hydrogen peroxide 
(0.04% w/w) decomposition in 0.05 M potassium phosphate, pH 7.0. One unit of catalase 
activity was defined by the enzyme quantity that produced an absorbance reduction of 0.43 per 
minute at 240 nm in this system. 
 
I. Transfection assays 
Principle 
Small interfering RNA (siRNA) also referred to as silencing RNA or short interfering 
RNA is used in the gene silencing technique to suppress gene expression (Figure 9.5). 
Typically consisting of 20-25 nucleotide double stranded RNA (dsRNA), siRNA is used to 
induce RNAi particularly in mammalian cells. Intracellular delivery of siRNA induces RNAi - 
a biological mechanism when siRNA molecules activate RNA-induced Silencing Complex 
(RISC). Guided by the antisense strand of the siRNA, RISC degrades the target mRNA thus 
inhibiting its translation. 
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Figure 9.5 Schematic representation of transfection assays using small interfering RNA (siRNA). 
 
Protocol  
Galectin-1, GLUT1 or caveolin-1 were depleted in human bladder cancer cells using a 
pool of three target-specific 20-25 nt siRNA. UM-UC-3 bladder cancer cells were transfected 
in 6- or 96-well culture plates, at 60-80% confluence, with galectin-1 hsiRNA. HT-1376 
bladder cancer cells were transfected in 6- or 96-well culture plates, at 60-80% confluence, 
with GLUT1 or caveolin-1 hsiRNA. Cells were also transfected with a scrambled siRNA in 
parallel as controls.  
For each transfection, cells were treated for 5 h with 2.4 µM of siRNA in transfection 
medium containing 0.5 µL/cm2 of transfection reagent. After incubation, complete media was 
added and the cells were incubated for 24, 48 or 72 h. Galectin-1 or GLUT1 downregulation 
was evaluated 24, 48 or 72h h post-transfection by Western blotting. The uptake and PDT 
experiments were performed 24 h post-transfection with GLUT1 hsiRNA, 48 h post-
transfection with galectin-1 hsiRNA or caveolin-1 hsiRNA. 
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siRNA
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siRNA
RISC
RISC activation
Target mRNA
mRNA cleavage
Chapter IX. Methods and Materials 
 
271 
 
J. Intracellular levels of Reactive Oxygen Species after photodynamic assays 
Principle 
The ROS generation after PDT can be detected using the dichlorofluorescein 
(H2DCFDA), dihydroethidium (DHE) and mitochondria peroxy yellow 1 (MitoPY1) probes, 
by fluorescence microscopy and fluorescence spectroscopy techniques. H2DCFDA is able to 
cross the cell membrane and their acetate groups are removed by intracellular esterases, 
producing H2DCF. H2DCF reacts with several cytotoxic oxygen species producing DCF that 
can be used as a measure of intracellular ROS levels. DHE probe diffuses across cell 
membrane, exhibiting blue fluorescence. In the presence of ROS (particularly superoxide 
anion) this probe is oxidized to ethidium, which intercalates within the cell´s DNA, staining 
the nucleus with bright red fluorescence. MitoPY1 is a fluorescent probe used to detect 
mitochondrial ROS. The intracellular fluorescence of the probes was normalized to total 
protein quantity by Bicinchoninic Acid Assay.16 
 
Protocol: Reactive oxygen species evaluation by fluorimetry 
The cells were plated in 96-wells black plates. Immediately after photodynamic 
treatment and washings, cells were incubated with either 2 μM or 5 μM of H2DCFDA, DHE 
or MitoPY117in PBS (in dark conditions) for 1 h at 37°C. The excitation and emission filters 
used for the H2DCFDA probe were 485/20 nm and 528/20 nm, respectively. For the DHE or 
MitoPY1 probes, the excitation and emission filters used were 485/20 nm and 590/35 nm, 
respectively. After fluorometric measurement, cells were lysed with 1% (w/v) SDS solution in 
PBS (pH 7.0) and total protein concentration was determined as previously described by 
Bicinchoninic Acid Assay.  
 
Protocol: Reactive oxygen species evaluation by fluorescence microscopy  
Coverslips were coated with poly-L-lysine (diluted 1:10, v/v, in sterile PBS) for 1 h at 
room temperature. The cells were plated carefully in 12-wells culture plates. The cells were 
                                                          
16Details about protein determination are described in determination of intracellular photosensitizer 
concentration by fluorimetry section 
17 H2DCFDA and DHE were prepared in DMSO as stock solutions with a concentration of 5 mM, under a nitrogen 
atmosphere. The stock solutions were then kept in the dark at -20 ºC. 
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treated with the photosensitizer and the photodynamic treatment was performed. After PDT 
treatments, cells were incubated with 5 μM of ROS probe in PBS (in dark conditions) for 1 
hour at 37°C. The cells were washed twice for 5 min each in PBS. After that, the cells were 
fixed in 4% w/v PFA for 10 min at room temperature. The samples were washed with PBS (3 
x 5 min). The coverslips were mounted using the VectaSHIELD mounting medium, sealed 
with nail polish and stored at 4 ºC until visualization under the fluorescence microscope. 
 
K. Redox quenching assays 
Principle 
The role of type I and type II oxidative mechanisms in cell toxicity after PDT, can be 
evaluated using specific quenchers of 1O2 (sodium azide and histidine) and free radical 
scavengers (cysteine), respectively. MitoTEMPO can also be used as a specific scavenger of 
mitochondrial hydrogen superoxide. 
 
Protocol 
The cells were plated in 96-wells black plates for 24 h before treatment. Immediately 
after PS uptake, the cells were washed and the redox quenchers (sodium azide, histidine and 
cysteine at concentration of 50 nM or 10 µM MitoTEMPO) were added to the cells in growth 
culture medium. After incubation with the redox quenchers for 10 min, the photodynamic 
treatment (in the presence of the redox quenchers) was performed. The effect of the presence 
of quenchers on cell viability was evaluated 24 h after photodynamic therapy by the MTT 
viability assay.  
 
L. Western blotting assays 
Principle 
The presence of specific proteins in a complex mixture extracted from cells can be 
studied by Western blotting using specific antibodies (Figure 9.6). Moreover, with this 
technique it is possible to quantify the levels of the proteins. For that, denaturated proteins 
present in the mixture are separated in a polyacrylamide gel by electrophoresis, accordingly to 
their size, following the methodology of Laemmli. Then, the separated proteins in the gel are 
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electrotransferred to a membrane using the method of Towbin and a specific unlabeled 
primary antibody is used to stain the target antigen. After wash, a labeled secondary antibody 
is used to detect the presence of the primary antibody, and thus the target protein. The proteins 
can be visualized as bands, using the ECL (enhanced chemiluminescence) or fluorescence 
detection methods. For ECL detection, the horseradish peroxidase (HRP), which is conjugated 
with the secondary antibody, in the presence of hydrogen peroxide and an enhancer, catalyzes 
the oxidation of luminol, emitting light. The emitted light can be detected using a CCD camera 
for light capture. For fluorescence detection, a secondary antibody coupled with a fluorescent 
dye is used. 
 
Figure 9.6 Schematic representation of Western blotting. 
 
Protocol: Sample preparation  
For immunodetection of proteins cells were plated in 6-wells culture plates before 
treatment. The cells were then treated with the photosensitizer and the photodynamic 
treatment was performed. After treatment, the cells were washed twice with ice-cold PBS and 
lysed by addition of ice-cold RIPA buffer with fresh protease inhibitors. The cell lysates were 
then transferred to microtubes with the help of a rubber policeman (cell scrapper) and 
incubated on ice during 30 min. During incubation, samples were vortexed 10 sec every 10 
min.18 The total cell lysates were centrifuged at 18,000 g for 16 min, at 4 ºC. The supernatant 
was transferred to a new microcentrifuge tube. The supernatants were used for protein 
concentration determination, followed by denaturation with Laemmli buffer. 
 
                                                          
18 These vortex steps are important for the cell disruption. 
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Protocol: Determination of total protein 
The protocol used for the determination of protein concentration was the same as 
described before, with some differences: 
The samples were diluted in RIPA buffer 1:9 (v/v) and in a 96-wells plate, the following 
solutions were pipetted to each well: 
- 25 µL of sample buffer: RIPA buffer, 
- 25 µL of sample, blank (sample buffer), standard (prepared in the sample buffer at 
concentrations ranging from 12.5-800 µg/mL using the BSA standard at 2 mg/mL), 
- 200 µL of BCA working Reagent (50 parts of BCA reagent A mixed with one part of 
BCA reagent B). 
 
Protocol: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis and Blotting 
After determination of protein concentration, the samples were denaturated with 6x 
Laemmli buffer. The samples were heated at 37 ºC for 30 min, or boiled19 during 5 min at 95 
ºC. Protein samples (60 µg) was loaded on 8%, 10% or 12% polyacrylamide gels and the 
proteins were separated by electrophoresis. The electrophoresis was stopped when the dye 
front reached the bottom of the gel.  
Following gel electrophoresis, the separated protein mixtures were transferred to a solid 
support for further analysis. The polyvinylidene difluoride membranes (PVDF) were first 
activated with 100% MeOH, and then soaked in Milli-Q water and equilibrated in transfer 
buffer. All the material used in the blotting (sponges, sheets of filter paper), as well as the gels 
were also equilibrated in transfer buffer. The gel and the PVDF membrane were assembled 
into a sandwich along with sheets of filter paper and sponges. The separated proteins were 
then transferred to the PVDF membranes (using ice cold transfer buffer) for 90 min under 
agitation, with the tank in ice (and using a cooling coil inside the tank). At the end, the baking 
of the membranes was performed by incubation at 50 ºC for 20 min. 
 
 
                                                          
19 The samples should not be boiled when the analysis of GLUT1 protein is aimed due to the formation of GLUT1 
aggregates after boiling. 
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Protocol: Antibodies incubations, detection and quantification 
The membranes were placed into blocking buffer for 1 h at room temperature with 
gentle agitation. The membranes were incubated with the primary antibody (diluted in the 
blocking buffer) for 2 h at room temperature or overnight at 4 ºC, under low agitation. After 
incubation, the membranes were rinsed in TBST (3 x 10 min) at room temperature. The 
appropriate secondary antibody conjugated with the enzyme horseradish-peroxidase diluted 
1:10,000 (v/v) or IRDye® 800CW 1:15,000 (v/v) in 2.5% (w/v) non-fat milk (prepared in 
TBST) was added, and the membranes were incubated for 1 h at room temperature, under 
moderate agitation. After incubation with the secondary antibodies, the membranes were 
washed in TBST (3 x 10 min), with agitation. To demonstrate equivalent protein loading, all 
the membranes were re-probed for the protein β-actin. For the detection using the secondary 
antibody conjugated with the enzyme horseradish-peroxidase, the membranes were placed on 
the chemiluminescence detection system20 (proteins side up), incubated with the substrate 
solution (1:1, v/v, mixture of luminol/enhancer and peroxide buffer) for 1 min following 
manufacturer instructions, and then the images were acquired. For the detection using the 
secondary antibody IRDye® 800CW, membranes were imaged on the Odyssey Infrared 
Imaging System (proteins side down). The intensity signal of the bands was quantified using 
the software ImageJ 1.42q and the fold change in protein levels was expressed as follows and 
then normalized to the control situation: Fold change in protein expression=Protein band 
intensity/β-actin band intensity. 
 
M. Immunocytochemistry assays 
Principle 
The distribution of specific proteins through the sample can be visualized by 
immunocytochemistry. First, the cells are fixed to retain their shape and structure 
(morphology) and location of all cellular proteins and to disable intrinsic proteolytic enzymes. 
The cells are then permeabilized with a mild detergent, so the antibodies could have access to 
the cytoplasm. After that, specific unlabeled primary antibody binds to the target molecule, 
and the secondary antibody (covalently attached to a fluorophore) recognizes the primary 
                                                          
20 To prevent drying, the membranes were placed in a nylon transparent sheet. 
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antibody. At the end, the images can be obtained using a fluorescence microscope, showing 
the subcellular distribution of the protein of interest. 
 
Protocol: Sample preparation, adherent cells  
Coverslips were coated with poly-L-lysine (diluted 1:10, v/v, in sterile PBS) for 1 h at 
room temperature. Cells were plated in 12-wells culture plates before treatment. For the 
treatments with the PSs, the cells were treated and the photodynamic treatment was 
performed. 
 
Protocol: Fixation, permeabilization, blocking and incubation with the antibodies 
After washing with PBS, the cells were fixedin 4% w/v PFA for 10 min at room 
temperature. The samples were washed with PBS (3 x 5 min). The cells were treated with 
permeabilization buffer during 10 min. Then, the cells were washed with washing buffer, for 5 
min. The cells were incubated with the blocking buffer for 30 min, in a humidified chamber. 
After blocking, the cells were incubated with the primary antibody diluted in PBST buffer 
during 1 h at room temperature, in a humidified chamber. The primary antibody solution was 
decanted and the samples were washed with washing buffer (3 x 5 min). The cells were 
incubated with the secondary antibody and DAPI (1 µg/mL) diluted in PBST buffer for 1 h (at 
room temperature) in a humidified chamber in the dark. The cells were washed in the dark 
three times with the washing buffer, 5 min each wash. The coverslips were mounted using the 
glycergel mounting medium and sealed with nail polish. The samples were stored in an 
appropriate box at 4 ºC until acquisition of images by fluorescence microscopy. 
 
N. Endocytic inhibitors assays 
Principle 
Specific pathways of endocytosis involved in the uptake of PSs can be studied using 
pharmacological inhibitors that transiently block endocytic pathways. Uptake studies can be 
performed at 4 ºC and in the presence of NaN3 to determine whether the uptake is an active 
process. Clathrin-dependent endocytosis can be inhibited using hypertonic sucrose and 
chlorpromazine [13]. Dynasore can be used to inhibit dynamin-dependent endocytosis [14]. 
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Filipin, methyl-β-cyclodextrin and nystatin can be used to inhibit caveolae-dependent 
endocytosis [13]. 
 
Protocol 
The cells were plated in 96-wells plates for 24 h before treatment. The cell culture 
medium was removed and the cells were washed with PBS. The cells were incubated during 
30 min with 20 mM NaN3, 0.45 mM sucrose, 5 µM chlorpromazine, 40 µM dynasore, 2.5 
µg/mL filipin, 5 mM methyl-β-cyclodextrin or 25 µM nystatin at 37 ºC. The cells were then 
incubated in darkness with 5 µM PcGal16 (in the continued presence of the respective 
inhibitor) for 1.5 h at 37 ºC. For studies at 4 ºC, cells were incubated with 5 µM PcGal16 for 
1.5 h at 4 ºC. Uptake and PDT assays were then performed as aforementioned.  
 
O. Cell-surface biotinylation assays 
Principle 
Cell-surface proteins expression can be studied by Western blot after biotinylation and 
isolation of those proteins. Cells are labeled with a thiol-cleavable amine-reactive biotinylation 
reagent. The Sulfo-NHS-SS-biotin is a cell-membrane impermeable where the sulfo-NHS 
ester group reacts with an amine to form a stable amide bond with the amine-containing 
protein (Figure 9.7A and 9.7B). Cells are subsequently lysed with a mild detergent and the 
labeled proteins are isolated using immobilized beads (such as NeutrAvidin beads, Figure 
9.7C). The bound proteins are released from the beads by incubating with a solution 
containing DTT (Figure 9.7C). 
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Figure 9.7 Schematic representation of cell-surface protein biotinylation. 
 
Protocol 
Cells were plated in 6-wells culture plates before treatment. Cell-surface biotinylation 
was performed as previously described [15]. Prior to surface protein biotinylation, all reagents 
were cooled to 4 ºC. The cells were washed twice with ice-cold PBS containing 0.5 mM 
MgCl2 and 1 mM CaCl2. Next, cells were incubated with 1 mL of the same ice-cold solution 
containing 1 mg/ml of freshly added Sulfo-NHS-SS-biotin21 for 30 min at 4ºC, with gentle 
agitation. The medium was discarded and the plates were washed thrice with ice-cold PBS 
containing 0.5 mM MgCl2, 1 mM CaCl2, and 100 mM glycine22. The cells were scrapped in 
ice-cold RIPA buffer and kept on ice for 15 min. The cell homogenates were centrifuged at 
18,000 g for 16 min at 4 ºC. The supernatants were then transferred to 1.5 mL eppendorf 
microfuge tubes containing 20 µL NeutrAvidin beads.23 After 2 h incubation at 4°C under 
agitation, the NeutrAvidin supernatant (non-biotinylated proteins)24 was collected and 
denaturated with Laemmli buffer and used for Western blotting. The beads were washed thrice 
                                                          
21Sulfo-NHS-SS-biotin does not penetrate the plasma membrane because of the charged sulfonate group, thus 
biotinylation is restricted to the cell surface. 
22PBS containing glycine is used to quench any unreacted biotin reagent. 
23 Before use, NeutrAvidin beads were washed thrice with RIPA buffer. 
24 As the proteins at the cell surface are biotinylated, the non-biotinylated proteins correspond to intracellular 
proteins. 
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with RIPA buffer. The NeutrAvidin-bound proteins (biotinylated proteins) were eluted from 
the beads by adding 20 µL 2x Laemmli buffer25, denaturated and used for Western blotting.  
 
P. Cellular fractionation 
Principle 
Each organelle has characteristics (size, shape and density for example) which make it 
different from other organelles within the same cell. If the cell is broken open in a gentle 
manner, each of its organelles can be subsequently isolated. The process of breaking open 
cells is homogenization and the subsequent isolation of organelles is fractionation. Isolating 
the organelles requires the use of physical chemistry techniques, and those techniques can 
range from the use of simple sieves, gravity sedimentation or differential centrifugation 
(Figure 9.8), to ultracentrifugation of fluorescent labeled organelles in computer generated 
density gradients. 
 
Figure 9.8 Schematic representation of cell fractionation by differential centrifugation. 
 
Protocol 
Cellular fractionation was performed as previously described [16]. After PDT, the cells 
were washed twice with ice-cold PBS and lysed with ice-cold hypotonic buffer (10 mM NaCl, 
1.5 mM MgCl2 and 10 mM Tris-HCl at pH 7.5). The cell lysates were transferred to 
                                                          
25DTT in Laemmli buffer allows the release of the proteins from beads. 
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microtubes with the help or a rubber policeman (cell scrapper) and incubated on ice during 10 
min. The cell suspension was then transferred into a Dounce homogenizer. To disrupt the 
membranes, 40 up-and-down strokes were performed. The pellet containing the nuclei, intact 
cells and large membrane fragments was obtained after centrifugation at 1,300 g for 10 min at 
4 ºC. The supernatant was recovered and transferred into clean microtubes which were then 
centrifuged at 17,000 g during 20 min at 4º C to obtain the mitochondrial fraction. The pellet 
rich in plasma membrane and the supernatant rich in cytosolic fraction were obtained after 
centrifugation at 20,000 g during 2h. After centrifugations, the pellets were resuspended in 
100 µL of ice-cold hypotonic buffer. The cellular fractions were used for determination of PS 
fluorescence and for protein concentration determination as described in Western blot section, 
followed by denaturation with Laemmli buffer. 
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9.4 In vivo biological assays 
 
9.4.1 Equipment and common materials 
 
A. Equipment for bioluminescent imaging 
Bioluminescent imaging was performed using IVIS Lumina XR system (Caliper Life 
Sciences) in combination with its Living Image Software. 
 
B. Equipment for photodynamic therapy 
The illumination system used was the Light Source Model Lc-122 from Lumacare, 
equipped with a halogen/quartz 250 W lamp coupled with the optic fiber probe (400-800 nm). 
The fluence rates were determined with the energy meter Coherent FieldMaxII-Top with a 
Coherent PowerSens PS19Q energy sensor. 
 
C. Materials 
Type II polycarbonate cages in individually ventilated caging (IVC) systems were from 
VentiRack Bioscreen TM. 
The SuperFrost Plus glass slides (Menzel-Glaser) were from Thermo Fisher Scientific. 
 
9.4.2 Plasmids, buffers, reagents and chemical products 
 
pGL2 luciferase reporter vector was obtained from Promega. pcDNA6.2GW/Em-GFP, 
pcDNA-ENTR-BP, pLenti6 and blasticidin were from Invitrogen. STAR-Rdpro cells and 
polybrene were from Sigma. D-luciferin was from Perkin Elmer. 
 
9.4.3 Photosensitizers 
 
PorGal8 and ChlGal8 were synthesized as described in synthesis of galactose-
conjugates section. 
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9.4.4 Cells 
 
HT-1376 and UM-UC-3 bladder cancer cells were obtained from ATCC and cultured as 
described in in vitro section. 
 
9.4.5 Softwares 
 
The Living Image software was used to calculate photon flux during bioluminescent 
imaging acquisition. 
GraphPad Prism (v.5.00, GraphPad Software) was used for most of the displayed 
graphs, as well as for the statistical analysis.  
 
9.4.6 Ethics statement 
 
All procedures involving animals were conducted according to the statements on the 
directive 2013/113/EU of the European Parliament and of the Council Portuguese law (DL 
113/2013) and all relevant legislations. All experiments were approved by the Portuguese 
Veterinary Direction (ORBEA-IBILI-FMUC-06-2015). The authors have an accreditation for 
animal research given from Portuguese Veterinary Direction (Ministerial Directive 1005/92). 
We adhere to the ARRIVE guidelines for reporting animal research [17]and to the guidelines 
for the welfare and use of animals and cancer research [18]. 
The mice were purchased from Charles River (National Cancer Institute Frederick) and 
maintained under specific-pathogen-free conditions in the animal care facility of IBILI, 
Faculty of Medicine, University of Coimbra (Coimbra, Portugal). 
The mice were housed in type II polycarbonate cages in individually ventilated caging 
(IVC) systems enriched with sterelized cardboard tubes and shelters. The mice were fed with 
sterilized standard laboratory diet and received sterile water ad libitum. The animals were 
housed at approximately 22 ºC, 60% relative humidity, and a 12 h light, 12 h dark cycle was 
maintained. All mice were quarantined and acclimated to laboratory conditions for 1 week 
before experimentation. 
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PDT treatments were performed with mice under a heat pad to maintain body heat and 
only the tumor areas were irradiated. As the PDT experiments were performed with mice 
outside of microbiological safety cabinets; simple measures (use of latex gloves and face 
masks, disinfection of the working bench with 90% alcohol for 3 min) were taken to prevent 
infections. 
Early endpoints were applied during the experiments to increase the precision of the 
results and to decrease non-specific systemic effects [18]. The mice were euthanized (cervical 
dislocation) and subjected to necropsy examination when the tumor volume of the control and 
single PDT groups reached approximately 500 mm3 (normally at days 9 and 11 after 
treatment, respectively), when ulcerating lesions occurred, when an animal had lost > 10% of 
its body weight, or when a mouse appeared seriously ill. At the end of the experiments (13 and 
15 days after PDT with PorGal8 and ChlGal8, respectively), all remaining animals were 
sacrificed and subjected to a gross necropsy examination. 
 
9.4.7 Statistical analysis 
 
Statistical analyses were carried out using a statistics program (GraphPad Prism; 
GraphPad Software). Student’s t-test was used to compare the treatment effects with that of 
control. P-value was considered at the 5% level of significance to deduce inference of the 
significance of the data. All graphs and statistics were prepared using the GraphPad Prism 5.0 
software.  
 
9.4.8 Protocols 
 
A. In vivo studies with PorGal8 
Principle 
The most common in vivo approach used in PDT experiments is based on subcutaneous 
tumors in laboratory mice. Human xenograft tumors can be obtained by engraftment of human 
tumor cells into athymic nude mice or into severe combined immunodeficient mice that are T- 
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and B-cell deficient. Mouse xenograft models bearing luciferase-expressing cancer cells have 
been established to monitor PDT efficacy with non-invasive bioluminescence imaging.  
Bioluminescence imaging relies on the detection of light produced from cells tagged 
with luciferase. The firefly luciferase gene is most commonly used in animal tumor models. 
Luciferase expression is imaged following an intraperitoneal injection of the substrate D-
luciferin [19]. Luciferase oxidizes luciferin in the presence of ATP and molecular oxygen to 
form an electronically excited oxy-luciferin species. Visible yellow-green to yellow-orange 
light is emitted following the relaxation of excited oxy-luciferin to its ground state. 
 
Protocol: Lentivirus production and transduction in UM-UC-3 bladder cancer cells 
The lentiviral vector was generated by Doctor José Ramalho at Laboratório de Biologia 
Celular e Molecular FCM/CEDOC - Universidade Nova de Lisboa. The coding sequence for 
firefly (Photinus pyralis) luciferase was amplified from pGL2 luciferase reporter vector by 
polymerase chain reaction PCR (forward primer- ctgttgctagcatggaagacgccaaaaacataaagaaa, 
reverse primer- gctgaggatccttacattttacaatttggactttccgc), digested with NheI/BamHI and cloned 
into pcDNA-ENTR-BP with the same restriction enzymes. pcDNA-ENTR-BP, a Gateway® 
mammalian expression vector was generated based on pcDNA6.2GW/Em-GFP. In order to 
generate a polylinker containing a multi-cloning site, two DNA sequences 
(aaagctagcgatctcgagctcaagcttcgaattctgcagtcgacggtaccgcgggcccgggatccagcggccgctctagataactgat
ca and 
tcgatgatcagttatctagagcggccgctggatcccgggcccgcggtaccgtcgactgcagaattcgaagcttgagctcgagatcgcta
gcttt) chemically synthesized were annealed and ligated into pcDNA6.2GW/Em-GFP 
previously digested with DraI/XhoI. In order to generate recombinant lentiviruses, the firefly 
luciferase was subcloned into pLenti6 using the Gateway system. Recombinant lentiviruses 
were produced by transient transfection. pMD2.G (envelope-coding plasmid) and psPAX2 
(which expresses Gag, Pol and Rev) were gifts from Didier Trono (Addgene plasmid #12259 
and #12260 respectively). All plasmids, including pLenti6 Luc transfer vector were 
transfected into STAR-Rdpro cells by JetPrime protocol (Polyplus). Supernatant was 
harvested at 48 h later and used to transduce UM-UC-3 bladder cancer cells in the presence of 
polybrene (6 µg/mL). Transduced cells were selected using blasticidin (8 µg/mL). Isolated 
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clones were screened for their luciferase activities using an IVIS Lumina XR equipment 
(Figure 9.9). To isolate single cell clones, cells were subjected to limited dilution. Individual 
clones were selected for luciferase activity using an IVIS Spectrum. 
 
Figure 9.9 Schematic representation of transduction in UM-UC-3 bladder cancer cells. 
 
Protocol: Mice  
Male nude Balb/c nu/nu mice were used for biodistribution and PDT studies with 
PorGal8. We used a total of 27 animals in the experiments (divided into 5 experimental 
groups, n = 3 mice for biodistribution studies and n = 6 mice per group of PDT experiments) 
which were 5 to 8 weeks of age and weighed 20-25 g at the start of the experiments.  
 
Protocol: Inoculation of tumor cells 
A cell suspension of 2 x 106 UM-UC-3luc+ cells in PBS (cooled on ice in a tube) was 
inoculated subcutaneously (0.1 mL) under the skin in the dorsal flank regions by using a 
sterile syringe with a 21-gauge needle. The mice were monitored daily, tumor growth was 
followed by bioluminescent imaging and tumor volume was measured using an external 
caliper. 
 
Protocol: Assessment of tumor volume 
All measurements of tumor volume were carried out by the same investigator (who was 
blinded to the experimental groups) to maximize the reproducibility of the data. The tumor 
growth was observed daily, monitored over time by bioluminescent imaging and measured 
once they become palpable. To calculate tumor volume, the greatest longitudinal diameter 
(length) and the greatest transverse diameter (width) from each tumor were determined using 
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an external caliper. Each tumor´s volume was calculated using the following formula: tumor 
volume=length x width2 x 0.5.One week after the injection of UM-UC-3luc+, tumors whose 
volume reached approximately 50 mm3 were selected for the PDT studies.  
 
Protocol: Study design 
Based on previous studies, describing UM-UC-3luc+ bladder cancer cells to develop a 
xenograft tumor model [20], we determined the sample size using G*Power 3.1 for all power 
calculations. We required groups of at least 6 mice to achieve appropriate power for anticancer 
analysis (effect size: a 50% decrease in the bioluminescent signal at 5 days after treatment 
with PDT; significance level: 5%; desired power of the experiment: 80%). When the volume 
of xenografts reached approximately 50 mm3 (normally 7 days after cells inoculation), the 
tumor-bearing mice were randomly divided into the following 5 groups (Figure 9.10):  
Group I) 5 µmol/kg of PorGal8 injected intraperitoneally for biodistribution studies, 
Group II) no treatment,  
Group III) no PorGal8 injection and PDT at 50.4 J/cm2 (i.e. 28 mW/cm2 for 30 min, 
negative control),  
Group IV) 5 µmol/kg of PorGal8 injected intraperitoneally and no PDT (mice treated 
with PorGal8 in darkness), 
Group V) PDT at 50.4 J/cm2 performed 24 h after intraperitoneal injection of 5 µmol/kg 
of PorGal8 (PDT treatment group; Table 9.5).  
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Figure 9.10 Experimental design for in vivo studies with PorGal8 (arrows represent time period after which 
euthanasia took place). 
 
Table 9.5 Experimental conditions used in in vivo studies with PorGal8. 
Compound 
Dose 
(µmol/kg) 
Irradiation 
system 
Potency 
(mW/cm2) 
Irradiation 
time (min) 
PDT 
treatment 
Model 
PorGal8 
5  
(intraperitoneal) 
Lumacare 
(400-800 nm) 
28 30 Single 
Xenograft (Male nude 
Balb/c nu/nu mice, UM-
UC-3luc+ cells) 
 
Protocol: In vitro and in vivo bioluminescent imaging 
For in vitro luciferase assay, D-luciferin was added to the cell culture medium to obtain 
a final concentration of 150 µg/mL. The bioluminescent imaging was performed 10 min after 
adding the substrate into the cells using an IVIS 100 imaging system. Photon flux was 
calculated using Living Image software and represented as photons/sec/cm2/sr. 
Bioluminescence values were then represented as percent photon flux of untreated or vehicle 
control values. 
For in vivo imaging, the mice were first anesthetized (2 mg/kgintraperitoneal cocktail of 
a 2:1 50 mg/mL ketamine in 2.5% chlorpromazine). D-luciferin was then injected 
intraperitoneally (150 mg/kg) by using a sterile syringe with a 21-gauge needle. The mice 
were imaged using an IVIS 100 imaging system. Bioluminescence values were calculated by 
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measuring photons/sec/cm2/sr in the region of interest surrounding the bioluminescence signal 
from the tumor. 
 
Protocol: Biodistribution assays 
On day 0 (normally 4-5 ppm), the animals of biodistribution study group (n = 3) were 
injected intraperitoneally with 5 µmol/kg of PorGal8 (freshly prepared in PBS with a 
percentage of DMSO of 0.2% v/v) by using a sterile syringe with a 21-gauge needle. At 5 h 
and 24 h post-injection, the mice were anesthetized (2 mg/kg intraperitoneal cocktail of a 2:1 
50 mg/mL ketamine in 2.5% v/v chlorpromazine) and fluorescence images were captured 
using an IVIS 100 imaging system (excitation at 430 nm and emission 695-770 nm). After 
final imaging, animals were euthanized (cervical dislocation) and subjected to necropsy 
examination. Tumor and organs (kidney, heart, liver and lung) were removed for imaging to 
confirm signal content and assess the tumor-targeting efficacy of PorGal8. 
 
Protocol: Photodynamic Therapy study 
On day 0 (normally 4-5 ppm), the animals of Groups IV and V were injected 
intraperitoneally with PorGal8 as previously described. On day 1 (24 h after injection of 
PorGal8) the tumors of animals, from Groups III and V, were light irradiated. Light irradiation 
(white light 400-700 nm) was performed with the illumination system LC-122 LumaCare). 
One day after treatments, the mice were monitored daily, bioluminescent imaging was 
repeated twice a week after treatment and the tumor volume was measured.  
The observations and assessments of the treated group (PDT treatment group) were 
compared with the negative control groups (negative control groups II, III and IV). 
 
B. In vivo studies with ChlGal8 
Protocol: Mice  
Male Swiss nude (nu/nu) mice were used for PDT studies with ChlGal8. We used a total 
of 24 animals in the experiments (divided into 4 experimental groups, n = 6 mice per group) 
which were 5 to 8 weeks of age and weighed 20-25 g at the start of the experiments.  
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Protocol: Inoculation of tumor cells 
The xenograft tumor model was developed using HT-1376 human bladder cancer cells. 
A cell suspension of 2 x 106 HT-1376 cells in PBS was inoculated subcutaneously (0.1 mL) 
under the skin in the dorsal flank regions by using a sterile syringe with a 21-gauge needle.  
 
Protocol: PDTstudy design 
Based on previous studies, describing HT-1376 bladder cancer cells to develop a 
xenograft tumor model [21], we determined the sample size using G*Power 3.1 for all power 
calculations [22, 23]. We required groups of at least 6 mice to achieve appropriate power for 
anticancer analysis (effect size: a 50% decrease in tumor volume at 5 days after treatment with 
PDT; standard deviation: 80; significance level: 5%; desired power of the experiment: 80%).  
When the volume (assessment of tumor volume is described in detail in in vivo studies 
with PorGal8 section) of xenografts reached approximately 50 mm3 (normally 10 days after 
cells inoculation), the tumor-bearing mice were randomly divided into the following 4 groups 
(n = 6 per group, Figure 9.11):  
Group I) no ChlGal8 injection and PDT at 36 J/cm2 (i.e. 30 mW/cm2 for 20 min, 
negative control);  
Group II) 3.33 µmol/kg of ChlGal8 injected intratumorally and no PDT (mice treated 
with ChlGal8 in darkness); 
Group III) PDT at 36 J/cm2 performed 1.5 h after intratumoral injection of 3.33 µmol/kg 
of ChlGal8 (single PDT group); 
Group IV) PDT at 36 J/cm2 performed 40 min after single PDT (repeated PDT group).  
On day 0 (4-5 pm), the animals of negative control, single PDT group and repeated PDT 
group were anesthetized (2 mg/kg intraperitoneal cocktail of a 2:1 50 mg/mL ketamine in 
2.5% v/v chlorpromazine) and injected intratumorally with 3.33 µmol/kg ChlGal8 (freshly 
prepared in PBS with a percentage of DMSO of 0.3% v/v) by using a sterile syringe with a 21-
gauge needle. On the same day, 1.5 h after injection of ChlGal8 the tumors of animals, from 
single and repeated PDT groups, were light irradiated. Light irradiation (white light 400-800 
nm) was performed with the illumination system LC-122 LumaCare) with light > 500 nm. 
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The tumors of mice from repeated PDT group were light irradiated for a second time, 40 
min after the first irradiation time. One day after treatments, the mice were monitored daily 
and the tumor volume was measured as described in Supporting Information. The observations 
and assessments of the treated groups (single and repeated PDT groups) were compared with 
the negative control groups (negative control groups I and II). 
 
Figure 9.11 Experimental design (arrows represent time period after which euthanasia took place). 
 
Table 9.6 Experimental conditions used in in vivo studies with ChlGal8. 
Compound 
Dose 
(µmol/kg) 
Irradiation 
system 
Potency 
(mW/cm2) 
Irradiation 
time (min) 
PDT treatment Model 
ChlGal8 
3.33 
(intratumoral) 
Lumacare  
(> 500 nm) 
30 20 
Single  
Repeated (40 min 
dark period 
interval) 
Xenograft (Male 
Swiss nude nu/nu, 
HT-1376 cells) 
 
C. Immunohistochemistry assays 
Principle 
Immunohistochemistry (IHC) is a method for demonstrating the distribution and 
location of proteins in tissue sections. Immunohistochemical staining follows the same basic 
principles of immunocytochemistry and it is accomplished with antibodies that recognize the 
target protein. The antibody-antigen interaction is then visualized using either chromogenic 
detection, in which an enzyme conjugated to the antibody cleaves a substrate to produce a 
colored precipitate at the location of the protein, or fluorescent detection, in which a 
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fluorophore is conjugated to the antibody and can be visualized using fluorescence 
microscopy. 
 
Protocol 
Intact tumors were embedded in OCT matrix and snap frozen in dried ice. The samples 
were stored at -80 ºC until used. Serial cryostat sections (10 μm) of both control and PDT 
tumors were placed on the same slide to minimize methodological variation during 
immunostaining. Sections were air dried and fixed in cold acetone for 10 min. The sections 
were then washed with PBS, permeabilized for 30 min with 0.25% v/v Tx-100 in PBS with 
0.02% w/v BSA (PBS/BSA) and blocked with 10% v/v normal goat serum before incubation 
overnight at 4 ºC with primary antibodies: rabbit anti galectin-1 (1:100 v/v), moue anti E-
cadherin (1:100 v/v). Sections were then rinsed with PBS and incubated with DAPI for 
nuclear staining and the secondary fluorescent antibodies for 1 h at room temperature. The 
coverslips were mounted using the glycergel mounting medium and sealed with nail polish. 
The samples were stored in an appropriate box at 4 ºC until acquisition of images by 
fluorescence microscopy. 
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